




(86) Date de dépôt PCT/PCT Filing Date: 2002/06/20	(51) Cl.Int. ⁷ /Int.Cl. ⁷ C12N 15/56, C12N 15/76, C12N 15/70, C07H 21/00, C12N 15/10, C07K 19/00, C12Q 1/68, C12N 15/62, C12Q 1/40, C11D 3/33, C12N 9/28, C11D 3/26, C12N 1/20, G01N 33/573
(87) Date publication PCT/PCT Publication Date: 2003/01/09	(71) Demandeur/Applicant: HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN, DE
(85) Entrée phase nationale/National Entry: 2003/12/23	(72) Inventeurs/Inventors: BREVES, ROLAND, DE; KOTTWITZ, BEATRIX, DE; MAURER, KARL-HEINZ, DE; ECK, JUERGEN, DE; ...
(86) N° demande PCT/PCT Application No.: EP 2002/006842	(74) Agent: OGILVY RENAULT
(87) N° publication PCT/PCT Publication No.: 2003/002711	
(30) Priorité/Priority: 2001/06/29 (101 31 441.8) DE	

- (54) Titre : NOUVEAU GROUPE D'\$G(A)-AMYLASES, ET PROCEDE D'IDENTIFICATION ET D'OBTENTION DE NOUVELLES \$G(A)-AMYLASES
- (54) Title: A NOVEL GROUP OF \$G(A)-AMYLASES AND A METHOD FOR IDENTIFICATION AND PRODUCTION OF NOVEL \$G(A)-AMYLASES

(57) **Abrégé/Abstract:**

The invention relates to a novel group of α -amylases, belonging to a common sequence region and proteins sufficiently similar to said α -amylases with amylolytic function, methods for production thereof and diverse possible applications for said amylolytic proteins, in particular in washing and cleaning agents. The invention further relates to a PCR-based method for identification and production of novel α -amylases from isolated genomic DNA, in particular from DNA isolated from collections of micro-organisms and particular primer oligonucleotides and application thereof in said method.



(72) Inventeurs(suite)/Inventors(continued): LORENZ, PATRICK, DE; ZINKE, HOLGER, DE

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG(19) Weltorganisation für geistiges Eigentum
Internationales Büro(43) Internationales Veröffentlichungsdatum
9. Januar 2003 (09.01.2003)

PCT

(10) Internationale Veröffentlichungsnummer
WO 03/002711 A2


- (51) Internationale Patentklassifikation: **C12N** 51, 40593 Düsseldorf (DE). **MAURER, Karl-Heinz** [DE/DE]; Dechenstr. 5, 40699 Erkrath (DE). **ECK, Jürgen** [DE/DE]; Siegfriedstrasse 138, 64646 Heppenheim (DE). **LORENZ, Patrick** [DE/DE]; Beethovenstrasse 19, 69493 Hirschberg (DE). **ZINKE, Holger** [DE/DE]; Darmstädter Str. 36, 64673 Zwingenberg (DE).
- (21) Internationales Aktenzeichen: PCT/EP02/06842
- (22) Internationales Anmeldedatum:
20. Juni 2002 (20.06.2002)
- (25) Einreichungssprache: Deutsch
- (26) Veröffentlichungssprache: Deutsch
- (30) Angaben zur Priorität:
101 31 441.8 29. Juni 2001 (29.06.2001) DE
- (81) Bestimmungsstaaten (*national*): AU, BR, CA, CN, CZ, DZ, HU, ID, IL, IN, JP, KR, MX, PL, RO, RU, SG, SI, SK, UA, US, ZA.
- (84) Bestimmungsstaaten (*regional*): europäisches Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).
- (71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme von US): **HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN** [DE/DE]; Henkelstr. 67, 40589 Düsseldorf (DE).
- Veröffentlicht:
— ohne internationalen Recherchenbericht und erneut zu veröffentlichen nach Erhalt des Berichts
- (72) Erfinder; und
- (75) Erfinder/Anmelder (nur für US): **BREVES, Roland** [DE/DE]; Dr. Redlich-Str. 17, 40882 Ratingen (DE). **KOTTWITZ, Beatrix** [DE/DE]; Urdenbacher Allee
- Zur Erklärung der Zweibuchstaben-Codes und der anderen Abkürzungen wird auf die Erklärungen ("Guidance Notes on Codes and Abbreviations") am Anfang jeder regulären Ausgabe der PCT-Gazette verwiesen.

(54) Title: A NOVEL GROUP OF \$G(A)\$-AMYLASES AND A METHOD FOR IDENTIFICATION AND PRODUCTION OF NOVEL \$G(A)\$-AMYLASES

(54) Bezeichnung: EINE NEUE GRUPPE VON \$G(A)\$-AMYLASEN SOWIE EIN VERFAHREN ZUR IDENTIFIZIERUNG UND GEWINNUNG NEUER \$G(A)\$-AMYLASEN

(57) Abstract: The invention relates to a novel group of α -amylases, belonging to a common sequence region and proteins sufficiently similar to said α -amylases with amylolytic function, methods for production thereof and diverse possible applications for said amylolytic proteins, in particular in washing and cleaning agents. The invention further relates to a PCR-based method for identification and production of novel α -amylases from isolated genomic DNA, in particular from DNA isolated from collections of micro-organisms and particular primer oligonucleotides and application thereof in said method.

(57) Zusammenfassung: Die vorliegende Erfindung betrifft eine neue Gruppe von α -Amylasen, die einem gemeinsamen Sequenzraum angehören, sowie zu diesen α -Amylasen hinreichend ähnliche Proteine mit amyolytischer Funktion, Verfahren zu deren Herstellung und diverse Einsatzmöglichkeiten für diese amyolytischen Proteine, insbesondere in Wasch- und Reinigungsmitteln. Sie betrifft auch ein PCR-basiertes Verfahren zur Identifizierung und Gewinnung neuer α -Amylasen aus isolierter genomischer DNA, insbesondere aus isolierter DNA von Sammlungen von Mikroorganismen sowie bestimmte Primer-Oligonukleotide und deren Anwendung in einem solchen Verfahren.



WO 03/002711 A2

WO 03/002711

PCT/EP02/06842

**A novel group of α -amylases and a method for
identification and production of novel α -amylases**

The present invention relates to a novel group of α -
5 amylases belonging to a common sequence region and to
proteins with amylolytic function which are
sufficiently similar to said α -amylases, to methods for
production thereof and to various possible uses for
said amylolytic proteins, in particular in detergents
10 and cleaning agents. The invention further relates to a
PCR-based method for identifying and producing novel α -
amylases from isolated genomic DNA, in particular from
DNA isolated from collections of microorganisms, and to
particular primer oligonucleotides and application
15 thereof in said method.

α -Amylases (E.C. 3.2.1.1) hydrolyze α -1,4-glycosidic
bonds of starch and starch-like polymers such as, for
example, amylase, amylopectin or glycogen, which bonds
20 are located inside the polymer, with the formation of
dextrins and β -1,6-branched oligosaccharides. They are
very much among the most important industrially
utilized enzymes, for two reasons: on the one hand,
like many substrate-degrading enzymes, they are usually
25 released by microorganisms into the surrounding medium
so that it is possible to obtain them on the industrial
scale from the culture medium by fermentation and
purification with comparatively little effort. On the
other hand, amylases are required for a broad spectrum
30 of applications.

First and foremost among the industrial uses of α -
amylases is the production of glucose syrup. Other
examples are the use as active components in detergents
35 and cleaning agents, the use for treatment of raw
materials in the manufacture of textiles, the use for
producing adhesives or for producing sugar-containing
food or food ingredients.

An example of an amylase which is particularly intensively used industrially is *Bacillus licheniformis* α -amylase which is supplied by Novo Nordisk A/S, Bagsvaerd, Denmark under the trade name Termamyl[®]. The amylase derived from *B. subtilis* and *B. amyloliquefaciens*, respectively, and disclosed in US application US 1 227 374 is sold by the same company under the name BAN[®].

10

This amylase molecule and its close relatives have been further developed in numerous inventions whose object was to optimize their enzymic properties for specific applications with the aid of various molecular-biological modifications. Such optimizations may relate, for example, to the substrate specificities, the stability of the enzyme under various reaction conditions or to the enzymic activity itself. Examples of such optimizations, which may be mentioned here, are the following applications: EP 0410498 for sizing textiles and WO 96/02633 for starch liquefaction.

Since developments which consist merely of optimizations of only a few known starting enzymes are possibly limited with respect to the achievable results, an intensive search for comparable enzymes for other natural sources is carried out in parallel. Starch-cleaving enzymes, for example from *Pimelobacter*, *Pseudomonas* and *Thermus*, have been identified for food production, cosmetics and pharmaceuticals (EP 0 636 693), and enzymes of the same type from *Rhizobium*, *Arthrobacter*, *Brevibacterium* and *Micrococcus* (EP 0 628 630), from *Pyrococcus* (WO 94/19454) and from *Sulfolobus* for starch liquefaction at elevated temperatures and strongly acidic reaction conditions (EP 0 727 485 and WO 96/02633), respectively. *Bacillus* sp. amylases (WO 95/26397 and WO 97/00324) have been found for the use at alkaline pH. Due to their low

35

- 3 -

sensitivity to detergents, other amylases from various *Bacilli* (EP 0 670 367) are suitable for use in detergents or cleaning agents.

5 Further optimizations of the enzymes isolated from natural sources for the particular field of application may be carried out, for example, via molecular-biological methods (for example according to US 5171673 or WO 99/20768) or via chemical modifications
10 (DE 4013142). The patent application WO 99/43793, for example, describes a development of the known Novamyl® α -amylase, in which sequence similarities between Novamyl® and known cyclodextrin glucanotransferases (CGTases) are utilized in order to construct a number
15 of related molecules with the aid of molecular-biological techniques. Said molecules are α -amylases with additional CGTase-specific consensus sequences (boxes) and functions or, conversely, CGTases with additional regions and functions typical for α -
20 amylases, or chimeras of the two molecules. The purpose of this development is to optimize Novamyl® for these applications.

The application WO 99/57250, for example, provides the
25 teaching of linking enzymes suitable for the use in detergents and cleaning agents via chemical linkers to a binding domain which increases the effective enzyme concentration on the material to be cleaned.

30 A modern direction of enzyme development comprises combining elements of known proteins related to one another via random methods to give new enzymes having properties have not been obtained previously. Such methods are also listed under the generic term
35 'directed evolution' and include, for example the following methods: the StEP method (Zhao et al. (1998), *Nat. Biotechnol.*, Volume 16, pp. 258-261), random priming recombination (Shao et al., (1998), *Nucleic*

Acids Res., Volume 26, pp. 681-683), DNA shuffling (Stemmer, W.P.C. (1994), Nature, Volume 370, pp. 389-391) and RACHITT (Coco, W.M. et al. (2001), *Nat. Biotechnol.*, Volume 19, pp. 354-359).

5

The recombination via methods of this kind requires the presence of sufficiently long regions on each of the nucleic acids used in order to achieve hybridization under the particular conditions. Starting sequences
10 with identities which are more than 45% to one another at the amino acid level should be regarded as practicable for a successful hybridization and more than 50% for forcing the homologous recombination. At least two different sequences which are homologous to
15 one another already define a sequence region which includes any novel sequences theoretically derivable from said starting sequences via recombination. For this purpose, they may also have homologies of less than 45%, if the nucleic acids derived therefrom can be
20 made to recombine by any of the methods established in the prior art.

Despite all of these developments, however, there is the unchanged task of finding, in addition to the few
25 natural amylolytic enzymes which are currently industrially utilized in unmodified form or in the form of further developments, further enzymes which *a priori* have a broad spectrum of applications and which may serve as starting points for application-specific
30 further developments, in particular for random recombination methods.

The great genetic variety of the Gram-positive bacteria order of Actinomycetales, in particular of the genus
35 Streptomyces, has hardly been investigated previously for amylolytic proteins suitable for industrial purposes. Only two Japanese patent applications are to be contemplated in this context. The application

JP-A 62-143999 discloses an α -amylase from a representative of the genus *Streptomyces*, which is suitable for the use in detergents or cleaning agents. This organism, *Streptomyces* sp. KSM-9 or FERM P-7620, comes from a natural habitat and grows in alkaline medium. Said document describes the amylolytic enzyme merely via enzymic parameters and its suitability for the use in detergents and cleaning agents, but not via its DNA sequence or amino acid sequence.

10

The enzyme disclosed in the application JP-A 2000-60546 and derived from *Streptomyces* sp. TOTO-9805 or FERM BP-6359 has enzymic properties similar to those of the *Streptomyces* sp. KSM-9 enzyme. However, said application also characterizes said enzyme merely via enzymic parameters and not via the amino acid or nucleotide sequence. As a result of this, both amylases are available neither for heterologous expression and production nor for application-specific selection and optimization, since both traditional mutagenesis methods and directed evolution methods (EP-PCR, sequence shuffling, family shuffling) are based on the corresponding nucleic acid sequences.

25 The present invention is thus primarily based on the object of identifying natural α -amylases which have not been described previously and which themselves are suitable for possible industrial uses or which may serve as bases for application-specific further developments.

35 Preferably, this object should be considered as having been achieved by finding a plurality of α -amylases or partial sequences of a plurality of α -amylases, which are related to one another and can be homologized, since it is possible to derive a sequence region from such a homologization, which in turn can serve as starting point for generating further enzymes. The

finding of α -amylase sequences as diverse as possible should be particularly advantageous, since this opens up a correspondingly broader sequence region with a corresponding multiplicity of possible variations; on
5 the other hand, homology of the sequences obtained to one another should still be high enough in order to make a recombination via known methods possible. Preferably, at least some sequences should have homologies to one another of in each case from 50 to
10 60% identity at the amino acid level.

Part of the object was to obtain the nucleic acids coding for α -amylases of this kind, since said nucleic acids are essential both for the biotechnological
15 production and for the further development of said enzymes.

Another part of the object was to find those organisms which naturally produce the α -amylases in question.

20

Another part of the object was to find a method by which such a pool of α -amylases can be provided.

As another part of the object, it should be possible to
25 utilize the α -amylases, α -amylase fragments or α -amylase genes obtained or fragments thereof for finding or developing new enzymes.

Another part of the object was to make possible the
30 biotechnological production of the α -amylases found or derivable α -amylases.

Another part of the object was to define possible industrial uses for the α -amylases found.

35

The first object is achieved by amylolytic proteins which are thus the first subject matter of the invention and whose amino acid sequences comprise a

portion of which 98%, preferably 99%, particularly preferably 100%, are described by the consensus sequence of SEQ ID NO. 263, in particular via the subregion corresponding to positions 8 to 93. These
5 include amylolytic proteins having the amino acid sequences indicated in the sequence listing under SEQ ID NO. 34 to 262, preferably the enzymes treated in the examples, in particular the enzymes derived from the species *Streptomyces* sp. B327* and B400B and enzymes
10 which are sufficiently similar thereto or which can be derived therefrom by methods known per se. Preferred representatives can be isolated from natural organisms, in particular from those of the order Actinomycetales.

15 It is possible to derive from said sequences via homologization a sequence region which in turn can serve as starting point for generating further enzymes.

The invention secondly relates to nucleic acids coding
20 for amylolytic proteins whose amino acid sequence comprises a portion of which 98%, preferably 99%, particularly preferably 100%, are described by the consensus sequence of SEQ ID NO. 263, in particular via the subregion corresponding to positions 8 to 93. These
25 correspondingly preferably include the nucleic acids coding for the respective proteins of the first subject matter of the invention but also particular oligonucleotides which can be used in methods for finding such genes or gene fragments (see below).

30 The invention thirdly relates to the natural organisms containing nucleic acids coding for the proteins or protein fragments of the first subject matter of the invention. Particularly preferred embodiments thereof
35 are the strains *Streptomyces* sp. 327* and *Streptomyces* sp. B400B which have been deposited under the numbers DSM 13990 and DSM 13991, respectively.

The invention fourthly relates to PCR-based methods for identifying and/or obtaining new amylases from a collection of organisms or nucleic acids, which methods are characterized in that PCR primers having in each
5 case a variable 3' region and a 5' region highly homologous to regions of known amylases are used. Methods of this kind may be designed in various ways and be extended by optional process steps: these include sequencing the genes or gene fragments
10 obtained, deriving peptides which may be characterized via immunochemical methods or via their biochemical properties. Further embodiments relate to the design of the primers with respect to the variability or selection of the regions from which they are derived;
15 in particular, the primers used in the examples are preferred embodiments. Another possible embodiment relates to the origin of the material serving as PCR template, with collections of Actinomycetales being preferred. In further embodiments, the PCR products are
20 studied via expression banks. Particular preference is given to a reaction process which leads to a multiplicity of similar products via which a sequence region can be defined.

25 The invention fifthly relates to the α -amylases, α -amylase fragments or α -amylase genes or fragments thereof, obtained by a method of the previous subject matter of the invention, for finding or developing new enzymes, by using said α -amylases, α -amylase fragments
30 or α -amylase genes or fragments thereof either themselves for the screening for or development of novel primers or for the fusion or linkage to another protein or gene.

35 The invention sixthly relates to vectors having the nucleic acids of the second subject matter of the invention, to host cells transformed with such vectors and to all biotechnological methods for preparing a

protein or derivative according to the first subject matter of the invention.

The invention seventhly relates to the possible industrial uses for the α -amylases found. These include detergents or cleaning agents which are characterized in that they comprise a protein or derivative according to the first subject matter of the invention, methods for starch liquefaction, in particular for producing ethanol, temporary bonding methods and various possible uses, in particular for the treatment of raw materials or intermediates in the manufacture of textiles, in particular for desizing cotton, for preparing linear and/or short-chain oligosaccharides, for hydrolyzing cyclodextrins, for liberating low-molecular weight compounds from polysaccharide supports or cyclodextrins, for preparing food and/or food ingredients, for preparing animal feed and/or animal feed ingredients and for dissolving starch-containing adhesive bonds.

A **protein** means in accordance with the present application a polymer which is composed of the natural amino acids, has a substantially linear structure and adopts usually a three dimensional structure to exert its function. In the present application, the 19 proteinogenic, naturally occurring L-amino acids are indicated by the internationally customary 1- and 3-letter codes.

30

An **enzyme** in accordance with the present application means a protein which exerts a particular biochemical function. **Amylolytic proteins** or enzymes with amylolytic function mean those which hydrolyze α -1,4-glycosidic bonds of polysaccharides, in particular those bonds located inside the polysaccharides, and which are also referred to as α -1,4-amylases (E.C. 3.2.1.1) or **α -amylases** for short.

35

Numerous proteins are formed as "**preproteins**", i.e. together with a **signal peptide**. This then means the N-terminal part of the protein, whose function usually is to ensure the export of the produced protein from the producing cell into the periplasm or into the surrounding medium and/or the correct folding thereof. Subsequently, the signal peptide is removed from the remaining protein under natural conditions by a signal peptidase so that said protein exerts its actual catalytic activity without the initially present N-terminal amino acids. For example, the **native** α -amylase from *Streptomyces* sp. B327* is 461 amino acids in length, as shown in SEQ ID NO. 6. As illustrated in SEQ ID NO. 5, the signal peptide of this enzyme in comprises 30 amino acids so that the **mature enzyme** has a length of 431 amino acids.

Owing to their enzymic activity, preference is given for industrial applications to the **mature peptides**, i.e. the enzymes processed after their preparation, over the preproteins.

Pro-proteins are inactive precursors of proteins. Their precursors with signal sequence are referred to as **pre-pro-proteins**.

Nucleic acids mean in accordance with the present application the molecules which are naturally composed of nucleotides, serve as information carriers and code for the linear amino acid sequence in proteins or enzymes. They may be present as single strand, as a single strand complementary to said single strand or as double strand. For molecular-biological work, preference is given to the nucleic acid **DNA** as the naturally more durable information carrier. In contrast, an **RNA** is produced to implement the invention in a natural environment such as, for example, in an

- 11 -

expressing cell, and RNA molecules essential to the invention are therefore likewise embodiments of the present invention.

5 In the case of DNA, the sequences of both complementary strands in in each case all three possible reading frames must be taken into account. The fact that different codon triplets can code for the same amino acids so that a particular amino acid sequence can be
10 derived from a plurality of different nucleotide sequences which possibly have only low identity must also be taken into account (**degeneracy of the genetic code**). Moreover, various organisms differ in the **use of these codons**. For these reasons, both amino acid
15 sequences and nucleotide sequences must be incorporated into the scope of protection, and nucleotide sequences indicated are in each case to be regarded only as coding by way of example for a particular amino acid sequence.

20 The information unit corresponding to a protein is also referred to as **gene** in accordance with the present application.

25 It is possible for a skilled worker, via nowadays generally known methods such as, for example, chemical synthesis or polymerase chain reaction (PCR) in combination with molecular-biological and/or protein-chemical standard methods, to prepare the appropriate
30 nucleic acids up to complete genes on the basis of known DNA sequences and/or amino acid sequences. Such methods are known, for example, from the "Lexikon der Biochemie" [Encyclopedia of Biochemistry], Spektrum Akademischer Verlag, Berlin, 1999, Volume 1, pp. 267-
35 271 and Volume 2, pp. 227-229.

Changes in the nucleotide sequence, as may be produced, for example, by molecular-biological methods known per

- 12 -

se, are referred to as **mutations**. Depending on the type of change, **deletion**, **insertion** or **substitution mutations** or those in which various genes or parts of genes are **fused** to one another (**shuffling**) are known, for example; these are gene mutations. The corresponding organisms are referred to as **mutants**. The proteins derived from mutated nucleic acids are referred to as **variants**. Thus, for example, deletion, insertion, substitution mutations or fusions result in deletion-, insertion-, substitution-mutated or fusion genes and, at the protein level, to corresponding deletion, insertion or substitution variants, or fusion proteins.

Fragments mean all proteins or peptides which are smaller than natural proteins or than those proteins which correspond to completely translated genes, and which may, for example, also be obtained synthetically. Owing to their amino acid sequences, they may be related to the corresponding complete proteins. They may adopt, for example, identical structures or exert proteolytic activities or partial activities such as complexing of a substrate, for example. Fragments and deletion variants of starting proteins are in principle very similar; while fragments represent rather relatively small pieces, the deletion mutants rather lack only short regions and thus only individual partial functions.

At the nucleic acid level, the **partial sequences** correspond to fragments.

Chimeric or **hybrid** proteins mean in accordance with the present application those proteins which are composed of elements which naturally originate from different polypeptide chains from the same organism or from different organisms. This procedure is also called **shuffling** or **fusion mutagenesis**. The purpose of such a

- 13 -

fusion may be, for example, to cause or to modify a particular enzymic function with the aid of the fused-to protein part. In accordance with the present invention, it is unimportant as to whether such a
5 chimeric protein consists of a single polypeptide chain or of a plurality of subunits between which different functions may be distributed. To implement the latter alternative, it is possible, for example, to break down a single chimeric polypeptide chain into a plurality of
10 polypeptide chains by a specific proteolytic cleavage, either posttranslationally or only after a purification step.

Proteins obtained by **insertion mutation** mean those
15 variants which have been obtained via methods known per se by inserting a nucleic acid fragment or protein fragment into the starting sequences. They should be classified as chimeric proteins, due to their similarity in principle. They differ from the latter
20 merely in the size ratio of the unaltered protein part to the size of the entire protein. In such insertion-mutated proteins the proportion of foreign protein is lower than in chimeric proteins.

25 **Inversion mutagenesis**, i.e. a partial sequence conversion, may be regarded as a special form of both deletion and insertion. The same applies to a regrouping of various molecule parts, which deviates from the original amino acid sequence. Said regrouping
30 can be regarded as deletion variant, as insertion variant and as shuffling variant of the original protein.

Derivatives mean in accordance with the present
35 application those proteins whose pure amino acid chain has been chemically modified. Those derivatizations may be carried out, for example, biologically in connection with protein biosynthesis by the host organism.

- 14 -

Molecular-biological methods may be employed here. However, said derivatizations may also be carried out chemically, for example by chemical conversion of an amino acid side chain or by covalent binding of another
5 compound to the protein. Such a compound may also be, for example, other proteins which are bound, for example, via bifunctional chemical compounds to proteins of the invention. Such modifications may influence, for example, substrate specificity or the
10 strength of binding to the substrate or cause transient blocking of the enzymic activity if the coupled-to substance is an inhibitor. This may be useful for the period of storage, for example. Likewise, derivatization means covalent binding to a
15 macromolecular support.

Proteins may also be combined, via the reaction with an antiserum or a particular antibody, to groups of **immunologically related** proteins. The members of a
20 group are distinguished in that they have the same antigenic determinant which is recognized by an antibody.

In accordance with the present invention, all enzymes,
25 proteins, fragments and derivatives, unless they need to be explicitly referred to such, are included under the **generic term 'proteins'**.

Vectors mean in accordance with the present invention
30 elements which consist of nucleic acids and which contain a particular gene as characteristic nucleic acid region. They are capable of establishing said gene as a stable genetic element replicating independently of the remaining genome in a species or a cell line
35 over several generations or cell divisions. Vectors are, in particular when used in bacteria, special plasmids, i.e. circular genetic elements. Genetic engineering distinguishes between, on the one hand,

- 15 -

those vectors which are used for storage and thus, to a certain extent, also for genetic engineering work, the "**cloning vectors**", and, on the other hand, those which perform the function of establishing the gene of interest in the host cell, i.e. enabling expression of the protein in question. These vectors are referred to as **expression vectors**.

Comparison with known enzymes which are deposited, for example, in generally accessible databases makes it possible to deduce the **enzymic activity** of an enzyme under consideration from the amino acid sequence or nucleotide sequence. Said activity may be modified qualitatively or quantitatively by other protein regions which are not involved in the actual reaction. This could relate to, for example, enzyme stability, activity, reaction conditions or substrate specificity.

Such a comparison is carried out by relating similar sequences in the nucleotide or amino acid sequences of the proteins under consideration to one another. This is called **homologization**. Relating the relevant positions to one another in the form of a table is referred to as **alignment**. When analyzing nucleotide sequences, again both complementary strands and in each case all three possible reading frames must be taken into account, likewise the degeneracy of the genetic code and the organism-specific codon usage. Meanwhile, alignments are produced by computer programs, for example by the FASTA or BLAST algorithms; this procedure is described, for example, by D.J. Lipman and W.R. Pearson (1985) in *Science*, Volume 227, pp. 1435-1441.

A compilation of all matching positions in the comparative sequences is referred to as **consensus sequence**.

- 16 -

Such a comparison also allows a statement about the similarity or **homology** of the comparative sequences to one another. This is expressed in **percent identity**, i.e. the proportion of identical nucleotides or amino acid residues at the same positions. A wider definition of the term homology also includes the conserved amino acid substitutions in this value. This is then referred to as **percent similarity**. Such statements may be made about whole proteins or genes or only about individual regions.

The generation of an alignment is the first step in defining a **sequence space**. This hypothetical space encompasses any sequences to be derived by permutation in individual positions, which result from taking into account all variations occurring in the relevant individual positions of said alignment. Each hypothetically possible protein molecule is a point in said sequence space. For example, two amino acid sequences which are substantially identical and have only at two different positions in each case two different amino acids thus create a sequence space of four different amino acid sequences. A very large sequence space is obtained if further sequences are found which are in each case homologous to individual sequences of a space. Such high homologies which exist in each case in pairs enable also sequences with very low homologies to be recognized as belonging to a sequence space.

Homologous regions of different proteins are those having the same functions which can be recognized by matches in the primary amino acid sequence. This ranges up to complete identities in very small regions, the "boxes", which comprise only a few amino acids and usually exert functions essential for the overall activity. The **functions of the homologous regions** mean very small partial functions of the function exerted by

- 17 -

the complete protein, such as, for example, the formation of individual hydrogen bonds for complexing a substrate or transition complex.

5 The term **amylolytic protein of the invention** thus means not only one having the pure function of hydrolyzing α -1,4-glycosidic bonds, which can be attributed to the few amino acid residues of a putative catalytically active site. The term additionally encompasses all
10 functions supporting the hydrolysis of a α -1,4-glycosidic bond. Such functions may be achieved, for example, by individual peptides and by one or more individual parts of a protein by acting on the actually catalytically active regions. The term amylolytic
15 function also encompasses only such modifying functions, since, on the one hand, it is not necessarily known exactly which amino acid residues of the protein of the invention actually catalyze the hydrolysis, and, on the other hand, particular
20 individual functions may not be excluded definitively from the outset from involvement in the catalysis. The auxiliary functions or partial activities include, for example, binding of a substrate, of an intermediate or final product, activation or inhibition or mediation of
25 a regulatory effect on the hydrolytic activity. This may also be, for example, the formation of a structural element located far away from the active site or a signal peptide whose function relates to exporting the produced protein out of the cell and/or to the correct
30 folding thereof and without which usually no functional enzyme is produced *in vivo*. Overall, however, the result must be a hydrolysis of α -1,4-glycosidic bonds of starch or starch-like polymers.

35 In accordance with this, for example, the fragments of the α -amylases indicated in the sequence listing under SEQ ID NO. 34 to 262 are to be regarded as amylolytic proteins, since they are by nature components of larger

proteins which overall are capable of hydrolyzing the α -1,4-glycosidic bonds of starch or starch-like polymers.

5 Within the scope of the present application, a distinction must be made between **screening** (hybridization screening or DNA screening) and **activity assay**. In general, the "screening" of transformants means a detection reaction suitable for identifying
10 those clones in which the desired transformation event has taken place. It is usually geared, as, for example, in the case of the familiar blue-white selection, towards detection of a biochemical activity which the transformants have obtained or which is no longer
15 present, after recombination has taken place. This type of biochemical detection reaction is referred to as **activity assay** in accordance with the present application.

20 **Screening** refers to the screening of a gene bank containing particular nucleic acids and the thereby possible identification of sufficiently similar nucleic acid sequences. This is carried out, for example, via Southern or Northern blot hybridizations, as are quite
25 well known from the prior art. However, this term also includes, for example, PCR-based methods of the invention for identifying and/or obtaining new genes from a collection of organisms or nucleic acids, which methods are characterized in that PCR primers having a
30 variable 3' region and a 5' region with high homology to corresponding regions of known genes are used.

The **performance of an enzyme** means its efficacy in the industrial area considered in each case. Said
35 performance is based on the actual enzymic activity but, in addition, depends on further factors relevant for the particular process. These include, for example, stability, substrate binding, interaction with the

material carrying said substrate or interactions with other ingredients, in particular synergies. Thus, for example, the study of whether an enzyme is suitable for use in detergents or cleaning agents considers its contribution to the washing or cleaning performance of an agent formulated with further components. For various industrial applications, it is possible to further develop and optimize an enzyme via molecular-biological techniques known per se, in particular the abovementioned techniques.

The following microorganisms have been deposited according to the Budapest Treaty on the international recognition of the deposit of microorganisms from April 28, 1977 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b in 38124 Braunschweig, Germany on 01.15.2001: the isolate Actinomycetales/*Streptomyces* sp. B327* under accession number DSM 13990 and the isolate Actinomycetales/*Streptomyces* sp. B400B under accession number DSM 13991.

According to the present application, said microorganisms are in particular characterized in that they contain genes for α -amylases, whose complete DNA sequences and amino acid sequences are indicated in the sequence listing under SEQ ID NO. 5 and 6 and under SEQ ID NO. 7 and 8, respectively.

The object is achieved by providing according to the invention a multiplicity of α -amylases all of which are to be regarded as representatives of a particular sequence space which is defined by a partial sequence of said α -amylase, namely a portion of the $(\alpha\beta)_8$ -barrel structural element known for amylases. Any amylolytic proteins whose amino acid sequence comprises a portion belonging to said specific sequence space and

- 20 -

sufficiently similarly proteins are amylases of the invention.

Said sequence space is depicted in figure 3 and in the
5 sequence listing under SEQ ID NO. 263 in two different
ways, namely as abbreviations or combinations of all
sequences found, showing a partial sequence of
amylolytic proteins which comprises 100 positions.
Sequence variations occur in 86 of these positions.
10 Thus, for example, position 6 in the illustration of
figure 3 is occupied by the amino acid X₀ which may be
either isoleucine or leucine. The same information is
provided by the sequence protocol in the lines
preceding the consensus sequence, followed by the
15 combination of all possible sequences to an artificial
consensus sequence. It should be noted in particular
that the amino acids of individual positions, for
example in position 28, may be occupied by a single or
else a sequence of two or more amino acids.

20

The consensus sequence shown has only very low variance
in positions 1-7 and 94-100, which results from the
PCR-based method developed for identifying this
sequence, which is further described below and in the
25 examples: these partial sequences correspond to the DNA
regions to which the primers used for amplification
have bound. Depending on the stringency of the
conditions under which this binding takes place,
deviating nucleotide sequences may also be bound and
30 amplified; with comparatively low selectivity, the DNA
product obtained thus does not completely correspond to
the template at these sites. For this reason, the scope
of protection is directed in particular towards the
subregion corresponding to positions 8 to 93 of the
35 consensus sequence shown.

This consensus sequence which describes the sequence
space is based on 231 homologizable partial sequences

- 21 -

of α -amylases, which are depicted in the sequence listing under SEQ ID NO. 2, 4 and SEQ ID NO. 34 to 262 and which define the abovementioned sequence space by their variations in defined individual positions.

5

The derivation of a consensus sequence of this kind will be illustrated below; technical details can in each case be found in the examples of the present application.

10

The sequences of α -amylases (E.C. 3.2.1.1), for example of Gram-positive eubacteria of various genera of the order Actinomycetales (*Streptomyces*, *Thermomonospora* etc.), may be obtained from generally accessible
15 databases. Comparison thereof, for example via producing an alignment, allows identification of sequence regions which are conserved between the species. A broad sequence space is obtained by detecting those conserved regions which flank variable
20 sequence regions. These conserved regions are also referred to as sequence anchors, since the variable sequence regions become available via them. The blocks A to E highlighted in figure 1 were identified as conserved sequence blocks. It is possible to derive
25 from their amino acid sequences or, rather better, from their nucleotide sequences PCR primers which, as forward and reverse primers, should be directed toward each other in such a way that a PCR in each case comprises the variable region.

30

Suitable templates for the PCR may be genomic DNA preparations of known, but also unknown, bacteria isolates, for example from soil samples. They should be available in pure culture to provide afterwards pure
35 PCR products and pure enzymes. Samples of this kind may be taken simply from nature and cultured by applying particular conditions (e.g. pH, aeration, utilizable substrate, presence of otherwise toxic compounds,

- 22 -

incidence of light, etc.) in which appropriate unicellular organisms grow which may then be isolated with methods known per se and further cultured under the appropriate conditions.

5

The following articles provide an overview over methods for isolating actinomycetes and streptomycetes:

- 10 - Nüesch (1965): "Isolierung und Selektionierung von Actinomyceten"; Zbl. Bakt. I., Supplement 1, pp. 234-252;
- Williams & Cross (1971): "Actinomyces"; in: Norris, J.R., Ribbons, D.W. (Editor) *Methods in Microbiology*, Acad. Press, London, Volume 4, pp. 295-334;
- 15 - Williams & Wellington (1982): "Principles and Problems of selective Isolation of Microbes", in: Bullock, J.D., Nisbet, L.J., Win-stanley, D.J. (Editor), "Bioactive Microbial Products: Search and Discovery", Acad. Press London, pp. 9-26; and
- 20 - Wellington & Cross (1983): "Taxonomy of antibiotic-producing actinomyces and new approaches for their selective isolation", *Progr. Industr. Microbiol.*, Volume 17, pp. 7-36.

25 In the example, an appropriate collection of Actinomycetales isolates having *Streptomyces* properties was used. In this example, the isolation had been carried out starting from soil samples with addition of the antibiotic nystatin to suppress the accompanying
30 flora.

Positive results were obtained from the corresponding PCR mixtures, in particular with the primer combination GEX024 (forward)/GEX026 (SEQ ID NO. 9, and 10,
35 respectively) which have been derived from the sequence regions C (GEX024) and D (GEX026) (Figure 1) and correspond to the amylase domains $\beta 4$ and $\beta 7$ of the $(\alpha\beta)_8$ barrel structure, as defined in the article "Alpha-

- 23 -

Amylase family: molecular biology and evolution" (Janecek, S. (1997), *Prog. Biophys. Mol. Biol.* 67 (1), pp. 67-97). Said primers produced PCR products of approx. 300 bp in length of all isolates assayed.

5

Said PCR products were sequenced. The deduced amino acid sequences are listed in the sequence listing under SEQ ID NO. 2, 4 and 34 to 262. A comparison of these partial sequences with the entries in the GenBank
10 enzyme database (National Center for Biotechnology Information NCBI, National Institutes of Health, Bethesda, MD, USA) confirms that all of these partial sequences are amylase partial sequences. The result of this comparison is depicted in table 1 which also
15 indicates in each case the most similar database entries for the partial sequences found and the degree of homology between these two sequences.

Table 1: List of 231 individual sequences and % identity to their closest relatives in GenBank (NCBI; Release 121.0); determined by the FASTA program on 2.2.2001.

5

Streptomyces sp. ...	SEQ ID NO. according to sequence listing	Closest database hit	Identity (%)
B327*	2	Y13332	92
B400B	4	M15540	74.2
B1002	34	AL352956	81
B1003B	35	AL352956	80
B1006	36	M15540	85.6
B1008A1	37	U51129	77
B1009A	38	Y13332	88
B1010	39	Y13332	88
B1011	40	Y13332	90
B1012B	41	Y13332	89
B1014A1	42	Y13332	91
B1017C	43	Y13332	91
B1019	44	Y13332	90
B101A	45	Z85949	83
B101B	46	Y13332	88
B102	47	M18244	64
B1020C	48	U51129	96
B1022A	49	Y13332	85
B1028	50	Z85949	74
B1029	51	AL352956	80
B1030A	52	Z85949	81
B1035B	53	M25263	74
B1036	54	Y13332	85
B1037A	55	M25263	82
B1039A	56	AL352956	86
B103A	57	Z85949	82
B1041A1	58	Y13332	91
B1043A	59	AL352956	97
B1044C	60	AL352956	75
B1045	61	Y13332	91
B1046A	62	AL352956	90

B1047A1	63	Z85949	97
B1048A	64	AL352956	96
B1049A	65	AL352956	86
B1050A	66	Z85949	85
B1052A2	67	AL352956	88
B1053	68	M18244	97
B1059	69	M15540	75.3
B1060	70	M25263	80
B1061B	71	Z85949	80
B1065	72	M25263	79
B1067A	73	AL352956	81
B1068	74	M25263	79
B1069B	75	M18244	92
B106C	76	Y13332	89
B107	77	U51129	87
B1070A	78	Y13332	92
B1071	79	M25263	79
B1072A	80	Y13332	94
B108	81	M25263	92
B109A	82	Y13332	86
B114C	83	Y13332	88
B115	84	Y13332	90
B117A1	85	Y13332	88
B118	86	M25263	80
B119E	87	U51129	75
B120alt	88	Y13332	88
B123	89	M18244	92
B124	90	Y13332	89
B125C	91	Z85949	89
B126A	92	Y13332	86
B127A	93	Y13332	85
B128B	94	U51129	85
B130B	95	M25263	93
B131	96	M25263	92

B134	97	M25263	92
B135A	98	Y13332	86
B137	99	M25263	78
B138	100	U51129	85
B138A	101	U51129	85
B138A2	102	U51129	86
B140	103	M25263	92
B141	104	M25263	92
B142	105	X57568	77
B143	106	M25263	92
B148A	107	Y13332	88
B152A	108	M25263	82
B153(B)	109	AL352956	89
B154A	110	Y13332	87
B156B	111	AL352956	89
B157C	112	Y13332	88
B158A	113	Y13332	89
B159	114	Y13332	89
B160B	115	Y13332	88
B161A	116	X57568	86
B166B	117	U51129	89
B168	118	Y13332	88
B179	119	M25263	82
B181C	120	Y13332	89
B183B	121	X57568	97
B184	122	M18244	96
B185(B)	123	Y13332	88
B186A	124	Y13332	83
B187A	125	AL352956	88
B187A2	126	AL352956	88
B194A	127	Z85949	62
B194B1	128	Y13332	87
B196A2C	129	Y13332	87
B196B	130	Y13332	87

B197B	131	Y13332	87
B198C2	132	Y13332	92
B200B	133	Y13332	88
B201A	134	Y13332	87
B202A	135	Y13332	87
B202B	136	Y13332	88
B206A	137	Y13332	87
B207	138	Y13332	90
B208B	139	Z85949	85
B209B	140	Y13332	87
B210	141	Z85949	89
B211A	142	Y13332	88
B212B1	143	Y13332	88
B213	144	Y13332	86
B214B	145	AL352956	79
B214C	146	M25263	83
B215	147	Y13332	88
B218D2	148	Y13332	87
B219A	149	Y13332	88
B220B	150	Y13332	88
B221A	151	Y13332	88
B222(B)	152	Z85949	88
B223A	153	U51129	88
B224(A)	154	Y13332	87
B225B	155	AL352956	73
B226B	156	AL352956	88
B227B2	157	Z85949	76
B228B	158	U51129	88
B230B1	159	AL352956	75
B231A	160	Z85949	74
B233C	161	Z85949	76
B234	162	Y13332	88
B235A	163	Z85949	76
B237A	164	Y13332	89

B238A	165	Y13332	89
B240A	166	Y13332	87
B241B2	167	Y13332	88
B242A1	168	M25263	78
B243C	169	U51129	86
B244B2	170	AL352956	75
B246	171	Y13332	89
B247A	172	Z85949	74
B248B2	173	AL352956	81
B249A	174	AL352956	75
B249C	175	U51129	77
B250A2	176	Y13332	87
B251B	177	Y13332	88
B252A	178	U51129	86
B253	179	Y13332	89
B253A	180	U51129	87
B255B2	181	Y13332	89
B256A	182	Y13332	88
B259A	183	Y13332	88
B261	184	U51129	96
B278	185	Z85949	87
B279	186	Y13332	88
B280C	187	Y13332	88
B284A	188	Y13332	86
B286A	189	Y13332	87
B287	190	M25263	81
B292A	191	M25263	95
B3001org	192	Y13332	84
B3002org	193	Z85949	74
B3003org	194	Y13332	88
B3017	195	X57568	77
B306	196	Y13332	84
B308	197	Y13332	87
B311	198	M25263	81

B315	199	Y13332	87
B317	200	X57568	82
B318	201	M25263	76
B319	202	Y13332	87
B320A	203	Y13332	89
B321	204	M25263	78
B322A	205	Y13332	89
B323	206	M25263	83
B326	207	Y13332	84
B327B	208	X57568	94
B335org	209	M25263	83
B345	210	Y13332	88
B346	211	Y13332	91
B347	212	X59159	45.2
B348	213	Y13332	85
B350	214	Y13332	90
B352	215	Y13332	90
B353	216	Y13332	76
B354	217	Y13332	87
B355	218	Y13332	87
B356	219	Y13332	92
B357	220	X57568	75
B358	221	M25263	80
B359	222	Y13332	89
B360	223	Y13332	86
B361	224	M18244	44.2
B362	225	Y13332	87
B363org	226	U51129	86
B366	227	Y13332	89
B368	228	Y13332	86
B370	229	AL352956	80
B371	230	Y13332	92
B372	231	Y13332	88
B373	232	Y13332	88

B374B	233	Y13332	89
B375	234	Y13332	89
B376	235	Y13332	91
B380	236	Y13332	87
B382	237	Y13332	85
B390	238	M25263	83
B392A	239	AL352956	97
B393	240	Z85949	74
B394	241	Z85949	76
B395	242	Y13332	88
B396(A)	243	Y13332	90
B400	244	Y13332	88
B4006	245	Y13332	89
B4006B	246	X59159	94.2
B400A	247	Y13332	88
B400A2	248	Y13332	92
B400B3	249	M25263	80
B400C	250	X57568	94
B400C2	251	M18244	91
B400D	252	M25263	89
B400D2	253	M25263	89
B400E	254	M25263	79
B400G	255	Y13332	87
B400G2	256	Y13332	87
B400I	257	M25263	81
B400J	258	X59159	45.7
B400K	259	X59159	45.7
B400L	260	X59159	45.7
B402	261	M25263	90
B907	262	M25263	80

- 31 -

The comparison with the sequences deposited in the database shows that the most similar proteins have homologies of 97% identity. In the case of *Streptomyces* sp. B1053 α -amylase, the most similar protein is the enzyme with accession number M18244, which is the α -amylase of *Streptomyces limosus*, in the case of the enzymes of *Streptomyces* sp. B1043A and B392A, it is the enzyme with accession number AL352956 (α -amylase of *Streptomyces coelicolor* A3(2)) and, in the case of *Streptomyces* sp. B1047A1 α -amylase, it is the enzyme with the accession number Z85949, which is the α -amylase B of *Streptomyces lividans*.

An alignment of these 231 sequences is possible; in the present example one such alignment was produced with the aid of the Clustal X[®] program, version 1.64b (standard settings; described in: Thompson, J.D., Higgins, D.G. and Gibson, T.J. (1994), "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice", *Nucleic Acids Res.*, Volume 22, pages 4673-4680). As already indicated above, the consensus sequence can be found in figure 3 and SEQ ID NO. 263 in two alternative representations.

This consensus sequence, and therefore the corresponding sequence space defined by the variable amino acids, are therefore based on 231 individual sequences which were obtained from natural sources. Said sequence space comprises, by calculation, approx. 10^{51} different amino acid sequences all of which are described by said consensus sequence. Despite this large number, there are up until now no known amylases having a homologous region which is more than 97% identical to any of these sequences.

This consensus sequence thus defines an entirely new group of α -amylases. It indicates a region which is located between the two conserved regions C and D depicted in figure 1. This region is a secondary structural element, namely the domains $\beta 4$ and $\beta 7$ of the $(\alpha\beta)_8$ barrel structure, as defined in the article by S. Janecek (1997) in *Prog. Biophys. Mol. Biol.* 67 (1), pp. 67-97, and is regarded as being characteristic and a necessary structural element for the enzyme family of α -amylases, since it ensures optimal spatial arrangement of the other functional part of the molecule, in particular of the active site.

Independently thereof, however, a different rearrangement of domains is also conceivable for newly found or generated sequences. Therefore, all those α -amylases which contain at any position a partial sequence which can be described by the consensus sequence of SEQ ID NO. 263 are also embodiments of the present invention.

The amino acid sequences inside said sequence space are identical within the desired order of magnitude. Thus the two partial sequences of the α -amylases of *Streptomyces sp.* B327* and B400B are homologous to one another with 57% identity at the amino acid level. Overall, the minimum value determined for two of the 231 individual sequences determined was 32% identity and the maximum value was 99% identity at the amino acid level. Thus, each of the sequences found is at least 32% identical to any other sequence within said sequence space. Some values are substantially higher, as can also be estimated on the basis of the values in table 1, since frequently the same known proteins were found to be most similar to the various sequences.

Homologies of more than 30% at the amino acid level between the sequences used are regarded as being

- 33 -

required for methods of obtaining new enzymes via random recombination (e.g., according to Zhao et al. (1998), *Nat. Biotechnol.*, Volume 16, pp. 258-261, Shao et al., (1998), *Nucleic Acids Res.*, Volume 26, pp. 681-
5 683 or Stemmer, W.P.C. (1994), *Nature*, Volume 370, pp. 389-391) and values of more than 45% are advantageous. In providing now this sequence space, in particular its actually disclosed representatives, a pool of related sequences with sufficient sequence
10 homology is provided which makes possible further application-relevant optimization by directed evolution. The diversity of the comprised sequences, on the other hand, suggests varying amylolytic properties with respect to, for example, optimal temperatures or
15 stability to external influences.

Any molecules belonging to said sequence space or groups therefrom, sequence subspaces so to speak, may be selected for such methods. This depends on how many
20 variants are to be generated or whether only particular subregions are to be varied. Two of the sequences belonging to said space already define a separate sequence (sub)space.

25 Since for the consensus sequence sequences of two or more amino acids are allowed in individual positions such as, for example, that of amino acid 28, and since other positions such as 45 or 70 may also remain unoccupied, homologies may also result within this
30 consensus sequence defined by 100 amino acid positions, whose percentages are not integers.

For this reason, any amylolytic proteins whose amino acid sequence comprises a portion of which 98% and,
35 increasingly preferably, 98.25%, 98.5%, 98.75%, 99%, 99.25%, 99.5%, 99.75%, and particularly preferably 100%, are defined by the consensus sequence of SEQ ID NO. 263 are claimed according to the invention. As

- 34 -

setforth above, this applies in particular to the subregion corresponding to positions 8 to 93.

5 This argumentation applies particularly to those amylolytic proteins whose amino acid sequence comprises a portion of which 98% and, increasingly preferably, 98.25%, 98.5%, 98.75%, 99%, 99.25%, 99.5%, 99.75%, and particularly preferably 100%, are identical to any of the amino acid sequences indicated in SEQ ID NO. 34 to
10 SEQ ID NO. 262, in particular across the subregion corresponding to positions 8 to 93 according to the consensus sequence of SEQ ID NO. 263.

15 For the relevant partial sequences have been determined for said proteins in the above-described manner and are provided by the sequence listing. The result of the database search, which is depicted in table 1, was that there is up until now no known α -amylase which contains any of the partial sequences indicated. The highest
20 homology found was 97% (see above). These amino acid sequences define a sequence space which is also included within the scope of protection. Thus each point of said sequence space is a partial sequence of the invention and a solution of the prescribed object.

25 In particular, those enzymes which carry conserved substitutions [lacuna] either or both of the apparently highly conserved positions 11 and 75 which are occupied throughout with histidine and leucine, respectively, in
30 the consensus sequence are included within the scope of protection. Said substitutions include any of the basic amino acids lysine, arginine or proline for the histidine and/or any of the aliphatic amino acids glycine, alanine, valine or isoleucine for the leucine.

35 The α -amylases of said sequence space are characterized in that said genes coding for said α -amylases can be used as templates in a PCR together with the primer

- 35 -

pair GEX024/GEX026 to amplify fragments which can be defined by the consensus sequence of SEQ ID NO. 263 and which are identical to any of the partial sequences indicated in the sequence listing. Owing to the nature of the PCR, the subregions from positions 8 to 93 are particularly characteristic for the fragments in question.

This was shown in example 1 for the following *Streptomyces* sp. strains: B101A, B114C, B134, B135A, B138A, B152A, B153(B), B156B, B157C, B158A, B160B, B161A, B373, B375, B380, B390, B392A and B394. Sequencing of the PCR products of the genomic DNA of said Actinomycetales isolates from various natural habitats and deduction of the corresponding amino acid sequence resulted in the sequences which are listed in the sequence listing under the following numbers: 45, 83, 97, 98, 101, 108, 109, 111, 112, 113, 115, 116, 232, 234, 236, 238, 239 and 241.

As table 1 reveals, the amylase of the strain *Streptomyces* sp. B392A has the highest degree of homology of the amylases listed here to a known α -amylase in the region of the consensus sequence. Said homology is 97% to the *Streptomyces coelicolor* A3(2) α -amylase (database entry AL352956). These amino acid sequences define a sequence space which is subspace of the sequence space defined by the consensus sequence of SEQ ID NO. 263 and which is included within the preferred scope of protection. Thus, each point of said sequence space is a partial sequence of the invention and a preferred solution of the prescribed object.

In other words, any α -amylases are claimed whose amino acid sequences can be homologized in a subregion with the consensus sequence of SEQ ID NO. 263, having in said region only those amino acids which are located at the corresponding position in any of these three

- 36 -

sequences. In accordance with this, they may be traced back to any of said sequences in each position of said portion.

5 For this reason, any amylolytic proteins whose amino acid sequence comprises a portion which is 98% and, increasingly, preferably, 98.25%, 98.5%, 98.75%, 99%, 99.25%, 99.5%, 99.75%, and particularly preferably 100%, identical to any of said sequences or which can
10 be traced back directly to any of said sequences in each homologous position are claimed according to the invention. As set forth above, this applies in particular across the subregion corresponding to positions 8 to 93.

15 In the examples, the α -amylases of the strains *Streptomyces* sp. B327*, B400B, and B327 are studied in more detail. The subregions of these amylases, which correspond to the consensus sequence (SEQ ID NO. 263)
20 are depicted in the sequence listing under SEQ ID NO. 2, 4 and 208. Table 1 reveals that the *Streptomyces* sp. B327B α -amylase has the highest degree of homology to any of these amylases, as determined by a database search. Said degree of homology is 94% identity to the
25 *Streptomyces griseus* α -amylase (database entry X57568).

Said amino acid sequences define a sequence space which is a subspace of the sequence space as defined by the consensus sequence of SEQ ID NO. 263 and which is
30 included within the particularly preferred scope of protection. Thus, each point of the sequence space defined by said sequences is a partial sequence of the invention and a particularly preferred solution of the prescribed object. They can be derived by using, via an
35 alignment across the region corresponding to the consensus sequence of SEQ ID NO. 263, in the sequential amino acid positions in each case those amino acids

- 37 -

which are located at the same site in any of the starting sequences mentioned.

For this reason, any amylolytic proteins whose amino acid sequence comprises a portion which is 95% and, increasingly preferably, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5%, and particularly preferably 100%, identical to any of these sequences are claimed according to the invention. As set forth above, this applies in particular across the subregion corresponding to positions 8 to 93.

The α -amylases of the strains *Streptomyces* sp. B327* and B400B are homologous to one another with 57% identity over the entire length of their amino acid sequence, as can be gaged from the alignment of the figure 5, for example. This value makes them appear particularly suitable for random methods for generating new sequences for amylolytic proteins.

These two amylolytic enzymes define, via their complete amino acid sequences indicated also in SEQ ID NO. 6 and 8, respectively a separate sequence space corresponding to the complete proteins. Further members of this space which can be derived from these two sequences by recombination of the amino acids prescribed in the relevant positions likewise achieve the object. They can be deduced via an alignment corresponding to figure 5 by each of said positions being occupied by an amino acid located at the homologous site in either of the two starting sequences.

According to the invention, conserved substitutions should also be possible here. These include substitutions within the following amino acid groups:

- aliphatic amino acids: G, A, V, L, I;
- sulfur-containing amino acids: C, M;
- aromatic amino acids: F, Y, W;

- 38 -

- hydroxyl group-containing amino acids: S, T;
- acid amide group-containing amino acids: N, Q;
- acidic amino acids: D, E;
- basic amino acids: H, K, R, P.

5

Preference is given to those amino acid positions which can be traced back directly to either of the two starting sequences, i.e. which are identical to either of the two prescribed amino acids, over said conserved
10 substitutions.

Thus, any amylolytic proteins whose amino acid sequences can be traced back via a conserved substitution, preferably directly, in each individual
15 homologous position to either of the two sequences of *Streptomyces* sp. B327* and B400B are included within the scope of protection of the present invention.

The object given is preferably achieved by amylolytic
20 proteins having an amino acid sequence which is at least 93% identical to the amino acid sequence indicated in SEQ ID NO. 6, preferably in positions 31 to 461, particularly preferably in positions 210-300. Said amino acid sequence is that of the α -amylase of
25 the invention from the *Streptomyces* sp. B327* Actinomycetales isolate.

Example 4 of the present application illustrates in detail how to obtain such a sequence containing a
30 complete gene. To this end, an expression gene bank is conveniently prepared, i.e. the genomic DNA of the starting organisms in which the special gene is to be found is fragmented and expressed in isolated host organisms.

35

Genes, at least α -amylase genes of Actinomycetales, may be cloned and isolated by carrying out expression cloning in the heterologous host organism *Escherichia*

coli, as example 4 shows. According to Horinouchi et al. (Horinouchi, S. Uozumi, T. Beppu, T. (1980): "Cloning of *Streptomyces* DNA into *Escherichia coli*: Absence of Heterospecific Gene Expression of *Streptomyces* Genes in *E. coli*"; Agric. Biol. Chem., Volume 44 (2), pp. 367-381) a heterologous recognition of the promoters from actinomycetes in the *E. coli* host organism cannot be assumed. Thus it is advisable to use externally inducible promoters, for example the β -Galactosidase promoter of the *E. coli* lac operon (lac promoter) which is inducible by IPTG (isopropylthiogalactoside). Thus, addition of IPTG can induce expression of the genes under the control of said promoter in host strains having a *lacIq* genotype (e.g. JM109).

The *E. coli* strains JM 109, DH 10B and DH 12S proved suitable for cloning the α -amylases derived from Actinomycetales and for the activity-dependent detection thereof, since, although they have the periplasmic enzymes encoded by *maIS* (Freundlieb, S., Boos, W. (1986): "Alpha-amylase of *Escherichia coli*, mapping and cloning of the structural gene, *maIS*, and identification of its product as a periplasmic protein"; J. Biol. Chem. 261 (6), pp. 2946-2953), they showed no significant release of amylase under the experimental conditions. The (Gram-negative) *E. coli* strains JM 109, DH 10B and DH 12S also proved to be suitable hosts with respect to recognizing the ribosomal binding sites (*Shine Dalgarno* sequences) of the amylase genes of the (Gram-positive) Actinomycetales and recognizing the amino-terminal signal sequences and exporting out of the cell to produce the mature enzyme. Obviously, expression of amylases of streptomyces was also nontoxic to the host cells.

- 40 -

Purified genomic DNA from the strains to be studied, from Actinomycetales isolates in example 4, must therefore thus be partially cleaved and a manageable size range related to the expected size of the gene be
5 ligated into appropriately linearized plasmid vectors. The minimum number of clones to be generated for each gene bank is based on the average insert size and the desired covering of the genome. In the case of the Actinomycetales α -amylases, the resulting insert size
10 was from 3 to 5 kb, with a number of clones to be obtained of 40 000.

As an alternative to generating a genomic bank, it is also possible to construct a cDNA bank which is based
15 on the mRNAs, i.e. the actually expressed genes. However, genomic banks are more likely to produce positive results in the case of genes whose expression in the starting organisms is only low or weak, however.

20 The clones obtained are assayed for recombination taking place, for example via the known blue/white selection, and finally for expression of the protein of interest. In the present example, the α -amylase was detected via its enzymic activity. Alternatively,
25 however, an immunochemical detection or a screening via hybridization with known probes would also be possible, for example.

The latter possibility is particularly suitable for
30 genes which are expressed in the host cells weakly, if at all. To this end, it is possible to use, for example, nucleic acid fragments as can be obtained by the PCR described in examples 1 to 3. Those probes which can be derived on the basis of the partial
35 sequences or primer sequences indicated in the sequence listing may also be suitable. When translating the amino acid sequence back to a nucleotide sequence, the particular codon usage should be taken into account.

Said codon usage depends on the starting organisms from which the gene bank has been generated.

5 It is then possible to derive the corresponding DNA sequences from clones tested positively, according to methods known per se. Moreover, said clones are the starting points for all subsequent clonings, modifications, etc.

10 In the case of the *Streptomyces* sp. B327* Actinomycetales isolate (see example 2), the sequence listing depicts the complete DNA sequences obtained in this way and amino acid sequences derived therefrom under SEQ ID NO. 5 and 6.

15 The open reading frame of *Streptomyces* sp. B327* α -amylase (SEQ ID NO. 5) starts with a GTG start codon which is translated into methionine rather than valine to initiate translation. This is also indicated in the
20 sequence listing in the section "misc_feature": for positions 1 to 3, the feature "INIT_MET" applies. In addition, sequences corresponding to the ribosomal binding sites, i.e. the Shine-Dalgarno sequences, are located within up to 10 nucleotides upstream of said
25 start codon.

Overall, the gene comprises 1386 nucleotides coding for a total of 461 amino acids. The first 30 amino acids of these are predicted to be typical signal sequences of
30 Gram-positive bacteria, as can be expected of a secreted enzyme. This is indicated in the sequence listing (SEQ ID NO. 5) by the feature "mat_peptide" which applies to positions 91 to 1383, since this region codes for the mature protein. In the amino acid
35 sequence (SEQ ID NO. 6), positions 201 to 300 correspond to the region which was amplified in PCR typing (example 3), using the primer pair GEX024/GEX026.

The DNA sequences and amino acid sequences obtained for the native and the mature protein of *Streptomyces sp.* B327* α -amylase and the corresponding nucleotide sequence were used to screen the following databases for the most similar entries: Genpept/GenBank (National Center for Biotechnology Information NCBI, National Institutes of Health, Bethesda, MD, USA) and Swiss-Prot (Geneva Bioinformatics (GeneBio) S.A., Geneva, Switzerland; <http://www.genebio.com/sprot.html>). The search was carried out on different days, in each case via the server of the EMBL-European Bioinformatics Institute (EBI) in Cambridge, United Kingdom (<http://www.ebi.ac.uk>). The sequence comparisons were carried out according to the FASTA method (W. R. Pearson, D. J. Lipman, PNAS (1988) 85, pp. 2444-2448), i.e. using the Fasta3 program (Template: blosum62 and default parameters). The result is listed in table 2.

Table 2: Result of the search in the Genpept/GenBank and Swiss-Prot databases via the EMBL server, using the amino acid sequences of the native (complete) and the mature protein (without leader peptide) of *Streptomyces sp.* B327* α -amylase and the corresponding DNA sequences, in each case carried out using the FASTA program.

Sequence	Database	Date	Homology in % identity	Closest hit Acc. No.
complete DNA	EMBL 1.0, 2000; 65.0, 2000; GenBank 121, 2000, 1.0 2001	01.18.01	83.5	U51129
DNA without Leader	EMBL 1.0, 2000; 65.0, 2000; GenBank 121, 2000, 1.0 2001	01.16.01	84.8	U51129
complete protein	Genpept/GenBank 121, 2000	01.24.01	80	U51129
complete protein	Swiss-Prot 39.0, 2000,	01.04.01	78.7	P27350

	EMBL 1.0, 2000			
protein without leader	Genpept/GenBank 121, 2000	01.24.01	82.4	U51129
protein without leader	Swiss-Prot 39.0, 2000, EMBL 1.0, 2000	01.16.01	81.2	P27350

At the protein level, the *Streptomyces* sp. B327* α -amylase is most homologous to the GenBank database entry U51129; the homology is 80% identity across the sequence of the native protein and 82.4% for the mature protein. This most similar enzyme is *Streptomyces albus* α -amylase. In contrast, a search in the Swiss-Prot database produced values of 78.7 and 81.2%, respectively, identity for the entry P27350 as best hit which is *Streptomyces thermoviolaceus* α -amylase. Figure 5 depicts an alignment of the amino acid sequences of the α -amylases of *Streptomyces* sp. B327* and *Streptomyces albus*, which sequences are referred to there as U51129, and B327*, respectively.

Thus, any amylolytic proteins whose amino acid sequence is at least 85% and, increasingly preferably, 87.5%, 90%, 92.5%, 95%, 96%, 97%, 98%, 99%, and very particularly 100%, identical to the amino acid sequence indicated in SEQ ID NO. 6 are claimed in the present application. This applies preferably to positions 31 to 461 of the mature protein, i.e. as far as this can be estimated from the known sequences.

Said degree of identity applies preferably in positions 31 to 461 and particularly preferably in positions 210 to 300 of the increasingly preferred embodiments of more than 95% identity, since the sequence found to be most similar to the latter amino acid region which corresponds to the consensus sequence of figure 3 and SEQ ID NO. 263 is, as already indicated in table 1, a database entry which is 92% identical to said region.

- 44 -

This entry is Y13332, i.e. *Streptomyces* sp. T01 α -amylase.

5 The object of the invention is very particularly achieved by those amylolytic proteins whose amino acid sequence is identical to the amino acid sequence indicated in SEQ ID NO. 6, preferably in positions 31 to 461, particularly preferably in positions 210-300.

10 This protein found in *Streptomyces* sp. B327* may be expressed heterologously in various host cells, as illustrated in detail in examples 5 and 6. It is possible to use, for example, *Streptomyces lividans* TK24 which itself does not secrete any measurable
15 amounts of amylase into liquid media. An example of a suitable expression vector is the expression vector pAX5a (Faß S.H., Engels, J.W. 1996, "Influence of Specific Signal Peptide Mutations on the Expression and Secretion of the alpha-Amylase Inhibitor Tendamistat in
20 *Streptomyces lividans*", *J. Biol. Chem.*, Volume 271 (Number 25), pp. 15244-15252; Figure 6). Expression in this vector is under the control of the constitutive *ermE* promoter. Alternatively, expression in *E. coli* DH 12S, for example, is possible.

25 Example 6 investigates the enzymic properties of this heterologously produced protein. According to this, the maximum activity of *Streptomyces* sp. B327* α -amylase is at 41.3°C. Said amylase is most stable in the weakly
30 acidic to neutral pH range, as determined via its activity. It is more active in a medium with low SDS content than in one without SDS. The activity is slightly reduced in the presence of chelators of divalent cations. These properties make *Streptomyces*
35 sp. B327* α -amylase an interesting candidate for industrial applications. Further developments of this enzyme via molecular-biological methods are, within the

- 45 -

similarity range defined above, incorporated within the scope of protection of the present application.

Commercial applications of this amylolytic protein are
5 illustrated in more detail and by way of example further below.

An α -amylase of the invention was also obtained from the Actinomycetales isolate B400B, in the same way as
10 described above for *Streptomyces* sp. B327* α -amylase. The complete DNA sequence of the former and the amino acid sequence derived therefrom are depicted in the sequence listing under SEQ ID NO. 7 and 8.

15 The open reading frame of the nucleotide sequence comprises 1377 nucleotides in total. It starts with a TTG start codon which, like in the corresponding enzyme in *Streptomyces* sp. B327*, is translated as methionine rather than leucine to initiate translation. This is
20 also indicated in the sequence listing (SEQ ID NO. 7) in the section "misc_feature": the feature "INIT_MET" applies to positions 1 to 3. The subsequent region likewise comprises the ribosomal binding sites.

25 The first 29 amino acids are predicted to be an export signal sequence (of the proenzyme) so that the mature protein begins with the amino acid sequence TPPGE. This is indicated in the sequence listing (SEQ ID NO. 7) by the feature "mat_peptide" which applies to positions 88
30 to 1374, since this region codes for the mature protein. SEQ ID NO. 8 depicts the complete amino acid sequence in which the mature protein starts at position 30. The positions 200 to 296 correspond to the region which was amplified in PCR typing (example 3) using the
35 primer pair GEX024/GEX026. The protein comprises 458 amino acids.

This enzyme and, respectively, the DNA coding for this enzyme were subjected to the same database searches as the enzyme of strain B327*; table 3 summarizes the results of said searches.

5

Table 3: Result of the search in the Genpept/GenBank and Swiss-Prot databases via the EMBL server, using the amino acid sequences of the native (complete) and the mature protein (without leader peptide) of *Streptomyces sp.* B400B α -amylase and the corresponding DNA sequences, in each case carried out using the FASTA program.

Sequence	Database	Date	Homology in % identity	Closest hit Acc. No.
complete DNA	EMBL 1.0, 2000; 65.0, 2000; GenBank 121, 2000, 1.0 2001	01.19.01	81.9	U08602
DNA without Leader	EMBL 1.0, 2000; 65.0, 2000; GenBank 121, 2000, 1.0 2001	01.17.01	82.6	U08602
complete protein	Genpept/GenBank 121, 2000	01.24.01	76.8	U08602
complete protein	Swiss-Prot 39.0, 2000, EMBL 1.0, 2000	01.04.01	71.6	P08486
protein without leader	Genpept/GenBank 121, 2000	01.24.01	77.7	U08602
protein without leader	Swiss-Prot 39.0, 2000, EMBL 1.0, 2000	01.16.01	72.2	P08486

At the protein level, the *Streptomyces sp.* B400B α -amylase is most homologous to the GenBank database entry U08602; the homology is 76.8% identity across the sequence for the native protein and 77.7% for the mature protein. This most similar enzyme is *Streptomyces sp.* (GenBank Acc. No. U8602) α -amylase. In contrast, a search in the Swiss-Prot database produced values of 71.6 and 72.2%, respectively, identity for

20

- 47 -

the database entry P08486 as best hit which is *Streptomyces hygroscopicus* α -amylase. Figure 5 depicts an alignment of the amino acid sequences of the α -amylases of *Streptomyces* sp. B400B and *Streptomyces* sp. (GenBank Acc. No. U8602); the amino acid sequences in question are referred to there as U08602, and B400B, respectively.

Thus any amylolytic proteins whose amino acid sequence is at least 80% identical and, increasingly preferably, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, 96%, 97%, 98%, 99%, and very particularly 100%, identical to the amino acid sequence indicated in SEQ ID NO. 8 are claimed in the present application.

This applies preferably to positions 30 to 448 of the mature protein, i.e. as far as this can be estimated from the known sequences.

This applies particularly preferably to positions 200 to 296, since the sequence found to be most similar to this amino acid region which corresponds to the consensus sequence of figure 3 and SEQ ID NO. 263 is, as already indicated in table 1, a database entry (M15540) which is only 74.2% identical to said region and which is again the *Streptomyces hygroscopicus* α -amylase, since the EMBL entry M15540 corresponds to the entry P08468 in Swiss-Prot.

The object of the invention is very particularly achieved by those amylolytic proteins whose amino acid sequence is identical to the amino acid sequence indicated in SEQ ID NO. 8, preferably in positions 30 to 448, particularly preferably in positions 200 to 396.

This protein found in *Streptomyces* sp. B400B may be expressed heterologously in various host cells, for

- 48 -

example *Streptomyces lividans* or *E. coli*, as illustrated in detail in examples 4 and 5 and already indicated further above for *Streptomyces* sp. B327* amylase. It is thus available for all commercial applications, as are illustrated in detail and by way of example further below.

Further embodiments of the present invention are fragments of amylolytic proteins or amylolytic proteins obtainable by deletion mutation, which can be derived from any of the above-described proteins.

This includes, for example, those fragments which contribute to the complexing of a substrate or to the formation of a structural element required for hydrolysis. They may be individual domains, for example. Such fragments may be less expensive to produce, may no longer possess particular, possibly disadvantageous characteristics of the starting molecule, such as possibly an activity-reducing regulatory mechanism, or may develop a more advantageous activity profile. Protein fragments of this kind may also be prepared non-biosynthetically, for example chemically. Methods of this kind are known, for example, from "Lexikon der Biochemie" [Encyclopedia of Biochemistry], Spektrum Akademischer Verlag, Berlin, 1999, volume 2, pp. 194-196. Chemical synthesis, for example, may be advantageous when chemical modifications are to be carried out after synthesis.

The generation of amylolytic deletion variants appears useful for deleting inhibiting regions, for example. The result may be, in addition to the deletions, both a specialization and an extension of the application range of the protein.

According to WO 99/57250, it is thus possible, for example, to provide a protein of the invention or parts

thereof via peptidic or nonpeptidic linkers with binding domains of other proteins and thereby to render substrate hydrolysis more effective. It is likewise possible to link amylolytic proteins of the invention
5 also to proteases, for example, in order to obtain bifunctional proteins.

The proteins and signal peptides obtainable by cleaving the N-terminal amino acids from preproteins may also be
10 regarded as naturally produced fragments or deletion-mutated proteins. A cleavage mechanism of this kind may also be used in order to initially provide recombinant proteins with specific cleavage sites with the aid of particular sequence regions recognized by signal
15 peptidases. Thus it is possible to activate and/or deactivate proteins of the invention *in vitro*. It is also possible to remove by deletion individual regions comprising in each case no more than 15 consecutive, and increasingly preferably no more than in each case
20 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 consecutive amino acids and one amino acid from the molecule. This is particularly expedient when the contribution to the washing performance is not reduced or is even improved thereby.

25 According to the statements made above, increasingly preference is given to those fragments or deletion variants which comprise portions which, within the homology values indicated above, correspond completely
30 or partly to positions 210 to 300 of SEQ ID NO. 6 and, respectively, 200 to 296 of SEQ ID NO. 8, and particularly to those which comprise portions which, within the homology values indicated above, correspond to positions 8 to 93 of the consensus sequence of
35 figure 3 and SEQ ID NO. 263.

The object of the invention is furthermore achieved by amylolytic proteins obtainable by insertion mutation or

by amylolytic chimeric proteins, which comprise, at least in a portion imparting an amylolytic activity, any of the above-described proteins, particularly a corresponding mature protein, very particularly a portion of the above-described proteins which corresponds to positions 8 to 93 according to SEQ ID NO. 263.

According to the invention, the proteins obtained by the fusion are intended to have, cause or modify a function which is in the broadest sense amylolytic or a function supporting the hydrolysis of α -1,4-glycosidic bonds. That function may be exerted or modified by a molecule part which is derived from a protein of the invention and which is within the similarity range claimed above for this molecule part.

Such molecule parts may be portions which may be recognized via their consensus sequences or boxes as being homologous to the enzymes from other organisms. Such regions usually impart to the enzyme its characteristic enzymic functions and may also be distributed across various domains, i.e. globular regions of the protein molecule. The invention therefore also relates to those chimeric proteins which, owing to their construction, have, where appropriate, a lower identity across their entire amino acid and/or nucleotide sequence than defined above for the similarity range of the invention but which may be assigned to said range in at least one of the regions introduced by fusion and which exert in this portion the same functions as in an amylase which is within the above-defined homology range.

This applies to the proteins which can be derived from SEQ ID NO. 6 or 8 but also to the regions outside the consensus sequence depicted in SEQ ID NO. 263, since said sequence defines especially a highly variable

- 51 -

region of α -amylases, as shown in example 1.

Owing to their similarity in principle, the same also applies to variants to be obtained by insertion
5 mutation of the abovementioned amylolytic proteins. The purpose of insertion mutagenesis is, in particular, to combine individual properties of proteins of the invention with those of other proteins. Proteins or
10 chimeric proteins according to the invention are obtainable by insertion mutation if the regions which can be traced back via their homology to the abovementioned sequences have appropriate homology values and the variant obtained has an amylolytic function in the broadest sense due to said regions.

15 Thus it is possible, for example, by applying the teaching of WO 99/57250 to couple such an enzyme to a cellulose binding domain in order to increase the interaction with the substrate. Analogously, it is also
20 possible, for example, to fuse other deterative or cleaning-active enzymes to an amylase of the invention. In this connection, it is in principle immaterial whether the fusion takes place at the N or C terminals or via insertion.

25 Amylolytic derivatives of the abovementioned proteins mean those proteins which derive via chemical or biological, in particular molecular biological, modifications from those proteins which themselves have
30 amylolytic activity or which support the hydrolysis of internal α -1,4-glycosidic bonds and which are within the similarity range indicated above. Increasing preference is given to derivatives of the correspondingly preferred starting molecules.

35 These molecules are in particular molecules which can be obtained from low molecular weight compounds or from polymers by chemical coupling. The purpose of such a

modification, for example according to the teaching of WO 00/22103, may be a reduction in allergenic action, an optimization of the enzymic parameters, according to WO 99/58651, or an increase in stability, according to 5 EP 1088887. The proteins may also be modified via glycosylation by applying the teaching of WO 00/26354, for example.

Depending on the obtainment, working-up or preparation 10 of a protein, such a protein may be associated with various other substances, in particular if it has been obtained from natural producers of said protein. It may then, but also independently thereof, have been specifically admixed with particular other substances, 15 for example to increase its storage stability. Derivatives therefore also means any preparations of the abovementioned proteins. This is also independent of whether or not they actually produce said enzymic activity in a particular preparation, since it may be 20 desired that they have only low activity, if any, during storage and produce said activity only when used. This may be controlled, for example, via the folding state of the protein or may result from the reversible binding of one or more accompanying 25 substances or from another control mechanism.

The proteins of the invention may, especially during storage, be protected by stabilizers from, for example, denaturation, decay or inactivation, for example due to 30 physical influences, oxidation or proteolysis. Combinations of stabilizers which complement or enhance one another are also frequently used.

One group of stabilizers are reversible protease 35 inhibitors such as, for example, benzamidine hydrochloride and leupeptin, borax, boric acids, boronic acids, their salts or esters, peptide aldehydes or purely peptidic inhibitors such as ovomucoid or

specific subtilisin inhibitors. Further familiar enzyme stabilizers are amino alcohols such as mono-, di-, triethanol- and -propanolamine, aliphatic carboxylic acids up to C₁₂, dicarboxylic acids, lower aliphatic alcohols, but especially polyols such as, for example, glycerol, ethylene glycol, propylene glycol or sorbitol. Calcium salts are also used, such as, for example, calcium acetate or calcium formate, magnesium salts, a very large variety of polymers such as, for example, lignin, cellulose ethers, polyamides or water-soluble vinyl copolymers, in order to stabilize the enzyme preparation especially against physical influences or pH fluctuations. Reducing agents and antioxidants such as, for example, sodium sulfite or reducing sugars increase the stability of the proteins against oxidative decay.

The object of the invention is also achieved by amylolytic proteins or derivatives which share at least one antigenic determinant with one of the abovementioned proteins or derivatives.

For not only the pure amino acid sequence of a protein but also the secondary structural elements and three-dimensional folding thereof are crucial for exerting enzymic activities. Thus, domains whose primary structures differ distinctly from one another can form structures which substantially correspond spatially and thus make identical enzymic behavior possible. Such common features in the secondary structure are usually recognized as corresponding antigenic determinants by antisera or pure or monoclonal antibodies. Immunochemical crossreactions thus make it possible to detect and classify proteins or derivatives which are structurally similar to one another. Secondly, the immunological crossreaction can readily detect that an amylase of the invention is actually active in an appropriate agent, for example a detergent or cleaning

agent.

Therefore, the scope of protection of the present invention especially also includes those proteins or derivatives which have amylolytic activity and which
5 can be assigned to the above-defined proteins or derivatives of the invention, albeit possibly not via their homologies in the primary structure, but nevertheless via their immunochemical relationship.

10

Conversely, proteins or derivatives of the invention may be used for obtaining, identifying or studying related amylase genes or amylases. This is possible, for example, via any molecular-biological methods which
15 use antibodies against appropriate regions, for example when screening an expression gene bank.

The object of the invention is preferably achieved by the above-defined amylolytic proteins or derivatives if
20 they are obtainable from natural sources. These include samples of natural habitats, scaling-up cultures, cell cultures, isolates or cultured single organisms. Preference is given to microorganisms, since they can be cultured according to the methods established in the
25 prior art and be used directly for obtaining proteins or as starting points for molecular-biological methods.

However, they may also be organisms which themselves can be cultured only with difficulty, if at all, but
30 whose proteins or whose DNA can be isolated from natural habitats and analyzed via methods known per se. Mixtures of such organisms are also possible. Preference is given in each case to those strains which produce the amylolytic protein under controllable
35 conditions and release said protein into the surrounding medium.

Preferred microorganisms are, not least due to their

protein synthesis mechanism and export mechanism, Gram-positive bacteria of which preference is given to those of the order Actinomycetales, since there are appropriate methods available therefor, not least owing
5 to the information in the examples of the present application. As mentioned in the examples, the sequences for amylolytic proteins, on which the present application is based, in particular for part of the consensus sequence of SEQ ID NO. 263, were determined
10 from Actinomycetales.

Further preference is given to amylolytic proteins or derivatives which are characterized in that they are obtainable from a *Streptomyces* species, since in a
15 collection of microbial isolates of the order Actinomycetales, with the majority being of the genus *Streptomyces*, for example, more than 200 α -amylases and their natural producer strains were found and made available by the present application. Among these,
20 preference is given to the isolates or species *Streptomyces* sp. B327* and *Streptomyces* sp. B400B which have been deposited under accession numbers DSM 13990 and DSM 13991 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), since
25 from these the two particularly preferred embodiments of proteins of the invention were obtained, whose DNA and amino acid sequences are indicated in the sequence listing under SEQ ID NO. 5 to 8.

30 Some Actinomycetales can produce more than one α -amylase. In this case, it may be advantageous to culture a natural producer of a plurality of α -amylases which can possibly complement one another with respect to their biochemical properties. This may be utilized,
35 for example, for producing an enzyme cocktail with a broad action range. Strains of this kind thus characterize particularly advantageous embodiments of the present invention.

SEQ ID NO. 34 to SEQ ID NO. 262 describe the amino acid sequences which are derived from particular PCR products, as illustrated above and in example 1. They
5 have been obtained by reacting the nucleic acids isolated from a collection of several hundred Actinomycetales isolates as templates in polymerase chain reactions with the primer pairs GEX024 (SEQ ID NO. 9)/GEX026 (SEQ ID NO. 10) and GEX029 (SEQ ID
10 NO. 11)/GEX031 (SEQ ID NO. 12). The positions 8 to 93 according to the consensus sequence of SEQ ID NO. 263 are located within the primers GEX024 and GEX026 so that they can be regarded as particularly characteristic of the sequences found. Thus the nucleic
15 acids coding for these regions also characterize correspondingly preferred embodiments. The consensus sequence depicted in figure 3 and SEQ ID NO. 263 was derived from these individual sequences and defines a sequence space. Thus the present invention provides
20 amylases which comprise a portion which can be described substantially by said consensus sequence.

Therefore, the corresponding nucleic acids must also be regarded as solutions to the object of the invention
25 and thus as separate subject matter of the invention for the following reasons: firstly, proteins become molecular-biologically accessible when the corresponding genes are available. This applies to identification and characterization via mutagenesis up
30 to biotechnological production. The nucleotide sequences derived due to the codon usage which varies between the different organisms and ribonucleic acids are also included, since functional enzymes can be derived from them, too. Corresponding nucleic acids may
35 also be used for obtaining, identifying or studying amylase genes. Thus it is possible, for example, to design corresponding probes for screening gene banks.

- 57 -

Secondly, the abovementioned method for finding the α -amylases in question, which is detailed in the examples, is based on the PCR and thus on the corresponding nucleic acids. The sequence listing indicates not least the nucleotide sequences of two particularly preferred α -amylases (SEQ ID NO. 1, 3, 5 and 7); the nucleic acids coding for the remaining sequences can be deduced according to methods known per se.

10

Thus nucleic acids are claimed which code for amylolytic proteins whose amino acid sequences comprise a portion of which 98% and, increasingly preferably, 98.25%, 98.5%, 98.75%, 99%, 99.25%, 99.5%, 99.75%, and particularly preferably 100%, is described by the consensus sequence of SEQ ID NO. 263, in particular via the subregion corresponding to positions 8 to 93.

Nucleic acids which code for the variants possible according to the consensus sequence may be prepared according to generally known methods. For example, the "Lexikon der Biochemie" [Encyclopedia of Biochemistry], Spektrum Akademischer Verlag, Berlin, 1999, introduces in volume 1, pp. 267-271 methods for de-novo synthesis of DNA and in volume 2, pp. 227-229, the polymerase chain reaction (PCR). The sequences may be predefined according to the generally known coding system for amino acids, where appropriate using a codon usage which is characteristic of particular genera. Moreover, the DNA sequences indicated in SEQ ID NO. 1 and 3 may be used as starting points for synthesizing further nucleotide sequences by introducing the corresponding point mutations in those positions of said sequences which correspond to the desired variations of the invention.

For this purpose, all common and convenient methods may be used, as are known, for example, from the manual

Fritsch, Sambrook and Maniatis "Molecular cloning: a laboratory manual", Cold Spring Harbor Laboratory Press, New York, 1989. As example 5 indicates, a PCR may also be used for introducing individual base
5 substitutions into DNA.

An alternative possibility is to find, via a PCR, as described further above and in the examples, on nucleic acids from isolates of natural sources or of known
10 strains, new genes or gene fragments whose derived amino acid sequence is described by the consensus sequence of SEQ ID NO. 263.

As the examples illustrate on the basis of the
15 α -amylases from B327* and B400B, the complete genes belonging to the partial sequences may be found, for example, by expression cloning, screening of gene banks or comparable method steps. These include, for example, the cloning of genomic or cDNA into an expression
20 vector with an α -amylase deletion mutant. Streptomyces or Bacillus species are preferred for intermediate cloning steps.

The genetic and protein-biochemical methods listed
25 under the term protein engineering in the prior art are also based on the nucleotide sequence. Such methods may be used to further optimize proteins of the invention with regard to various uses, for example by point mutagenesis or fusion with sequences of other genes.

30 The object of the invention is preferably achieved by nucleic acids which code for amylolytic proteins whose amino acid sequences comprise a portion which is 98% and, increasingly preferably, 98.25%, 98.5%, 98.75%,
35 99%, 99.25%, 99.5%, 99.75%, and particularly preferably 100%, identical to any of the amino acid sequences indicated in SEQ ID NO. 34 to SEQ ID NO. 262, in particular via the subregion corresponding to positions

8 to 93 according to the consensus sequence of SEQ ID NO. 263.

For the definition of the abovementioned sequence space
5 was based on said α -amylases which, on the other hand, embody proteins or protein fragments which have been successfully assayed for amylase activity. Moreover, as summarized in table 1, there are up to now no known proteins which are more than 97% identical to any of
10 these protein fragments.

The nucleotide sequence to be deduced for each of these fragments may be readily introduced in mutagenesis, in particular optimization, steps or used for screening
15 for the complete sequences. This is illustrated in the examples on the basis of the α -amylases of B327* and B400B. A corresponding positive result can be expected for any other of the fragments disclosed in the sequence listing and SEQ ID NO. 13 to SEQ ID NO. 242. A
20 single negative result which may occur here may be attributed to strain-specific characteristics. Thus it is conceivable, for example, that the gene involved is a gene which has been produced by duplication and then been inactivated by mutation or a gene which is not
25 activated in the living cells for previously unknown reasons.

Thus each nucleic acid coding for the fragments disclosed in SEQ ID NO. 13 to SEQ ID NO. 242 is also an
30 alternative solution to the object on which the invention is based. At least it maps the path to a complete α -amylase and characterizes the latter in the region corresponding to the consensus sequence of SEQ ID NO. 263.

35

Further preferred embodiments of this subject matter of the invention are nucleic acids coding for amylolytic proteins whose amino acid sequence comprises a portion

which is 98% and, increasingly preferably, 98.25%, 98.5%, 98.75%, 99%, 99.25%, 99.5%, 99.75%, and particularly preferably 100%, identical to any of the amino acid sequences indicated in SEQ ID NO. 45, 83, 5 97, 98, 101, 108, 109, 111, 112, 113, 115, 116, 232, 234, 236, 238, 239 and 241 to any of said sequences or which can be traced back in each homologous position directly to any of said sequences, in particular via the subregion corresponding to positions 8 to 93 10 according to the consensus sequence of SEQ ID NO. 263.

For in example 1, the PCR products of DNA to be obtained using the two primer pairs GEX024/GEX026 and GEX029/GEX031 were obtained from the following isolates 15 or strains of *Streptomyces* sp.: B101A, B114C, B134, B135A, B138A, B152A, B153(B), B156B, B157C, B158A, B160B, B161A, B373, B375, B380, B390, B392A and B394. Figure 2 depicts the gel-electrophoretic fractionation thereof. Sequencing thereof and derivation of the 20 corresponding amino acid sequence resulted in the amino acid sequences mentioned.

Thus any nucleic acids which code for proteins having a portion which are within the above-defined similarity 25 range are embodiments of this subject matter of the invention. As illustrated above, this applies in particular to the subregion corresponding to positions 8 to 93 according to the consensus sequence of SEQ ID NO. 263.

30

Further preferred embodiments of this subject matter of the invention are nucleic acids coding for amylolytic proteins whose amino acid sequence comprises a portion which is 95% and, increasingly preferably, 96%, 96.5%, 35 97%, 97.5%, 98%, 98.5%, 99%, 99.5% and particularly preferably 100%, identical to any of the amino acid sequences indicated in SEQ ID NO. 2, 4 and 208, in particular via the subregion corresponding to positions

8 to 93 according to the consensus sequence of SEQ ID NO. 263, very particularly preferably a nucleic acid having a nucleotide sequence indicated in SEQ ID NO. 1 or 3.

5

For the complete proteins obtained via said partial sequences were tested for their biochemical properties in example 6. They therefore seem to be promising candidates for use in industrial processes or for
10 further optimization with regard to industrial processes. Similar properties are to be expected for the proteins which may be obtained starting from the nucleic acids of this subject matter of the invention.

15 Particularly preferred embodiments are those nucleic acids which code for an amylolytic protein whose amino acid sequence can be traced back via a conserved amino acid substitution, preferably directly, in each individual homologous position to any of the two
20 sequences SEQ ID NO. 6 or SEQ ID NO. 8.

For, as has already been illustrated above, these two amino acid sequences define a sequence space which encompasses the further embodiments of the present
25 invention via conserved substitutions or direct adoption of the amino acids prescribed in said two sequences. Accordingly, the corresponding nucleic acids are also embodiments of the present invention.

30 Referring back to the amino acid sequence is necessary, because direct adoption of one or other nucleobase from the two prescribed nucleotide sequences might result in a difference in the codons and thus in non-conserved substitutions at the amino acid level. The scope of
35 protection includes only those nucleotide sequences which code for proteins belonging to the same sequence space. They are obtained by adopting the relevant codons or by substituting with those codons which code

for the same amino acids (synonymous codons) or conserved amino acids according to the groups indicated above.

5 Preferred embodiments of this subject matter of the invention are those nucleic acids which are sufficiently similar to the α -amylase gene of *Streptomyces* sp. B327*, since they can be expected to code for enzymes equally as promising as the α -amylase
10 characterized in example 6 or to be introduced in methods for the optimization thereof.

Table 2 reveals that the gene most similar to B327* at the DNA level is the α -amylase gene from *Streptomyces*
15 *albus*, filed in GenBank under accession number U51129. Said gene is 83.5% identical with respect to the complete sequence indicated in SEQ ID NO. 5 and 84.8% identical with respect to the portion coding for the mature protein.

20 This portion is encoded by nucleotides 91 to 1383 in the sequence indicated in SEQ ID NO. 5. The nucleotides 628 to 900 correspond to the amino acids of the consensus sequence (figure 3 and SEQ ID NO. 263).

25 Thus those nucleic acids coding for amylolytic proteins, whose sequence is at least 85% identical to the nucleotide sequence indicated in SEQ ID NO. 5, preferably in positions 91 to 1383, particularly
30 preferably in positions 628 to 900, are claimed as preferred representatives of this subject matter of the invention.

Increasingly preferably those nucleic acids coding for
35 amylolytic proteins are claimed whose sequence is at least 87.5%, 90%, 92.5%, 95%, 96%, 97%, 98%, 99% and 100% identical to the nucleotide sequence indicated in SEQ ID NO. 5, preferably in positions 91 to 1383,

particularly preferably in positions 628 to 900.

Preferred embodiments of this subject matter of the invention are those nucleic acids which are
5 sufficiently similar to the α -amylase gene of *Streptomyces* sp. B400B, since they can be expected to code for enzymes equally as promising as the α -amylase characterized in example 6 or to be introduced in methods for the optimization thereof.

10

Table 3 reveals that the most similar gene at the DNA level is that for *Streptomyces* sp. α -amylase (GenBank Acc. No. U08602). These two sequences are 81.9% identical across the sequence coding for the native
15 protein and 82.6% identical with respect to the sequence for the mature protein.

The mature portion is encoded by nucleotides 88 to 1374 of the sequence indicated in SEQ ID NO. 7. The
20 nucleotides 598 to 888 correspond to the amino acids of the consensus sequence (figure 3 and SEQ ID NO. 263).

Thus those nucleic acids coding for amylolytic proteins, whose sequence is at least 85% identical to
25 the nucleotide sequence indicated in SEQ ID NO. 7, preferably in positions 88 to 1374, particularly preferably in positions 598 to 888, are claimed as preferred representatives of this subject matter of the invention.

30

Increasingly preferably those nucleic acids coding for amylolytic proteins are claimed whose sequence is at least 85%, 87.5%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% and 100% identical to the nucleotide
35 sequence indicated in SEQ ID NO. 7, preferably in positions 88 to 1374, particularly preferably in positions 598 to 888.

Correspondingly preferred embodiments of this subject matter of the invention are the nucleic acids which code for any of the above-defined amylolytic proteins or fragments.

5

This also includes those variants which in individual regions, although not over the entire length of their sequence, are within the above-defined similarity range. These include, for example, the nucleotide
10 sequences which, as set forth above, have been obtained by insertion or deletion mutation, chimeric proteins or protein fragments. However, "antisense constructs" are, for example via individual subsections, also embodiments of the present invention, since they can
15 produce sequence information about amylolytic proteins and be used for regulating the amylolytic activity.

The mutants obtainable via molecular-biological methods known per se include in particular those having single
20 specific base substitutions or randomized point mutations, deletions of individual bases or of partial sequences, fusions with other genes or gene fragments or other enzymes, insertions, shuffling mutagenesis or inversions. Mutations or modifications of this kind may
25 represent particular embodiments for specific applications.

A mutagenesis of this kind may be carried out target-specifically or via random-type methods. This may be
30 combined, for example, with a subsequent method for screening and/or selecting the cloned genes for activity. The genes obtained by mutation are subject to the scope of protection of the invention described herein, if they code for amylolytic proteins in the
35 broadest sense and are within the above-defined similarity range; in particular, with regard to the latter, in homologous and functionally relevant regions.

As is obvious from the previous statements and from example 1, the methods indicated may be used to characterize numerous organisms in that the latter
5 produce amylolytic proteins which comprise portions described by the consensus sequence of figure 3 or SEQ ID NO. 263.

Thus any natural organisms which comprise nucleic acids
10 coding for any of the proteins or protein fragments defined in the sequence listing under SEQ ID NO. 263 are a separate subject matter of the invention. They may be isolated from natural habitats and cultured according to methods known per se, in particular those
15 provided by the present application. In addition to any microbiological characterization, they can be identified by the fact that amplification products whose derived amino acid sequence can be described by the consensus sequence of figure 3 or SEQ ID NO. 263
20 can be obtained on the basis of their genomic DNA, using one of the PCR primers mentioned in example 1, in particular the pair GEX024/GEX026.

Preference is given to those natural organisms from
25 which an amino acid sequence can be derived in this way, which is identical to any of the sequences indicated in the sequence listing under SEQ ID NO. 34 to 262 and particularly preferably to any of the sequences indicated under SEQ ID NO. 2, 4, 6 or 8.

30 This applies to all organisms, for example eukaryotic cells, e.g. from cell cultures, or predominantly unicellular fungi such as yeasts.

35 This applies preferably to microorganisms, preferentially to bacteria, very particularly preferably to Gram-positive bacteria.

- 66 -

Among Gram-positive bacteria, preference is given to those of the order Actinomycetales, in particular of the genus *Streptomyces*.

5 Of these, in turn, preference is given to the two species *Streptomyces* sp. B327* and *Streptomyces* sp. B400B, in particular in the case of either of the two strains DSM 13990 or DSM 13991.

10 As illustrated above and in the examples, the multiplicity of α -amylases of the invention were provided via a specially developed method which therefore constitutes a separate subject matter of the invention.

15

Thus PCR-based methods for identifying and/or obtaining new amylases from a collection of organisms or nucleic acids are claimed, which methods are characterized in that PCR primers are used which in each case have a
20 variable 3' region and a 5' region highly homologous to regions of known amylases.

The polymerase chain reaction (PCR) method is established in the prior art and is described, for
25 example, in "Lexikon der Biochemie" [Encyclopedia of Biochemistry], Spektrum Akademischer Verlag, Berlin, 1999, volume 2, pp. 227-229. It is based on melting open, in the first step, a double-stranded DNA template at an elevated temperature, (2.) short single-stranded
30 DNA molecules, the primers or primer oligonucleotides, binding to positions of the melted-open DNA, which are sufficiently homologous for hybridization, at low temperature, and (3.) extending said short DNA molecules from the 5' to the 3' end at medium
35 temperature as in natural DNA synthesis. This produces in the first cycle two copies of the DNA region which is located between the two primer binding sites in the initially melted-open DNA. In (4.) a cyclic reaction

process, as is possible by using a heat-stable DNA polymerase, for example, an increasing number of cycles produces an exponentially increasing number of identical DNA molecules across the DNA region flanked
5 by the two primer sequences.

The method of the invention is characterized by novel primers for the PCR, which are characterized by a variable 3' section and a 5' region which is highly
10 homologous to DNA and/or amino acid regions of known amylases. The 5' regions of the primers are preferably regions which were found to be conserved regions in a sequence comparison at the protein level, preferably at the DNA level, with various homologizable amylases and
15 which are located adjacent to variable regions of the homologized genes or proteins in question. An assignment of this kind is depicted in figure 1, for example.

20 The border between the 3' and 5' primer regions defined in this way is identical to the border between the conserved and variable amylase regions, found via homologization. If doubt exists, the variable region starts where the synthesis (see below) has generated a
25 variance.

High homology in this connection means that said primers, in their 5' region, (a) are 100% identical to the regions under consideration of known enzymes or
30 consensus sequences or (b) if they are less than 100% identical, still have a sufficient degree of matches in individual positions in order to hybridize with a likewise homologizable template DNA in the region suggested by sequence comparison in the hybridization
35 phase of a PCR cycle and to make possible a DNA synthesis reaction in the further course of the PCR.

Variable or degenerated PCR primers have at defined

positions in each case a random mixture of a selection of two, three or four different nucleotides rather than one particular nucleotide, so that the identity of the primers rather than their overall length is varied. The
5 degree of variability of the primer pool obtained increases exponentially with the number of variable individual positions. These variations may be introduced during synthesis of the primers, in particular chemical synthesis, according to methods
10 known per se. This requires using, at the point in time at which the nucleotide for a particular position is incorporated, said reagent not as pure nucleotide but as nucleotide mixture. In this way, a number of primers with identical 5' regions are produced which divide
15 into numerous subpopulations containing any statistically possible nucleotides in the particular variable regions.

Said novel primers produce in the presence of gene
20 sequences of amylolytic proteins a product band corresponding to said proteins. They render the variable region located in between accessible and are therefore also referred to as sequence anchors.

25 The template used for the PCR of the invention may be any DNA preparations. Owing to the comparatively small amount of work required for a single sample, it is possible to set up a plurality of reaction mixtures in parallel. The method of the invention is thus
30 particularly suitable for screening a collection of nucleic acids prepared from a multiplicity of organisms according to methods known per se. The templates may also be cDNA or even mRNA preparations, if the PCR is designed accordingly, as is sufficiently described in
35 the prior art.

In a variation of the reaction process, the degenerated primers are added only to the first reaction cycles

- 69 -

and/or, after the first cycles, the primers which correspond to the constant regions of the primers important to the invention are added. A third possibility is to carry out two separate PCRs. In this way, the relevant genetic elements of the template are concentrated in the first cycles using the degenerated primers and then specifically amplified in the subsequent cycles.

10 The selection of said possibilities or further modifications, in particular in conducting the PCR, depends, for example, on the selectivity of primer binding or on the frequency of the DNA used as template containing the genetic element amplifiable in this way.

15 The selectivity of the PCR can be regulated via the reaction conditions in a manner known per se. At low temperatures, for example, the primers hybridize with DNA regions which are not identical and/or have only low homology; at higher temperatures, the selectivity increases. In this way it is possible to access α -amylase sequences which do not completely correspond to the previously known amylase genes, even in the highly homologous regions. On the other hand, primer binding must not be so unspecific that the proportion of genes not coding for amylases does not gain the upper hand compared to the desired product. The optimum must be determined in the individual case by varying the reaction conditions.

30 The multiplicity of possible variations make it possible to adapt to many different problems, for example to different starting DNA collections, and render the method of the invention a very flexible instrument for finding new amylase sequences.

35 This optimization is carried out against the background that, when studying DNA sequences from collections of related nucleic acids, advantageously a number of

α -amylase sequences should be obtained which, although themselves diverse, do not fall short of a certain degree of homology to one another (see above), since they may then be used for defining a sequence space and
5 for random mutagenesis methods such as shuffling, for example.

In this way, the primer combinations GEX029/GEX031 and in particular GEX024/GEX026 were found to be optimal
10 for a collection of DNA from Actinomycetales in example 1.

The PCR products obtained are used for the search for complete amylase sequences. Said PCR is thus a
15 screening step via which particular genes or gene fragments from a gene bank or collection of isolated nucleic acids are identified. The PCR fragments obtained or corresponding genes, including all of their deviations in individual positions, constitute a
20 sequence space. They are also typed in this way, since they may be regarded via this common sequence as representatives of a particular type of enzyme.

This screening reduces the global diversity to the
25 sequence space of those genes which code for particular enzymes having amylolytic activity. Said sequence space is of particular interest if it contains as large a sequence variability as possible of genes for such enzymes.

30 A preferred aim, to be taken into account even when constructing the primers, may be to obtain a variance space for particular enzyme regions such as particular enzymically interesting domains, for example. These are
35 usually domains which provide particular partial activities such as, for example, structural elements or enzymically active amino acids. The fragments forming such a sequence space may be fused to other known

- enzymes or enzyme fragments. They may also be introduced into evolutive techniques for developing new enzymes. Such evolutive techniques for random recombination of various fragments are illustrated, for example, in the patent applications WO 98/05764, WO 97/35966, EP 590689 and EP 229046. A PCR-based method of this kind is, for example, the StEP method described in WO 98/42832.
- 10 Another possible use of the PCR products is the screening of gene banks which is carried out using the DNA fragments obtained by said PCR or parts thereof as probe. To this end, in particular hybridization methods by which sequences with high or low homology can be
15 detected, depending on the stringency of the hybridizations, are established in the prior art. In this way it is possible to identify similar sequences for amylolytic proteins.
- 20 The PCR fragment and the sequence information obtained therewith itself may also be used as starting point for further PCR- and/or sequence-based methods for identifying, isolating or cloning the entire gene. To this end, for example, inverse PCR, A-PCR (anchored
25 PCR) or primer walking are described in the prior art. The complete genes obtained in this way are finally tested for their starch-cleaving activity in an activity assay, for example after cloning into an expression vector.
- 30 All of these methods may be linked in a useful manner to a subsequent assay of the genes or proteins obtained via possible intermediate steps for amylolytic activity. These variations characterize preferred
35 embodiments of this subject matter of the invention.

In one embodiment of this subject matter of the invention, the genes or gene fragments obtained are

sequenced.

Said sequencing may yield information about the identity of the fragments obtained, since, as
5 mentioned, the method depends on the selectivity of the PCR conditions. Thus it is possible, with low-selectivity conditions, for PCR products produced due to unspecific primer binding to fake positive results. Optional sequencing of the products thus avoids
10 unnecessary work. Large PCR products can be sequenced by applying primer walking, for example in a manner as carried out for the complete genes in example 4.

On the other hand, homologization, database searches
15 and the definition of a sequence space may, as examples 1 to 3 show, already be carried out via the PCR products derived from a portion of the gene. The formation of a particular PCR product may characterize individual strains or larger groups such as species or
20 genera and may represent a taxonomic classification feature. This is a valuable aid when culturing said strains.

One embodiment of methods of the invention is
25 characterized in deriving from the genes or gene fragments obtained peptides which are assayed for an epitope of a known amylase via an immunochemical method.

30 Examples suitable for this are also the products of the PCR of the invention. Thus, for example, screening may be carried out with the aid of antibodies which have been synthesized according to methods known per se on the basis of the derived peptides. The amylolytic
35 proteins and derivatives disclosed by the present application are available for particularly preferred embodiments.

- 73 -

As an alternative or in addition to sequencing or to an immunochemical method, α -amylases may also be identified owing to their enzymic activity.

5 Thus preference is given to those methods which are characterized in that peptides are derived from the genes or gene fragments obtained, which are assayed for a contribution to an amylolytic activity, preferably for amylolytic activity completely exerted by said
10 peptides. To this end, the PCR product or the complete gene obtained via a gene bank screen may be expressed by cloning, for example as in example 5.

Particularly long PCR fragments, as result in
15 particular from the choice of appropriate primers, may be cloned directly into expression vectors in the course of expression cloning, without providing accordingly other partial sequences in the vector. The clones obtained are then assayed for starch hydrolyzing
20 activity, for example by plating out on starch-containing agar plates.

In a preferred embodiment, the 3' region of at least one primer is highly variable or highly degenerated
25 and/or the 5' region of at least one primer is highly homologous to a region from known amylases.

Highly variable primers mean, for example, primers with 8-fold, 16-fold, 64-fold, 96-fold, 128-fold or even
30 higher degeneracy or primers with intermediate variabilities. The primers are regarded as highly homologous when the constant 5' regions deviate from the consensus sequence used for construction by no more than two nucleobases, preferably by no more than one
35 nucleobase, with completely identical sequences being particularly preferred.

The primers derived on the basis of figure 1 are listed

- 74 -

in example 1 in table 3 and in the sequence listing under SEQ ID NO. 9 to 33. The variable positions are indicated there in each case by the commonly used one letter codes stated, for example, in WIPO standard
5 ST.25. Thus, for example, the primer GEX024 (SEQ ID NO. 9) has in two positions the abbreviations "s" and "r", which may mean in each case either g or c (for s) and g or a (for r), respectively. Said primer thus has a 4-fold degeneracy. Correspondingly, it is understood
10 that, for example, the degeneracy of the primer GEX026 (SEQ ID NO. 10) is likewise 4 fold, that of the primer GEX029 (SEQ ID NO. 11) is 96 fold and that of the primer GEX031 (SEQ ID NO. 12) is 8 fold.

15 A method of the invention is based on the fact that it is possible to identify regions which are conserved between a plurality of amylases and which may be utilized for constructing the constant regions of the primers of the invention, thereby becoming sequence
20 anchors. Appropriate primers are listed in example 1; figure 1 depicts their position with respect to particular conserved regions.

Accordingly, preference is given to those methods of
25 the invention which are characterized in that the 5' region of at least one PCR primer is derived from a sequence region corresponding to a conserved amylase domain, preferably of a region corresponding to the amino acid positions (A) 58-91, (B) 94-141, (C) 155-
30 207, (D) 295-345 or (E) 392-427 of the *Streptomyces griseus* α -amylase, particularly preferably corresponding to one of the domains β 4 or β 7 of the $(\alpha\beta)_8$ barrel structure.

35 The latter were successfully used in example 1 on Actinomycetales DNA.

The amino acid sequences provided by the present

- 75 -

application and listed in the sequence listing may be used for synthesizing corresponding primers. This applies, for example, also to regions which are not located in the conserved regions but which emerge as
5 common partial sequences in subpopulations, for example individual representatives of the consensus sequence of SEQ ID NO. 263.

Preference is thus given to methods which are
10 characterized in that one, preferably two, PCR primers are used which can be derived from any of the amino acid sequences of a protein or fragment of the first subject matter of the invention.

15 On the other hand, preference is given to those methods which are characterized in that one, preferably two, PCR primers are used which result directly from any of the nucleotide sequences according to the second subject matter of the invention, since these already
20 have a nucleotide sequence which should, owing to the codon usage, be suitable in particular for amplifying sequences from Actinomycetales or other Gram-positive bacteria.

25 Among these, preference is given to methods which are characterized in that at least one primer comprises any of the sequences indicated in the sequence listing under SEQ ID NO. 9 to 33, in particular any of the sequences indicated in the sequence listing under SEQ
30 ID NO. 9 to 12.

Among these, preference is in turn given to methods which are characterized in that the primers are used in the combination of SEQ ID NO. 9 with SEQ ID NO. 10 or
35 of SEQ ID NO. 11 with SEQ ID NO. 12, since these were, as example 1 shows, successfully used for obtaining a multiplicity of α -amylases.

Methods of the invention can be carried out on individual samples. On the other hand, however, preference is given to methods which are characterized in that the template DNA used is isolated nucleic acids of a plurality of samples which can be any biologically useful collections, including, for example, collections of organisms, cell cultures, isolates or cultured individual strains, or is isolated nucleic acids of a sum of organisms, cell cultures, isolates, cultured individual strains or isolated nucleic acids.

Isolated nucleic acid may be purified from samples, for example outdoor isolates, thereby avoiding an isolation step, for example. In this way it is possible to subject a very broad range of different biological sources to a screening of the invention.

As an alternative to obtaining outdoor isolates, it is also possible to obtain various strains from the generally accessible collections of strains or of genetically modified organisms, preferably microorganisms. It is also possible to study various strains from culture collections (DSMZ, ATCC, CBS) by said method.

The method of the invention may also be applied to cell cultures, as generated, for example, from eukaryotes, in particular from humans. This is useful, for example, when the enzymes to be obtained are to be used owing to a particular physiological action or if said enzymes are to be particularly well tolerated, the latter applying in particular to cosmetic applications.

Collections of this kind are preferably those of mainly unicellular microorganisms such as fungi, yeasts, bacteria or cyanobacteria. Preference is given to bacteria, since these are most readily accessible to the microbiological and genetic methods established in

the prior art. Among these, particular preference is given to those of Gram-positive bacteria, since these come closest to industrial applications owing to their ability to export de novo synthesized proteins into the surrounding medium.

According to the remarks above and to the examples of the present application, increasing preference is given to the following methods:

10

Methods characterized in that the template DNA used is isolated nucleic acids of microorganisms, preferably of bacteria and particularly preferably of Gram-positive bacteria; those characterized in that members of the order Actinomycetales, in particular those of the genus Streptomyces, are involved and those characterized in that the members of the genus Streptomyces are *Streptomyces* sp. 327* or *Streptomyces* sp. B400B, in particular either of the two strains DSM 13990 and DSM 13991.

Preferred methods are characterized in that the genes or gene fragments obtained are introduced into an expression gene bank which is then assayed for amylolytic proteins or fragments of amylolytic proteins. Such an assay preferably involves hybridization of nucleic acids, an immunochemical method or an activity assay. Example 4 describes such an expression cloning.

30

The hybridization is carried out in a known manner, described, for example, in the manual by Fritsch, Sambrook and Maniatis "Molecular cloning: a laboratory manual", Cold Spring Harbor Laboratory Press, New York, 1989, by using a nucleic acid of a known amylase as probe in order to identify the sequences substantially complementary thereto in the gene bank. The desired degree of homology may be controlled here via the

35

choice of reaction conditions, i.e. the stringency. Identified sequences of the invention may be recognized via their homology to known amylases, with an activity assay serving as positive control.

5

Banks which already provide expression of the genes they contain are assayed on the basis of the gene products. Suitable for this are antibodies against known α -amylases, and the products found must likewise
10 be checked for their amylolytic activity. These methods are also established in the prior art. Alternatively, the isolated cells of expression banks can be assayed directly for their activity by applying them to starch-containing agar plates, as indicated in the examples.
15 Positive clones can then be recognized by their lysis halos.

Methods of one embodiment are characterized in that the isolated DNA is introduced into an expression vector
20 which provides transcriptional and translational control elements and optionally one or more fragments of an amylase gene so that the overall result in a positive case is an amylase activity.

25 Suitable for this are in particular those vectors into which a fragment obtained is recombined in such a way that complete enzymes are obtained. This can be implemented by means of expression vectors which contain a gene deleted in such a way that cloning of
30 the fragment cancels out exactly this deletion. This embodiment is particularly suitable for PCR fragments which are too short in order to code for a detectable amylolytic activity.

35 Particular preference is given to a method whose activity assay which follows the inventive PCR for screening isolated nucleic acids and which comprises three steps is as follows:

- 79 -

- (a) screening a gene bank, preferably one with complete genes, with the aid of the PCR fragment obtained or a probe derived therefrom,
 - (b) expressing the genes or gene fragments identified
5 in this way, and
 - (c) measuring the contribution to an amylolytic activity of the proteins or protein fragments obtained by said expression.
- 10 Said gene bank may conveniently be a genomic or a cDNA bank. It is possible to carry out the PCR of the invention and the activity assay on the same bank.

15 The term screening means a screening established in the prior art, in particular the abovementioned assaying of the banks via hybridization with nucleic acids. In this case, the partial sequences obtained by the PCR of the invention rather than partial sequences of known amylases are used. Screening the gene banks then serves
20 to identify clones which comprise the corresponding complete amylase gene.

Alternative methods known from the prior art comprise using the PCR fragment obtained as starting point for
25 an inverse PCR or an anchored PCR (a-PCR) or for sequencing by primer walking.

Preference is given to those methods in which the nucleic acids obtained after the PCR or the complete
30 genes are introduced into cloning vectors and transformed into host cells, prior to the activity assay. They are thus more readily accessible to the abovementioned sequencing and/or further cloning steps, including cloning into expression vectors.

35 The host cells to be used for this purpose are preferably strains of the genera *Escherichia coli*, *Streptomyces* or *Bacillus*.

Methods of the invention are carried out not only with regard to individual sequences but also in order to obtain a multiplicity of sequences which are homologizable and via which a sequence space can be defined, which in turn refers to the particular amino acid sequences, since it is the aim of the method of the invention to identify correspondingly different proteins. Thus, the amino acid sequences derivable from the PCR products must be contemplated in each case.

Accordingly, preference is therefore given to methods which are carried out or repeated on so many different PCR templates that at least two different amino acid sequences having a common consensus sequence are obtained, in particular via individual domains, partial activities, structural elements or complete genes and/or proteins.

It is the aim of these studies to generate a sequence space whose individual representatives have such a ratio in homology and variance that said sequence space can be introduced to random methods of mutagenesis and enzyme development, for example shuffling mutagenesis.

Accordingly, preference is therefore given to methods which are characterized in that a consensus sequence with sequence identities of at least two sequences contained therein of at least 30%, preferably at least 40%, particularly preferably at least 50%, is obtained.

A separate subject matter of the invention is the possibility of using the proteins or nucleic acids provided by the present application for finding further α -amylases.

Thus the use of a protein or derivative according to the first subject matter of the invention for

identifying an amylolytic protein is claimed, preferably in a method according to the fourth subject matter of the invention.

5 They may be used, for example, for deriving corresponding primers for methods of the invention. However, they may also be used for the abovementioned methods for generating antibodies for the immunochemical screening of an expression bank.

10

Nucleic acids according to the second subject matter of the invention may also be used for identifying and/or obtaining a new amylase, preferably in a method according to the fourth subject matter of the invention.

15

They may serve, for example, as template for developing primers for a PCR of the invention or may be available as deletion mutant in expression vectors so that
20 cloning into said vector leads to complementation for expression.

A possible use for proteins obtained according to a method of the invention results from fusion or linkage
25 to another protein, in particular for developing a new enzyme. In this way it is possible to prepare, for example, multifunctional enzymes by chemical coupling.

A possible use for nucleic acids obtained according to
30 a method of the invention results from their use for fusion to another nucleic acid, in particular for developing a new enzyme. This may be carried out via specific fusion of particular sequences or via a random recombination method.

35

Uses of this kind for specific fusion, utilizing highly homologous regions of the amino acid sequences, common restriction cleavage sites of the nucleic acids or via

PCR-based fusion, are preferred embodiments.

Another possibility is the use in a random recombination method, in particular by utilizing highly homologous regions of the amino acid sequences, common restriction cleavage sites of the nucleic acids or via PCR-based fusion.

The highly homologous regions of the amino acid sequences, which are usually conserved, function-carrying regions, may serve here as anchors for PCR primers, where appropriate of degenerated primers. Common restriction cleavage sites of the nucleic acids of two different genes make possible a direct fusion at the DNA level. Any methods established in the prior art and also the method of the invention, including its various embodiments, are available for combining the various gene regions.

Vectors comprising any of the nucleic acid regions of the second subject matter of the invention are included in a separate subject matter of the invention.

Such vectors are the preferred starting points for molecular-biological and biochemical studies of the gene in question or corresponding protein, for further developments of the invention and for amplifying and producing proteins of the invention.

Suitable vectors may be derived from bacterial plasmids, from viruses or from bacteriophages but may also contain elements of a wide variety of origins. Using the other genetic elements present in each case, vectors are able to establish themselves as stable units in the relevant host cells over several generations. In accordance with the invention, it is unimportant here whether they establish themselves as independent units extrachromosomally or integrate into

a chromosome. The system of choice out of the numerous systems known in the prior art depends on the individual case. Decisive factors may be, for example, the copy number attainable, the selection systems
5 available, among these especially resistances to antibiotics, or the culturability of the host cells capable of taking up said vectors.

Cloning vectors are preferred embodiments of this
10 subject matter of the invention.

Said cloning vectors are, in addition to storage, biological amplification or selection of the gene of interest, suitable for characterization of the gene in
15 question, for example via generation of a restriction map or sequencing. Cloning vectors are also preferred embodiments of the present invention, because they are a transportable and storable form of the claimed DNA. They are also preferred starting points for molecular-
20 biological techniques not linked to cells, such as the polymerase chain reaction, for example.

Expression vectors are preferred embodiments of this
25 subject matter of the invention.

Owing to the appropriate genetic elements, said expression vectors are capable of replicating in the host organisms optimized for the production of proteins and of expressing the contained gene there. Preferred
30 embodiments are expression vectors which themselves carry all the genetic elements necessary for expression. Promoters regulate transcription of a gene. Examples of the former are natural promoters originally located upstream of the genes in question. Since in the
35 case of most of the genes of the invention, however, said promoters cannot be assumed to be known, preference is given to those embodiments in which, after genetic fusion, known, other promoters are

provided for regulation of the transgene. The promoter here may be a promoter of the host cell, a modified promoter or else a completely different promoter from a different organism. Preferred embodiments are those
5 expression vectors which can be regulated by changing the culture conditions or by adding particular compounds, such as, for example, cell density or specific factors.

10 Expression vectors enable heterologous or homologous protein expression, depending on the particular genetic elements. Cell-free expression systems in which protein biosynthesis is mimicked *in vitro* may also be
15 embodiments of the present invention. Such expression systems are likewise established in the prior art and are based on the genes provided in cloning or expression vectors.

This subject matter of the invention includes host
20 cells which express or can be induced to express any of the proteins or derivatives of the invention, preferably by using an appropriate expression vector.

In-vivo synthesis of an amylolytic enzyme of the
25 invention by living cells requires the transfer of the corresponding gene into a host cell, i.e. transformation thereof. Suitable host cells are in principle any organisms, i.e. prokaryotes, eukaryotes or cyanophytes. Preference is given to those host cells
30 which are easily manageable genetically, with respect to, for example, transformation with the expression vector and its stable establishment. Moreover, preferred host cells are distinguished by good microbiological and biotechnological manageability.
35 This relates, for example, to easy culturability, high growth rates, low requirements on fermentation media and good rates of production and secretion for foreign proteins. Frequently, it is necessary to determine

experimentally the expression systems optimal for the individual case from the abundance of various systems available according to the prior art.

5 Preferred embodiments are those host cells whose protein production rate can be regulated, owing to genetic regulatory elements which may be provided, for example, on the expression vector or else may be present in said cells from the outset. Expression in
10 said cells may be induced, for example, by controlled addition of chemical compounds used as activators, by changing the culturing conditions or on reaching a particular cell density. This makes possible a very economical production of the proteins of interest.

15 A variant of this experimental principle is expression systems in which additional genes, for example those provided on other vectors, influence the production of proteins of the invention. Said additional genes may be
20 modifying gene products or those intended to be purified together with the protein of the invention, for example in order to influence its amylolytic function. They may be, for example, other proteins or enzymes, inhibitors or those elements which influence
25 the interaction with various substrates.

In a preferred embodiment, the host cell is characterized in that it is a bacterium, in particular one which secretes the protein or derivative produced
30 into the surrounding medium.

Preferred host cells are prokaryotic or bacterial cells. Bacteria usually distinguish themselves from eukaryotes by shorter generation times and lower
35 demands on the culturing conditions. This makes it possible to establish cost-effective methods for obtaining proteins of the invention.

- 86 -

Host cells characterized in that they are Gram-positive bacteria are a preferred embodiment.

Gram-positive bacteria, such as, for example, bacilli
5 or actinomycetes or other representatives of Actinomycetales, have no outer membrane so that secreted proteins are immediately released into the nutrient medium surrounding the cells, from which medium the expressed proteins of the invention can be
10 directly purified according to another preferred embodiment.

Host cells which are characterized in that they belong to the genus *Bacillus*, preferably to the species
15 *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis* or *Bacillus alcalophilus*, are a preferred embodiment.

Said host cells are established Gram-positive
20 expression systems.

Host cells which are characterized in that they belong to the order Actinomycetales, in particular to the genus *Streptomyces*, preferably to the species
25 *Streptomyces lividans*, particularly preferably to *S. lividans* TK24, or to the species *Streptomyces* sp. 327* or *Streptomyces* sp. B400B, in particular to either of the two strains DSM 13990 or DSM 13991, are a preferred embodiment.

30 For particularly preferred embodiments of proteins of the invention were obtained from representatives of said genus and, respectively, said species, as described above and in the examples. Owing to the
35 similar codon usage, said representatives are also particularly suitable for expressing the genes and gene fragments provided by the present invention.

They enable homologous protein expression in the case where they express their own genes. Said homologous protein expression may have the advantage that natural modification reactions in connection with translation
5 are carried out on the protein being produced in the same way as they would also proceed naturally. This may be carried out, for example, via an introduced vector which introduces into said cells the already present endogenous gene or inventive modifications of the same,
10 for example with multiple copies.

Host cells characterized in that they are Gram-negative bacteria are a preferred embodiment.

15 For most experience in biotechnological production has been obtained with Gram-negative bacteria such as, for example, *E. coli* or *Klebsiella*. These bacteria, moreover, secrete a multiplicity of proteins into the periplasmic space, i.e. the compartment between the two
20 membranes enveloping the cells. This may be utilized for special applications. On the other hand, however, preference may also be given to the specific release of the enzymes produced by Gram-negative bacteria into the extracellular space. A method for this is described,
25 for example, in the international patent application PCT/EP01/04227 with the title "Verfahren zur Herstellung rekombinanter Proteine durch gram-negative Bakterien" [Method for producing recombinant proteins by Gram-negative bacteria].

30 Preference is given to those host cells which are characterized in that they belong to the genus *Escherichia*, preferably to the species *Escherichia coli*, particularly preferably to any of the strains
35 *E. coli* JM 109, *E. coli* DH100B or *E. coli* DH 12S.

Said strains are established, generally accessible laboratory and production strains. The strain *E. coli*

DH 12S was used successfully for heterologous expression of the Actinomycetales genes obtained in example 6; this made it possible to obtain proteins with detectable α -amylase activity.

5

A further embodiment is host cells which are characterized in that they are eukaryotic cells, in particular those which posttranslationally modify the protein produced.

10

Examples of these are fungi or yeasts such as *Saccharomyces* or *Kluyveromyces*. This may be particularly advantageous, for example, if the proteins are intended to receive modifications specific in connection with their synthesis which are made possible by systems of this kind. They include, for example, binding of low-molecular weight compounds such as membrane anchors or oligosaccharides.

15

20 A further embodiment of this subject matter of the invention is methods for preparing a protein or derivative of the invention. For this purpose, nucleic acids of the invention are used, optionally using an appropriate vector and/or using an appropriate host cell or using a cell which produces said protein naturally. Among these, preference is given accordingly to the natural organisms discussed above.

25

Any of the elements already discussed above may be combined to methods in order to prepare proteins of the invention. In this connection, a multiplicity of possible combinations of method steps is conceivable for each protein of the invention. All of these implement the idea on which the present invention is based, namely to prepare quantitatively representatives of a type of protein defined via the amylolytic function and, at the same time, high homology to the sequences indicated in the sequence listings with the

30

35

- 89 -

aid of the corresponding genetic information. In each actual individual case, the optimal method must be determined experimentally.

5 In principle, the procedure here is as follows: nucleic acids of the invention in DNA form are ligated into a suitable expression vector. The latter is transformed into the host cell, for example into cells of a readily culturable bacterial strain which exports the proteins
10 whose genes are under the control of appropriate genetic elements into the surrounding nutrient medium or which accumulates said proteins inside the cell; elements regulating this may be provided, for example, by the expression vector. It is possible to purify the
15 protein of the invention from the surrounding medium or, with disruption of the cells, from the host cells themselves via a plurality of purification steps such as, for example, precipitations or chromatographies. A skilled worker is capable of transferring a system
20 which has been optimized experimentally on the laboratory scale to large-scale production.

The possible industrial uses for amylases of the invention are a separate subject matter of the
25 invention, since the underlying object had been to provide suitable amylases for various industrial processes. The most important of these processes will be discussed below.

30 Numerous possible applications for amylolytic enzymes, which are established in industry, are discussed in manuals such as, for example, the book "Industrial enzymes and their applications" by H. Uhlig, Wiley-Verlag, New York, 1998. The following compilation is
35 not to be understood as a final list but is a selection of the possible industrial uses. Should it turn out that individual proteins within the similarity range are, owing to their enzymic, i.e. amylolytic,

properties, suitable for additional possible applications not explicitly claimed herein, said possible applications are hereby included in the scope of protection of the present invention.

5

In one embodiment, the present invention relates to detergents and cleaning agents which are characterized in that they comprise a protein or derivative of the invention.

10

An important field of use for amylolytic enzymes is that as active components in detergents or cleaning agents for cleaning textiles or solid surfaces such as, for example, dishes, floors or tools. In these applications, the amylolytic activity serves to hydrolytically dissolve or detach from the underlying material carbohydrate-containing soilings, in particular those based on starch. In this connection, said enzymes may be applied alone, in suitable media or
15 else in detergents or cleaning agents. The conditions to be chosen for this, such as, for example, temperature, pH, ionic strength, redox ratios or mechanical influences, should be optimized for the particular cleaning problem, i.e. with respect to the
20 soiling and the support material. Thus usual temperature ranges for detergents and cleaning agents are from 10°C for manual agents via 40°C and 60°C up to 95° for machine agents or industrial applications. Preferably, the ingredients of the agents in question
25 are also matched to one another. Since in modern washing machines and dishwashers the temperature is usually continuously adjustable, any intermediate temperatures are also included. The other conditions may likewise be designed in a very variable manner via
30 the other components of said agents with respect to the
35 particular cleaning purpose.

Preferred agents of the invention distinguish

themselves by the washing or cleaning performance of said agent under any of the conditions definable in this way being improved by the addition of an amylolytic enzyme of the invention, in comparison with
5 the formulation without said enzyme. In this respect, preference is given to incorporating those amylolytic proteins into agents of the invention which are capable of improving the washing and/or cleaning performance of a detergent or cleaning agent.

10

Further preferred agents distinguish themselves in that the amylolytic enzymes and the other components remove the soilings synergistically. This is carried out, for example, by other components of said agents, such as,
15 for example, surfactants, solubilizing the hydrolysis products of the amylolytic proteins. A protein of the invention may be used both in agents for industrial consumers or industrial users and in products for the private consumer, with all presentations established in
20 the prior art and/or convenient presentations also being embodiments of the present invention.

The amylases are combined in agents of the invention, for example, with individual or several of the
25 following ingredients: anionic, cationic and/or nonionic surfactants, builders, bleaches, bleach activators, bleach catalysts, enzymes such as, for example, proteases, other amylases, lipases, cellulases, hemicellulases or oxidases, stabilizers, in
30 particular enzyme stabilizers, solvents, thickeners, abrasive substances, dyes, fragrances, graying inhibitors, color transfer inhibitors, foam inhibitors, corrosion inhibitors, in particular silver protectants, optical brighteners, antimicrobial substances, UV
35 protectants and other components known from the prior art.

Preferred agents are characterized in that they contain

- 92 -

0.000001 percent by weight to 5% by weight and, increasingly preferably, 0.00001 to 4% by weight, 0.0001 to 3% by weight, 0.001 to 2% by weight or 0.01 to 1% by weight of the amylolytic protein or
5 derivative.

Preferred agents are characterized in that they comprise more than one phase. These may include solid agents, in particular those in which at least two
10 different solid components, in particular powders, granules or extrudates, are present in an overall loose mixture or in which at least two solid phases are connected to one another, in particular after a joint compacting step. In addition, at least one of the
15 phases may contain an amylase-sensitive material, in particular starch, or be, at least partially, surrounded or coated by said material.

Likewise preferred agents are characterized in that
20 they are overall liquid, gel-like or paste-like. Preferably, the protein therein and/or at least one of the enzymes therein and/or at least one of the other components therein are present individually or encapsulated together with other components, preferably
25 in microcapsules, particularly preferably in those made of an amylase-sensitive material.

In a preferred embodiment, the amylolytic activity is modified, in particular stabilized and/or increased in
30 its contribution to the washing or cleaning performance of the agent, by any of the other components of the agent.

In accordance with these discussions, any washing or
35 cleaning processes which are based in at least one part on an α -amylase of the invention or preferably an agent of the invention is used are also embodiments of the present invention.

Any use of an α -amylase of the invention or preferably of an agent of the invention for washing or cleaning textiles or hard surfaces is also an embodiment of the present invention.

Another embodiment is the use of a protein or derivative of the invention for the treatment of raw materials or intermediates in the manufacture of textiles, in particular for desizing cotton.

Raw materials and intermediates in the manufacture of textiles, for example of those based on cotton, are provided with starch during their production and further processing, in order to improve the finish. This method, which is applied to yarns, to intermediates and to textiles, is called sizing. Amylolytic proteins of the invention are suitable for removing the starch-containing protective layer (desizing).

A further embodiment is methods for starch liquefaction, in particular for ethanol production, which are characterized in that therein a protein or derivative of the invention is used.

For starch liquefaction, starch soaked in water or buffer is incubated with amylolytic enzymes, thereby cleaving the polysaccharide into smaller parts, in the end primarily into maltose. Preference is given to using for such a process or a part thereof enzymes of the invention, if they can be readily adapted to a corresponding production process, owing to their biochemical properties. This may be the case, for example, if they are to be introduced in one step in addition to other enzymes which require the same reaction conditions. Particular preference is given to amylolytic proteins of the invention if interest is

focused especially on the products generated by said proteins themselves. Starch liquefaction may also be a step in a multistage process for producing ethanol or secondary products derived therefrom, for example
5 acetic acid.

Another embodiment is the use of a protein or derivative of the invention for preparing linear and/or short-chain oligosaccharides.

10

Owing to their enzymic activity, amylolytic proteins of the invention form from starch-like polymers primarily higher molecular weight oligosaccharides such as, for example, maltohexaose, maltoheptaose or maltooctaose,
15 after a relatively short incubation time. After a longer incubation time, the proportion of lower oligosaccharides such as, for example, maltose or maltotriose in the reaction products increases. If there is particular interest in certain reaction
20 products, it is possible to use appropriate variants of proteins of the invention and/or to design the reaction conditions accordingly. This is particularly attractive if mixtures of similar compounds rather than pure compounds matter, as, for example, in the generation of
25 solutions, suspensions or gels with only certain physical properties.

Another embodiment is the use of a protein or derivative of the invention for hydrolyzing
30 cyclodextrins.

Cyclodextrins are α -1,4-glycosidically linked, cyclic oligosaccharides of which those consisting of 6, 7 and 8 glucose monomers, the α -, β - and γ -cyclodextrins,
35 respectively (or cyclohexa-, -hepta- and -octaamyloses, respectively), are economically the most important. They may form inclusion compounds with hydrophobic guest molecules such as, for example, fragrances,

flavorings or pharmaceutical active substances, from which inclusion compounds the guest molecules can be released again when required. Depending on the field of use of the ingredients, for example for food
5 production, pharmacy or cosmetics, for example in appropriate products, such inclusion compounds are important to the final consumer. The release of ingredients from cyclodextrins is thus a possible use for proteins of the invention.

10

Another embodiment is the use of a protein or derivative of the invention for releasing low-molecular weight compounds from polysaccharide carriers or cyclodextrins.

15

Owing to their enzymic activity, amylolytic proteins of the invention may liberate low-molecular weight compounds also from other α -1,4-glycosidically linked polysaccharides. This may take place, as for the
20 cyclodextrins, at the molecular level as well as in larger systems such as, for example, ingredients encapsulated in the form of microcapsules. Starch, for example, is a material established in the prior art in order to encapsulate compounds such as, for example,
25 enzymes, which are intended to be introduced in defined amounts into reaction mixtures, during storage. The controlled process of release from such capsules may be assisted by amylolytic enzymes of the invention.

30 Another embodiment is the use of a protein or derivative of the invention for producing food and/or food ingredients.

Likewise, the use of a protein or derivative of the
35 invention for producing animal feed and/or animal feed ingredients is an embodiment of the present invention.

Wherever starch or starch-derived carbohydrates play a

part as food or animal feed ingredients, an amylolytic activity may be employed in producing these items. Said activity increases the proportion of monomers or oligomers compared to the polymeric sugar, possibly
5 benefiting, for example, the taste, digestability or consistency of the food product. This may be required for producing particular animal feed but also, for example, in the production of fruit juices, wine or other food products, if the proportion of polymeric
10 sugars is to be reduced and that of sweet and/or readily soluble sugars is to be increased. The possible use discussed further above for starch liquefaction and/or ethanol production may be regarded as the industrial variant of this principle.

15 Amylases in addition also counteract the loss of taste, known as staling, of bakery products (antistaling effect). For this purpose, they are conveniently added to the dough before baking. Thus, preferred embodiments
20 of the present invention are those in which proteins of the invention are used for making bakery products.

Another embodiment is the use of a protein or derivative of the invention for dissolving starch-
25 containing adhesive bonds.

Temporary bonding processes which are characterized in that a protein or derivative of the invention is used therein are also an embodiment of the present
30 invention.

In addition to other natural substances, starch has also been used as binder in paper production and bonding of different papers and cardboards already for
35 centuries. This relates, for example, to drawings and books. Over the course of long periods of time, unfavorable influences such as, for example, moisture can cause such papers to become wavy or to break,

leading possibly to complete destruction thereof. Restoration of such papers and cardboards may require dissolution of the adhesive layers, which is facilitated considerably by using an amylolytic protein
5 of the invention.

Plant polymers such as starch or cellulose and their water-soluble derivatives are used, inter alia, as adhesives or pastes. For this purpose, said polymers
10 must first swell in water and then, after application to the material to be glued, dry, thus attaching said material to the base. The enzyme of the invention may be added to such an aqueous suspension in order to influence the adhesive properties of the resulting
15 paste. However, it may also be added to the paste instead of or in addition to said function in order to stay, after drying, on the material to be glued in an inactive manner for a long time, for example several years. Changing the environmental conditions
20 specifically, for example by wetting, may then be used in order to activate the enzyme at a later time and thus cause the paste to dissolve. In this way it is possible to detach again the glued material more readily from the base. In this method, the enzyme of
25 the invention acts, owing to its amylolytic activity, as separating agent in a temporary bonding process or as "switch" for detaching the glued material.

Examples

30

Example 1

Construction of primer oligonucleotides for amplifying variable sequence regions of α -amylases

35 Based on comparisons of known sequences of α -amylases (E.C. 3.2.1.1) of Gram-positive eubacteria of various genera of the order Actinomycetales (*Streptomyces*, *Thermomonospora*, etc.) from GenBank (National Center

for Biotechnology Information NCBI, National Institutes of Health, Bethesda, MD, USA; updated November 1998), potentially conserved sequence regions were identified which flank sequence regions as variable as possible.

5 The conserved sequence blocks identified were the blocks A to E highlighted in figure 1. They extend over the following amino acid positions: A: 58-91, B: 94-141, C: 155-207, D: 295-345, E: 392-427. On the basis of the sequences of these regions, the oligonucleotides

10 compiled in table 4 were designed as primers of the invention; their sequences are indicated in the sequence listing under numbers 9 to 33. Their position relative to the conserved sequence blocks A to E within an α -amylase gene is illustrated in figure 1 by way of

15 the example of *Streptomyces griseus* α -amylase (GenBank Accession number X57568). They can be distinguished by their orientation to said gene into forward primer and reverse primer.

20 Table 4: PCR primers for amplifying partial α -amylase sequences of representatives of the order Actinomycetales

Indicated are in each case the names used in figure 1,

25 the corresponding numbers according to the sequence listing of the present patent application and the orientation of the primers relative to the amylase genes in question.

Name	SEQ ID NO.	Orientation
GEX015	13	forward
GEX016	14	forward
GEX017	15	forward
GEX018	16	forward
GEX019	17	reverse
GEX020	18	reverse
GEX021	19	reverse

Name	SEQ ID NO.	Orientation
GEX022	20	reverse
GEX023	21	forward
GEX024	9	forward
GEX025	22	reverse
GEX026	10	reverse
GEX027	23	forward
GEX028	24	forward
GEX029	11	forward
GEX030	25	reverse
GEX031	12	reverse
GEX036	26	forward
GEX037	27	forward
GEX038	28	reverse
GEX039	29	reverse
GEX040	30	forward
GEX041	31	forward
GEX042	32	reverse
GEX043	33	reverse

The templates used were genomic DNA preparations, obtained according to standard methods, of known and unknown bacterial isolates from various soil samples, which were present in each case as pure culture. The primers were used in combinations of in each case a *forward* primer with a *reverse* primer in each PCR. The PCR products were fractionated via agarose gel electrophoresis, as described below, and used for screening for complete genes.

The PCR reaction mixtures included those containing the primer combinations GEX024 (forward)/GEX026 (reverse) and GEX029 (forward)/GEX031 (reverse). These were derived from the sequence regions C (GEX024 and GEX029) and D (GEX026 and GEX031) (figure 1), which correspond to the amylase domains $\beta 4$ and $\beta 7$ of the $(\alpha\beta)_8$ barrel structure, as they are defined in the article "Alpha-

Amylase family: molecular biology and evolution" (Janecek, S. (1997), *Prog. Biophys. Mol. Biol.* 67 (1), pp. 67-97). The nucleotide sequences of these four primers are indicated in the sequence listing under SEQ ID NO. 9 to SEQ ID NO. 12.

These four primers produced in the PCR mixtures with the isolated nucleic acids of bacterial isolates reproducibly sized fragments. Figure 2 depicts an exemplary size analysis of the amplification products obtained of 20 randomly selected preparations of isolates of the order Actinomycetales, using the primer pair GEX024/GEX026 in figure 2A and the primer pair GEX029/GEX031 in figure 2B. The PCR conditions are indicated in example 2; after the reaction, in each case 1/10 of the reaction volume was fractionated in a 2.5% strength agarose gel. The reaction mixtures are based on the *Streptomyces* sp. strains compiled in the following table.

20

Table 5: *Streptomyces* sp. strains whose PCR products with the primer pairs GEX024/GEX026 and GEX029/GEX031 are depicted in figure 2.

Lanes	<i>Streptomyces</i> sp.	SEQ ID NO.
1	B101A	45
2	B114C	83
3	B134	97
4	B135A	98
5	B138A	101
6	B152A	108
7	B153 (B)	109
8	B161A	116
9	B156B	111
10	B157C	112
11	B158A	113
12	B160B	115

- 101 -

Lanes	<i>Streptomyces</i> sp.	SEQ ID NO.
13	B161A	116
14	B373	232
15	B375	234
16	B380	236
17	B390	238
18	B392A	239
19	B392A	239
20	B394	241

- Both primer pairs were used to amplify DNA fragments corresponding to a 300 bp band. A fragment of approx. 500 bp additionally appeared in some reaction mixtures.
- 5 Both products were identified as α -amylase sequences by sequencing (see example 2). The other primers, listed above and in the sequence listing, showed lower selectivity.
- 10 All strains listed in the sequence listing produced the same results; in particular, the 300 bp band was reproducible for all strains. All fragments, in particular the 300 bp fragments, that we were able to obtain in this way from the samples assayed can be
- 15 homologized. They correspond, in particular in the primer regions, to a large extent, albeit not necessarily completely, and this was sufficient in order to identify them by the method of the invention. They define, via their sequence variations to one
- 20 another, as indicated also in the sequence listing under SEQ ID NO. 263 and in figure 3, a sequence variance space within the group of amylolytic proteins.

Example 2

- 25 **Obtainment of genomic DNA from actinomycetes and PCR-based amplification and cloning of α -amylase gene sequences**

The applicability of the method of the invention was tested on a collection of several hundred individual isolates of the order Actinomycetales, which had been obtained from soil samples according to common micro-
5 biological methods. They were in each case cultured individual strains.

In this example, the isolation was carried out by standard methods, starting from soil samples, using GYM
10 medium (4.0 g/l glucose, 4.0 g/l yeast extract; 10 g/l malt extract, 2.0 g/l CaCO_3 , 10 g/l agar, pH 7.2) with addition of 50 $\mu\text{g/ml}$ nystatin to suppress the accompanying flora.

15 **Strain cultivation**

The actinomycetes strains were grown by inoculating 5 ml of GHPF medium (10 g/l glucose; 5 g/l peptone from casein; 5 g/l meat extract; 5 g/l yeast extract; 0.74 g/l $\text{CaCl}_2 \times 2\text{H}_2\text{O}$; pH 7.2) containing 50 μl of spore
20 suspension at the in each case strain-specific temperature (28°C to 50°C) and a shaker rate of 200 rpm.

After sufficient amounts of mycelium had formed, 200 ml
25 of YEME medium (3 g/l yeast extract; 5 g/l bacto tryptone; 3 g/l malt extract; 10 g/l D(+)glucose; 340 g/l sucrose; pH 7.2; after autoclaving, addition of 5 mM MgCl_2 and glycine, strain-specific 0.5-20 g/l) were inoculated with the entire preculture and
30 incubated with shaking at 170 rpm in a 1-liter flask with baffles at the same temperature and for 3 days.

DNA isolation

To prepare DNA, in each case 1 g of mycelium washed in
35 20% (v/v) glycerol was resuspended in 3 ml of TE25S buffer (25 mM Tris, pH 8.0; 25 mM EDTA; 0.3 M sucrose) with addition of 2 mg/ml lysozyme, inverted at 37°C for 30 min and, after addition of 4 ml of 2× Kirby mix (2%

- 103 -

SDS; 120 g/l sodium 4-aminosalicylate; 100 mM Tris, pH 8.0; 6% phenol, saturated with 50 mM Tris/pH 8.0 and supplemented with 0.1% hydroxyquinoline), inverted for a further 10 min. This was followed by extracting the aqueous phase twice with, successively, 8 and 3 ml of phenol/chloroform/isoamyl alcohol (25:24:1) by inverting in each case for 10 minutes and subsequently centrifuging at $2\,500 \times g$. The DNA was precipitated by adding 1/10 volume of 3M sodium acetate (unbuffered) and 0.6 volume of isopropanol with gentle inverting, spooled and purified five times with 70% ethanol. The pellet was taken up in 3 ml of HE buffer (10 mM HEPES, pH 8.0 with NaOH; 1 mM EDTA), incubated at 50-55°C for 1 h and dissolved at 4°C overnight.

Where appropriate, this may be followed by another purification step in order to remove components which may accompany the DNA and inhibit an amplification reaction. This was necessary for some DNA preparations in which initially no PCR product had formed (see below). In this case, the influence of inhibitory components in the DNA preparation had to be stopped by diluting (up to 1:100) or by purification via a QIAquick PCR purification column (Qiagen, Hilden, Germany) according to the manufacturer's instructions.

On the following day, the DNA was worked up by incubating at 37°C successively with 40 µg/ml RNaseA (heat-inactivated) and 0.5 mg/ml proteinase K, in each case for one hour. Subsequently, the aqueous phase was extracted in the same volume as phenol/chloroform/isoamyl alcohol (25:24:1), inverted for 10 min, centrifuged at $2\,500 \times g$ and precipitated as on the previous day, spooled, then washed and dissolved in 1 ml of HE buffer.

Amplification of the amylase sequences by the PCR of the invention

Prior to characterizing the amylase sequences, the latter were first amplified by the polymerase chain reaction (PCR) which was carried out using HotStar *Taq* polymerase (Qiagen, Hilden, Germany) and the amylase-specific primers (example 1, table 3). For this purpose, in each case 4 µl of the genomic DNA isolated by the above method were used in the presence of 200 µM dNTPs (each of dATP, dTTP, dCTP, dGTP), 20 pmol of in each case a forward primer and a reverse primer, 2.5 U of HotStar *Taq* polymerase (Qiagen, Hilden, Germany) and 1 × PCR buffer were used in a total volume of 50 µl. Fragments of from 280 to 500 bp in size were amplified in the following cycles: 1 cycle at 95°C for 15 min; 40 cycles at, in each case, 95°C for 30 s, 60°C for 30 s and 72°C for 30 s; 1 cycle at 72°C for 7 min.

The primer pair GEX024/GEX026, in particular, produced constant results for all genomic DNAs with respect to a 300 bp product which exhibited homologies to amylases in the sequencing (see example 1). In some DNA preparations, initially no product was formed. In this case, the influence of inhibitory components in the DNA preparation had to be stopped by diluting (up to 1:100) or by purification via a QIAquick® PCR purification column (Qiagen, Hilden, Germany) according to the manufacturer's information.

The bands (approx. 300 bp) obtained with the primer combination GEX024/GEX026 were sequenced by eluting them with the aid of the QIAEX II® kit from Qiagen (Hilden, Germany) and cloning them by means of the TOPO TA® kit (Invitrogen, Groningen, The Netherlands) into the pCR2.1-TOPO® vector, according to the manufacturer's instructions. The ligation products were used to transform *E. coli*-TOP® 10F (Invitrogen, Groningen, The Netherlands). After blue/white selection of recombinant clones on LB medium containing ampicillin (100 µg/ml), IPTG (100 mM), X-Gal (40

mg/ml), the plasmid DNA of white clones was checked, after mini preparation, for DNA insert in a restriction analysis with *EcoRI*.

5 The sequences of plasmids with DNA insert were analyzed in a routine manner in an ABI PRISM[®] 310 (Perkin Elmer, Weiterstadt, Germany) according to the manufacturer's instructions by means of AmpliTaq-FS-Big-Dye[®] terminator kit (Perkin Elmer, Weiterstadt, Germany)
10 using 200-500 ng of plasmid DNA, 10 pmol of primer (TopoF: 5'-GCTCGGATCCACTAGTAACG-3' and TopoR: 5'-CTCTAGATGCATGCTCGAG-3'), 4 µl of pre-mix in a total volume of 20 µl. The DNA sequences obtained were routinely and conceptionally transcribed into an amino
15 acid sequence, compared via the BlastX, BlastN and BlastP algorithms with the GenBank entries available and identified in this way as partial sequences of α -amylase genes. Table 1 indicates for each partial sequence obtained the amylolytic proteins entered in
20 publicly accessible databases, which have in each case the highest homology to the sequences in question. The partial sequences found are listed in the sequence listing under numbers SEQ ID NO. 2, 4 and 34 to 262 and combined in the consensus sequence of figure 3 and SEQ
25 ID NO. 263, respectively.

Special mention should be given to the partial sequences which were likewise amplified using the primer pair GEX024/GEX026 and which are depicted in the
30 sequence listing under numbers SEQ ID NO. 1 to SEQ ID NO. 4. The corresponding strains were denoted *Streptomyces* sp. B327* (SEQ ID NO. 1 and 2) and *Streptomyces* sp. B400B (SEQ ID NO. 3 and 4). The partial sequence obtained from the Actinomycetales
35 isolate *Streptomyces* sp. B327* comprises, including the primer regions, 302 base pairs and codes for 100 amino acids. The partial sequence obtained from the Actinomycetales isolate *Streptomyces* sp. B400B

comprises, including the primer regions, 293 base pairs and codes for 97 amino acids.

Example 3

5 Typing of microbial pure culture isolates and cloning of α -amylase gene sequences

The DNA sequences of α -amylases have been amplified, as described, from all of the streptomyces strains referred to in example 2 by a PCR of the invention using the primers GEX024/GEX026 and then cloned and sequenced. Thus, in total, 231 partial sequences of α -amylases were found which are listed in the sequence listing under numbers SEQ ID NO. 2, 4 and 34 to 262.

15 The individual *Streptomyces* sp. strains referred to therein, for example *Streptomyces* sp. B327* and *Streptomyces* sp. B400B, can be characterized due to the fact that it is possible to amplify therefrom fragments having an appropriate size and the partial amylase sequences indicated in the sequence listing via a PCR

20 using the primer pair GEX024/GEX026.

A consensus sequence was derived from said sequences with the aid of the alignment program Clustal X[®], Version 1.64 b (standard settings; described in: Thompson, J.D., Higgins, D.G. and Gibson, T.J. (1994), "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice", *Nucleic Acids Res.*, volume 22, pp. 4673-4680).

25 They may be regarded, via this common sequence, as representatives of a particular type of amylase. Said consensus sequence is displayed in two alternative representations in figure 3 and in the sequence listing

30 under SEQ ID NO. 263. The position of said consensus sequence was defined on the basis of the sequence of the PCR product of strain B327* with the primer pair GEX024/GEX026 (100 amino acids; SEQ ID NO. 2).

The amino acid positions 1 to 8 and 93 to 100 which appear to be practically invariable in the consensus sequence are prescribed by the PCR primer sequences (GEX024/GEX026). Owing to the selectivity of the PCR performed, only slight deviations were found within these regions. More stringent conditions (in particular higher annealing temperature) result in a lower number of positive results, namely those sequences which are in complete agreement with the primers in the primer regions. In contrast, owing to the complexity of the starting DNA, products which are more difficult to separate in agarose gels are increasingly produced under less stringent conditions. Among said products, the proportion of sequences no longer coding for amylases increases.

Otherwise, only the amino acid residues histidine in position 11 and leucine in position 75 are conserved in the sequences listed across all amylase fragments assayed. Some fragments contain in position 28 sequences of a plurality of amino acids rather than a single amino acid; these are also indicated in figure 3 and SEQ ID NO. 263 and, respectively, the individual sequences in question. Said individual sequences are the partial sequence TAGGE of the strain *Streptomyces* sp. B347 (SEQ ID NO. 212), the partial sequence TSGAE of the strain *Streptomyces* sp. B361 (SEQ ID NO. 204) and the partial sequence YPAWGGGK of the strain *Streptomyces* sp. B4006B (SEQ ID NO. 246). In addition, some fragments do not contain any amino acid in positions 29, 45, 46, 66, 70, 81, 82, 83 or 91 so that the individual numbering thereof deviates slightly from that of the consensus sequence; these fragments include, for example, those of the strains *Streptomyces* sp. B347, B361 and B1059.

The sequences shown have, as can be found in table 1

already shown hereinbefore, between about 45% and 97% sequence identity to known α -amylases. These sequences, too, partly exhibit a considerable variance. Thus, the amino acid sequences found of the α -amylases from
5 *Streptomyces* sp. B327* and B400B are merely 57% identical to one another.

Example 4

Detection of full-length gene sequences coding for α - 10 amylase by means of activity screening of expression gene banks

Complete α -amylase genes were cloned and isolated from Actinomycetales by choosing expression cloning in the
15 heterologous host organism *Escherichia coli*, namely the strain DH 12S. The promoter used was the IPTG (isopropylthiogalactoside)-inducible β -galactosidase promoter of the *lac* operons (*lac* promoter). Said promoter was provided on the pUC18 plasmid vector
20 (GenBank (National Center for Biotechnology Information NCBI, National Institutes of Health, Bethesda, MD, USA); accession number L08752; figure 4).

Preparation of expression gene banks for the particular 25 strains

Purified genomic DNA from the particular Actinomycetales strains, which had been obtained according to example 2, was partially cleaved with the restriction enzyme *Aci* I, and the size range from 3 to
30 5 kb was ligated into pUC18 plasmid vectors linearized with the restriction enzyme *Acc* I (figure 4). A desired 5-fold covering of the genome in a gene bank, with an average insert size of 4 kb and an estimated actinomycete genome size of 8 Mb, results in a figure
35 of 20 000 primary clones. Since expression starts from the *lac* promoter located on the plasmid but the inserts can integrate in each case in two orientations, this figure is increased to at least 40 000 clones, which

was the minimum number of clones obtained for each gene bank.

The optimal restriction parameters for the preparative
5 partial digestion of genomic DNA from actinomycetes
were determined by first carrying out restriction
kinetics using 6 µg of DNA and restriction enzyme
(AciI) at concentrations of from 0.1 to 0.4 U per µg of
DNA in 1 × buffer, where appropriate according to the
10 manufacturer's instructions with bovine serum albumin
(BSA), in a total volume of 15 µl. For this purpose,
the reaction mixtures were, initially without enzyme,
heated to 37°C. Thereafter, the particular reaction was
started by adding restriction endonuclease. At fixed
15 intervals of between 0 and 10 min, in each case 1.5 µl
of reaction mixture was added to 1 × stop buffer (6X:
10 mM Tris, pH 7.0; 20% glycerol; 0.1% SDS) on ice and
analyzed on a 0.7% strength agarose gel, thereby
determining individually for each DNA preparation the
20 optimal restriction time for a partial digest, which
was on average 4 to 5 min.

The preparative partial digestion was carried out as
described above, but with ten times the amount of
25 reaction mixture using 60 µg of chromosomal
actinomycete DNA and the previously optimized amount of
enzyme for the period which was in each case determined
individually. After stopping the reaction by adding 1 ×
stop buffer, the mixture was electrophoretically
30 fractionated on a 0.7% strength agarose gel, the gel
region containing DNA of 3-5 kb in size was excised and
isolated in dialysis tubes at 4°C by electroeluting for
two hours. The DNA was precipitated with 1/10 volume of
3 M sodium acetate and 2.5 volumes of ethanol, taken up
35 in a smaller volume and then, for further removal of
smaller fragments, subjected to a second gel electro-
phoresis with subsequent electroelution and another
concentration.

- 110 -

Ligation with the plasmid vector pUC18 was carried out at 16°C overnight in a total volume of 20 µl by using 150 ng of Acc I-linearized pUC18 vector which had been
5 dephosphorylated with CIAP (alkaline phosphatase from calf thymus) according to the manufacturer's instructions and 450 ng of partially cleaved genomic DNA, and also an appropriate amount of ligase (here 400 NEB units) in 1 × ligase buffer.

10 Competent *E. coli* DH 12S cells (Gibco Life Technologies, Karlsruhe, Germany) were transformed via electrotransformation. To this end, 1 µl of ligation mixture and 30 µl of cells were mixed, incubated on ice
15 in an electroporation cell for 1 min and treated in an electroporator (BTX[®] ECM399, Genetronics Inc., San Diego, CA, USA) according to the manufacturer's instructions. After immediate transfer to 1 ml of SOC medium (2% bacto tryptone; 0.5% yeast extract; 10 mM
20 NaCl; 2.5 mM KCl; pH 7.0, adjusted with NaOH; autoclaved; supplemented with 10 mM MgSO₄ and MgCl₂ and 20 mM D(+)glucose), there was a resting phase of 1 h at 37°C prior to plating.

25 The quality of the gene bank was tested by determining the total number of primary transformants generated and the number of insert-carrying clones via blue/white selection in a test plating. To this end, 1 and 10 µl of the ligation mixture were in each case plated out on
30 LB medium containing ampicillin, IPTG, X-Gal (as described above) and incubated at 37°C overnight. The actually cloned insert sizes were confirmed by isolating the plasmids of at least 10 white colonies of the test plating and carrying out a suitable
35 restriction digest with subsequent gel-electrophoretic size analysis.

- 111 -

Activity assay of the gene banks

First, the ability of the gene banks to break down starch was determined. To this end, LB agar containing 1% soluble starch (Merck, Darmstadt, Germany, Cat. No. #1252) was used on which clones capable of breaking down starch can be identified by lysis halos. This required the plates to be stored at 4°C for from two to four weeks, until said plates became cloudy, after which breakdown of starch was visible as a clearing up of said plates around the colonies. Additionally, soluble starch (approx. 0.6% w/v) labeled with Cibacron Brilliant Red® 3B-A (Aldrich, Taufkirchen, Germany) was used (Biely, P., Mislovicova, D., Markovic, O., Kalac, V. (1988): "A new chromogenic substrate for assay and detection of alpha-amylase"; *Anal. Biochem.*, volume 172 (1), pages 176-179), breakdown of starch being detectable by a fading of the reddish agar in the area of the positive clone. Prior to use, the plates were admixed in both cases with IPTG (100 mM) for inducing the promoter and with ampicillin (100 µg/ml) for exerting selection pressure on the transformants.

According to the titer of the bank generated in each case, a defined volume of the transformation mixture containing approx. 10 000 colonies per plate (14 cm in diameter) was plated out evenly by means of glass beads (primary plating). After incubating at 37°C for 16 hours, the plates were incubated at 28°C for amylase expression and release for another 24-48 h. The incubation at 28°C was usually indispensable for visualizing a breakdown of starch. Improved protein folding and permeabilization of the outer cell membrane may play a part here (Stathopoulos, C., Georgiou, G., Earhart, C.F. (1996): "Characterization of *Escherichia coli* expressing an Lpp' OmpA(46-159)-PhoA fusion protein localized in the outer membrane"; *Appl. Microbiol. Biotechnol.*, volume 45 (1-2), pages 112-119). This was thus accompanied by a release of the α-amylase produced

- 112 -

in each case, and a cell lysis, to be carried out additionally, for detecting cytoplasmic amylases which had not been exported was not required.

5 After isolating the colonies from the halo regions of the primary plating by renewed (secondary) plating on the same starch plates, amylase-forming single colonies were selected on the basis of renewed halo formation. For photo-archiving purposes, staining of the starch
10 plates, after securing the clones, with 50% lugol solution (Merck, Germany) for unambiguous visualization of starch-free regions (breakdown halos) has proved useful.

15 Figure 7 depicts an appropriately stained, starch-containing LB_{Amp}-agar plate to which in each case suspensions of positive clones of the secondary plating have been applied in drops.

20 **Isolation of individual clones**

The plasmid DNA of positive clones, obtained after minipreparation (kit from Qiagen, Hilden, Germany), used according to manufacturer's instructions) was studied for insert size in a restriction analysis with
25 *Eco* R I or *Sac* I/*Hind* III and then sequenced. Here, the insert-flanking M13 primers (M13 forward: 5'-GTAAAACGACGGCCAG-3'; M13 reverse: 5'-CAGGAAACAGCTATGAC-3') were used first in order to obtain finally the entire sequence via "primer walking" as known from the
30 prior art. The principle of this procedure is to derive new sequencing primers in a repeating sequence, starting from determined sequences and to use said primers for sequencing the adjoining, still unknown regions from which in turn the next sequencing primers
35 can be derived.

The complete DNA sequences and amino acid sequences derived therefrom, obtained in this way for the two

Actinomycetales isolates *Streptomyces* sp. B327* and *Streptomyces* sp. B400B isolates (see example 2) are depicted in the sequence listing under SEQ ID NO. 5 and 6 and, respectively, SEQ ID NO. 7 and 8.

5

Figure 5 depicts an alignment of the two complete α -amylases of *Streptomyces* sp. B 327* and *Streptomyces* sp. B400B with the amylase sequences most similar thereto, which were found in GenBank (National Center
10 for Biotechnology Information NCBI, National Institutes of Health, Bethesda, USA) on 1.24.2001. The latter sequences are on the one hand *Streptomyces albus* α -amylase, accession number U51129; this is 80% identical across the entire protein to *Streptomyces* sp. B327*. On
15 the other hand, *Streptomyces* sp. α -amylase (GenBank Acc. No. U8602) is 76.8% identical across the entire protein to *Streptomyces* sp. B400B.

Example 5

20 Heterologous expression of α -amylases in prokaryotic expression systems

In order to characterize the biochemical properties of the cloned α -amylases, the latter should be produced in
25 larger quantities and in soluble form. Said characterization was carried out for the complete amylase genes of *Streptomyces* sp. 327*, *Streptomyces* sp. B400B and the Actinomycetales isolate *Streptomyces* sp. B327B. The expression host used was *Streptomyces*
30 *lividans* TK24; the expression vector used was pAX5a (figure 6) in which expression is under the control of the constitutive *ermE* promoter.

To introduce the *Spe* I and *Eco* RI cleavage sites
35 required for cloning and to replace the relatively rare and therefore possibly relatively poorly translated start codons of the amylase genes of B327* (GTG) and B400B (TTG) with ATG, a PCR with appropriately modified

- 114 -

primers was carried out. Thus, for example, the forward primer: 5' aaaactagt**AAGGAGA**ACCCCCACaTGATATCGAG 3' and the reverse primer: 5' gaattcgccctt**TCAGCAGTTGGCCTTGCCCG** 3' were used for cloning the complete α -amylase of *Streptomyces* sp. 327*. New, noncomplementary nucleotides are represented in lower case here. In the forward primer, the recognition site for the restriction enzyme *Spe* I and the start codon are underlined, with the Shine-Dalgarno sequence being highlighted in bold type. In the reverse primer, the recognition site for the restriction enzyme *Eco* RI is underlined and the stop codon (in reverse orientation) is highlighted in bold type. The genomic clones isolated from the gene banks served as templates.

After subcloning the PCR products generated with *Pfx* Platinum polymerase in the vector pCR Blunt II TOPO (Invitrogen, Groningen, the Netherlands), directed insertion into the Streptomycte expression vector pAX5a was carried out, using the *Spe* I and *Eco* RI restriction cleavage sites. This was followed by protoplast transformation of *S. lividans* TK 24 according to Kieser et al. (Kieser, T., Bibb, M.J., Buttner, M.J., Chater, K.F., Hopwood, D.A. (2000): "PEG-assisted transformation of *Streptomyces* protoplasts with plasmid DNA. Rapid small-scale procedure." in: "Practical *Streptomyces* Genetics", The John Innes Foundation (publisher), Crows, Norwich, England) and plating out the transformants on the selective regeneration medium R2YE. Said medium consists of: 103 g of sucrose, 0.25 g of K₂SO₄, 0.12 g of MgCl₂·6H₂O, 10 g of glucose, 100 mg of Difco casaminoacids (Difco, Heidelberg, Germany), 10 ml of 0.5% strength (w/v) KH₂PO₄ solution, 80 ml of 3.68% strength (w/v) CaCl₂ solution, 1.5 ml of L-proline, 100 ml of TES buffer (pH 7.2; 2-([Tris(hydroxymethyl)-methyl]amino)ethanesulfonic acid), 0.2 ml of trace element solution (40 mg/l of ZnCl₂, 200 mg/l of

- 115 -

FeCl₃ × 6 H₂O, 10 mg/l of CuCl₂ × 2 H₂O, 10 mg/l of MnCl₂ × 2 H₂O, 10 mg/l of Na₂B₄O₇ × 10 H₂O, 10 mg/l of (NH₄)₆ MO₇O₂₄ × 4 H₂O) and 5 ml of 10% strength (w/v) Difco yeast extract (Difco, Heidelberg, Germany) to 1 l [lacuna] H₂O) containing 75 µg/ml of thiostreptone as selective antibiotic.

After replating to NBSA indicator plates (8 g/l of Nutrient Broth Difco, 15 g/l of Agar Serva, 1.5% (w/v) of soluble starch Merck #1252, pH 8.0; manufacturer: Difco, Heidelberg, Germany; Serva, Heidelberg, Germany; Merck, Darmstadt, Germany) and identification of amylase-positive clones which were recognized on the basis of the developing starch breakdown halos, cultivation in liquid culture to obtain enzymically active supernatants was carried out. For this purpose, a 5-ml preculture and, subsequently, a 50-ml main culture were cultured in 300-ml Erlenmeyer flasks with baffles by using GYM medium (4 g/l glucose, 4 g/l yeast extract, 10 g/l malt extract, 2 g/l CaCO₃) containing 75 µg/ml thiostreptone for 16 h and 4 days, respectively. The amylase-containing culture supernatant was obtained by removing the cell mass by centrifugation at 2 500 g for 15 min and subsequent filtration (0.45 µm) and immediately subjected to measurement or stored, after shock-freezing in liquid nitrogen, in a freezer at -20°C.

Example 6

30 Characterization of the amylolytic activity of α-amylase representatives

The detection in principle of the amylolytic activity of the two α-amylases of the invention from *Streptomyces* sp. B327* and B400B has already been described in example 4. Here, the enzymic properties of enzymes prepared heterologously according to example 5 will be studied in more detail.

Characterization of the enzymic properties

The characterization of the enzymic properties, which may be the basis for application-related selection of enzymes, is carried out with regard to the large variety of fields of application of α -amylases. The enzymes may be prepared here by cloning and heterologous expression of the gene sequences according to examples 4 and 5 and the procedure illustrated above.

The amylolytic activity was determined by means of the dinitrosalicylic acid assay (DNSA assay). Here, hydrolysis of a complex starch substrate is determined on the basis of the increase in reducing ends of the polysaccharide, the absorption at 540 nm of unreacted DNSA reagent serving as measure for the hydrolytic activity.

The assay was carried out by introducing into the sample and blank wells in a 96-well plate for PCR thermocyclers (0.2 ml "thin-wall plate" #3416, MPB (Molecular BioProducts, San Diego, USA) in each case 25 μ l of substrate solution (1% soluble starch Merck p.a. in 180 mM Tris-maleate buffer, pH 8.6 or in 180 mM corresponding assay buffer) and preincubating at 50°C, or at the particular assay temperature, in a thermocycler block for 5 min. After adding 20 μ l of enzyme solution per well, the substrate was converted at 50°C, or at the particular assay temperature, for 15 min. After adding 65 μ l of DNSA reagent (8.8 g of dinitrosalicylic acid, 250 g of potassium sodium tartrate, 6.3 g of sodium disulfite, 334 ml of 4.5% (w/v) NaOH, 915 ml of H₂O) to the sample wells and blank wells and adding 20 μ l of enzyme solution to the blank wells, the assay plate was immediately transferred to a thermoblock preheated to 100°C and incubated at 100°C for 20 min. The samples were

measured by transferring in each case 60 μ l of the assay mixture to 200 μ l of H₂O which had previously been introduced to a 96-well measuring plate (PS microplate, 96 well #655101, Greiner) and subsequently
5 determining absorption at 540 nm by means of a microtiter-plate spectrophotometer (Spectramax 190, Molecular Devices, Sunnivale, USA), using H₂O as reference. In each case three measurements were carried out; the evaluation was carried out by subtracting the
10 average of the 3 blank wells from the average of the 3 sample wells.

Temperature stability and temperature profile

The temperature stability was determined by
15 preincubating the solutions of recombinantly obtained α -amylases at various temperatures for 15 min and subsequently determining the remaining activity according to the above-described procedure at 50°C and 100 mM Tris-maleate, pH 8.6. The maximum stability of
20 α -amylase from *Streptomyces* sp. B327B was found to be at 45°C, but the effect of elevated temperatures up to 61°C was relatively moderate, with remaining activities of more than 80%. The other results are compiled in table 6, with the optimum of 45°C set to 100%.

25

Table 6: Temperature stability of α -amylase from *Streptomyces* sp. B327*

Preincubation temperature [°C]	Remaining activity, relative to that of 45°C [%]
45	100
50.4	94
55.8	86
61	84
64.7	46

30 The temperature profile was determined by carrying out

- 118 -

the reaction according to the above-described procedure at various temperatures and in 100 mM Tris-maleate buffer, pH 8.6. The maximum activity of α -amylase from *Streptomyces* sp. B327* was at 41.3°C. Higher
 5 temperatures resulted in distinct losses of activity in this enzyme (see table 7). In contrast, the activity of *Streptomyces* sp. B327B amylase was relatively constant over the temperature range assayed (see table 8).

10 Table 7: Temperature profile of α -amylase from *Streptomyces* sp. B327*

Temperature [°C]	Activity, relative to that of 41.3°C [%]
40	87
41.3	100
50.7	38
56	38
59.8	35

15 Table 8: Temperature profile of α -amylase from *Streptomyces* sp. B327B

Temperature [°C]	Activity, relative to that of 41.3°C [%]
40	103
41.3	100
50.7	117
56	92
59.8	83

It is evident that the α -amylase of *Streptomyces* sp. B327B is more stable than that of *Streptomyces* sp. B327* over a broader temperature range and up to higher
 20 temperatures. The amylolytic enzymes provided by the present invention thus distinguish themselves by a considerable viability with respect to their temperature sensitivity.

Stability to pH fluctuations

The activity of the α -amylase amylases was determined under various pH conditions by mixing the starch substrate solution in a pH range from 6.0 to 8.6 with the correspondingly adjusted 180 mM Tris-maleate buffer and, for pH 8.6 and higher, with 180 mM glycine-NaOH buffer. After diluting the substrate solution, the desired pH values and buffer concentrations of 100 mM Tris-maleate buffer and 100 mM glycine-NaOH buffer, respectively were obtained under assay conditions. Influences of the buffer system were canceled out by measuring at pH 8.6 in both buffer systems. The amylolytic activity at the particular pH values was determined as indicated above at 50°C. The results obtained are compiled in table 9 below. The activities of the two α -amylases from *Streptomyces* sp. B327* and B327 at pH 6.5 were set to 100% in each case; the respective values below relate to the latter.

Table 9: Amylolytic activity of the α -amylases from *Streptomyces* sp. B327* and the Actinomycetales isolate *Streptomyces* sp. B327B at alkaline pH values

Preincubation pH	Relative activity of <i>St.sp.</i> B327* α -amylase [%]	Relative activity of <i>St.sp.</i> B327B α -amylase [%]
6.5	100	100
8.6	38	129
10	21	84
12	13	43

Compared to the α -amylase of *Streptomyces* sp. B327*, that of *Streptomyces* sp. B327 is more stable in a more alkaline medium and also has higher stability and

higher amylolytic activity up to very high pH values.

Stability to surfactants

The stability to surfactants was determined by carrying
5 out two series of activity measurements. In the first,
 α -amylase was preincubated as described above with a
starch substrate solution containing 0.018% (w/v)
sodium dodecyl sulfate (SDS), thus resulting in a
concentration of 0.01% SDS in the assay mixture after
10 dilution. The activity was again determined at 50°C and
in 100 mM Tris-maleate buffer, pH 8.6. If these values
are set in each case to 100%, both α -amylases studied
have lower activities in the absence of SDS: that of
the α -amylase of *Streptomyces* sp. B327* has an activity
15 of 94.2% without SDS and that of *Streptomyces* sp. B327B
has one of 89%. This shows that randomly selected
representatives of the new group of α -amylases are
sufficiently stable in the presence of a surfactant
concentration typical for many applications.

20 The enzymic activity in the presence of potentially
stabilizing divalent ions and, respectively, in the
presence of chelators was characterized by incubating
randomly selected enzymes with 3.6 mM CaCl_2 containing
25 starch substrate solution (1% starch) or with a starch
substrate solution containing 1.8 mM EDTA, thus
resulting in final concentrations of 2 mM Ca^{2+} and 1 mM
EDTA, respectively, in the assay carried out as
described above. The remaining activity was again
30 determined at 50°C and 100 mM Tris-maleate buffer,
pH 8.6.

If the activities of both enzymes at 2 mM CaCl_2 are set
in each case to 100%, the activity of the α -amylase of
35 *Streptomyces* sp. B327* decreased to 91% in the presence
of 1 mM EDTA. The activity of the α -amylase of
Streptomyces sp. B327B decreases to 57% in the presence
of 1 mM EDTA. This shows that both enzymes have

- 121 -

remarkably high remaining activities in the presence of surfactants and chelators. However, both enzymes react to these influences in a distinctly different and diverse manner, as indicated by the different activities in the presence of chelators.

The results of this example indicate firstly that the inventive enzymes found are not only to be regarded as α -amylases owing to their DNA and protein sequences, but indeed also have a starch-cleaving activity. The deviations of both enzymes studied with respect to their requirements on reaction conditions can be regarded as evidence of the fact that the present invention provides a broad spectrum of amylolytic enzymes with individual differences, in addition to the basic homology.

Description of the figures

Figure 1: Position of the potentially conserved amino acid sequence blocks ("sequence anchor" A-E) in α -amylases (glycosyl hydrolase family 13, E.C. 3.2.1.1), derived from Actinomycetales α -amylase sequences, and relative positions of the PCR primers important to the invention which are listed in table 3 and indicated in the sequence listing (example 1).

The amino acid and DNA sequences comprising 567 amino acids and 1701 bp, respectively, of *Streptomyces griseus* α -amylase (GenBank (National Center for Biotechnology Information NCBI, National Institutes of Health, Bethesda, MD, USA), accession number X57568), having the conserved domains A to E which extend over the following amino acid positions: A: 58-91, B: 94-141, C: 155-207, D: 295-345, E: 392-427 are depicted by way of example.

Figure 2: Size analysis of the reaction products of the

- 122 -

inventive PCR of primer combinations
GEX024/GEX026 (**figure 2 A**) and GEX29/GEX031
(**figure 2 B**) on streptomycete DNA
(example 1).

5 The templates used here were preparations of genomic
DNA of the following 20 randomly selected *Streptomyces*
sp. Strains:

1: B101A, 2: B114C, 3: B134, 4: B135A, 5: B138A,
6: B152A, 7: B153B, 8: B161A, 9: B156B1, 10: B157C,
10 11: B158A, 12: B160B, 13: B161A, 14: B373, 15: B375,
16: B380, 17: B390, 18: B392A, 19: B392A, 20: B394.

The reaction products (1/10 of reaction volume) were
fractionated in each case in a 2.5% strength agarose
gel; both partially present products of approx. 300 bp
15 and approx. 500 bp in size were identified as amylase
sequences by sequencing.

Markers (M): 100 bp DNA ladder (in bp, from top to
bottom: 3000, 2000, 1500, 1200, 1031, 900, 800, 700,
600, 500, 400, 300, 200, 100).

20

Figure 3: Consensus sequence of α -amylases from 231
strains of the genus *Streptomyces* (SEQ ID
NO. 2, 4 and 34 to 262) with corresponding
variants for each position (example 3).

25 The consensus sequence is based on an alignment using
the program Clustal X[®], Version 1.64b (standard
settings; described in: Thompson, J.D., Higgins, D.G.
and Gibson, T.J. (1994), "CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment
30 through sequence weighting, position specific gap
penalties and weight matrix choice", *Nucleic Acids*
Res., volume 22, pages 4673-4680). The amino acid
positions 1-7 and 94-100 are substantially prescribed
by the PCR primer sequences (GEX024/GEX026 and
35 GEX029/031), depending on the selectivity of the PCR
carried out.

This is an alternative representation of the consensus
sequence indicated in SEQ ID NO. 263.

Figure 4: Diagrammatic representation of the plasmid vector pUC18 used for expression gene banks (GenBank (National Center for Biotechnology Information NCBI, National Institutes of Health, Bethesda, MD, USA), accession number L08752; example 4).

The vector was in each case linearized with the restriction enzyme *Acc I* in order to receive *Aci I*-fragmented, genomic streptomycete DNA.

ORI: origin of replication; *lacI*: *lac*-repressor gene; *lacZ*-alpha: gene for α -peptide of β -galactosidase; AmpicillinR: ampicillin resistance gene of β -lactamase.

Figure 5: Alignment of the two complete α -amylases of the invention of *Streptomyces sp.* B 327* and *Streptomyces sp.* B400B with the most similar α -amylase sequences found in GenBank (National Center for Biotechnology Information NCBI, National Institutes of Health, Bethesda, MD, USA) on 1.24.2001 (example 4).

The latter α -amylases are *Streptomyces albus* α -amylase (U51129) which is 80% identical to the amino acid sequence of B327* α -amylase across the length of the complete protein and *Streptomyces sp.* α -amylase (U08602) which correspondingly is 76.8% identical to that of *Streptomyces sp.* B400B (cf. tables 2 and 3).

Figure 6: The plasmid vector pAX5a used for expressing amylases in *Streptomyces lividans* TK 24 (example 5).

Where:

pUC19 ori: origin of replication in *E. coli*; AmpicillinR, ampicillin resistance gene (β -lactamase); ThiostreptonR, thiostreptone resistance gene; pIJ101, Replicon origin of replication in *Streptomyces*; *ermE*, *ermE* up promoter of *S. erythraea*

(described in: Faß S.H., Engels, J.W. 1996, "Influence of Specific Signal Peptide Mutations on the Expression and Secretion of the alpha-Amylase Inhibitor Tendamistat in *Streptomyces lividans*", *J. Biol. Chem.*,
5 volume 271 (number 25), pages 15244-15252).

By replacing the tendamistat sequence, genes to be cloned can be inserted via *SpeI* (5' end) and *EcoRI* (3' end) recognition sites into pAX5a and be expressed therein, starting from the constitutive *ermE* promoter.

10

Figure 7: Detection of the amylolytic activity of the inventive α -amylases of *Streptomyces* sp. B 327* and *Streptomyces* sp. B400B after heterologous expression thereof in
15 *Escherichia coli*.

After heterologously expressing the corresponding gene sequences in *Escherichia coli* (example 4), applying the transformed host cells to LB_{Amp}-agar plates containing 1% soluble starch and subsequently staining the plates
20 by means of Lugol's solution, the colonies whose cells express the imported gene sequences can be recognized by the breakdown halos.

For this figure, samples of clones derived by isolation from the transformation mixtures were applied:

- 25 1. Positive control: expression strain containing *Streptomyces griseus* α -amylase in pUC18);
2. Negative control (pUC18 without DNA insert);
3. Sample of an amylase-positive clone containing genomic DNA of *Streptomyces* sp. B400B;
30
4. and 5. Samples of two genomic clones of *Streptomyces* sp. B327*, obtained from the same transformation;
- 35 6. to 8. Samples of three genomic clones of *Streptomyces* sp. B327, obtained from the same transformation;
9. to 12. Samples of four genomic clones of

- 125 -

Streptomyces griseus, obtained from the same transformation.

SEQUENCE LISTING

<110> Henkel Kommanditgesellschaft auf Aktien

<120> A novel group of alpha-amylases and a method for identification
and production of novel alpha-amylases

<130> H 4890 PCT

<140>

<141>

<150> DE 10131441.8

<151> 2001-06-29

<160> 263

<170> PatentIn Ver. 2.1

<210> 1

<211> 302

<212> DNA

<213> Streptomyces sp. B327*

<220>

<221> CDS

<222> (2)..(301)

<400> 1

c	gtc	gac	ggc	ttc	cgc	atc	gac	acg	gcc	aag	cac	atc	ccg	gcg	acc	gac	49
	Val	Asp	Gly	Phe	Arg	Ile	Asp	Thr	Ala	Lys	His	Ile	Pro	Ala	Thr	Asp	
	1				5					10					15		

ctc	gcc	aac	atc	aag	tcg	cgt	ctg	acg	aac	ccc	tcg	gtc	tac	tgg	aag	97
Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Thr	Asn	Pro	Ser	Val	Tyr	Trp	Lys	
		20					25					30				

cag	gag	gtc	atc	tac	ggc	agc	ggg	gag	gcc	gtc	cag	ccc	acc	gag	tac	145
Gln	Glu	Val	Ile	Tyr	Gly	Ser	Gly	Glu	Ala	Val	Gln	Pro	Thr	Glu	Tyr	
	35					40				45						

acg	ggc	aac	ggg	gac	gtc	cag	gag	ttc	cgc	tac	gcc	tac	gac	ctc	aag	193
Thr	Gly	Asn	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Tyr	Asp	Leu	Lys	
	50				55				60							

cgc	gtc	ttc	aac	aac	gag	aac	ctc	gcc	tat	ctg	aag	aac	tac	ggc	gag	241
Arg	Val	Phe	Asn	Asn	Glu	Asn	Leu	Ala	Tyr	Leu	Lys	Asn	Tyr	Gly	Glu	
	65				70				75					80		

ggc	tgg	ggg	tac	ctg	aac	agc	tcg	gtg	gcc	ggc	gtc	tac	gtc	gac	aac	289
Gly	Trp	Gly	Tyr	Leu	Asn	Ser	Ser	Val	Ala	Gly	Val	Tyr	Val	Asp	Asn	
			85					90					95			

cac	gac	acc	gag	c												302
His	Asp	Thr	Glu													
			100													

<210> 2

<211> 100
 <212> PRT
 <213> Streptomyces sp. B327*

<400> 2
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Thr Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Ser Val Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 3
 <211> 293
 <212> DNA
 <213> Streptomyces sp. B400B

<220>
 <221> CDS
 <222> (2)..(292)

<400> 3
 c gtc gac ggc ttc cgc atc gac gcc gcc aag cac atg tcc gcc gac gac 49
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Ser Ala Asp Asp
 1 5 10 15
 gtc gcc gcg atc aag ggg aag atg agc gac ccg ggg ttc tgg gtc acc 97
 Val Ala Ala Ile Lys Gly Lys Met Ser Asp Pro Gly Phe Trp Val Thr
 20 25 30
 gag gtc atc cac ggc ggg gga gag gcg gtc cag ccg gag gag tac acc 145
 Glu Val Ile His Gly Gly Gly Glu Ala Val Gln Pro Glu Glu Tyr Thr
 35 40 45
 tcg atc ggg gac gcc gac gag ttc cgt tac ggc ggc cac ctc aag tcc 193
 Ser Ile Gly Asp Ala Asp Glu Phe Arg Tyr Gly Gly His Leu Lys Ser
 50 55 60
 gcc ttc cag ggc ggc ggc ctg ccc ggc ctg aag tcg atc gcc gac ggc 241
 Ala Phe Gln Gly Gly Gly Leu Pro Gly Leu Lys Ser Ile Ala Asp Gly
 65 70 75 80
 aaa ctg gcc ggc gcc tcc gcc cgt acg tac gtg gac aac cac gac acc 289

Lys Leu Ala Gly Ala Ser Ala Arg Thr Tyr Val Asp Asn His Asp Thr
 85 90 95

gag c
 Glu

293

<210> 4
 <211> 97
 <212> PRT
 <213> Streptomyces sp. B400B

<400> 4
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Ser Ala Asp Asp
 1 5 10 15

Val Ala Ala Ile Lys Gly Lys Met Ser Asp Pro Gly Phe Trp Val Thr
 20 25 30

Glu Val Ile His Gly Gly Gly Glu Ala Val Gln Pro Glu Glu Tyr Thr
 35 40 45

Ser Ile Gly Asp Ala Asp Glu Phe Arg Tyr Gly Gly His Leu Lys Ser
 50 55 60

Ala Phe Gln Gly Gly Gly Leu Pro Gly Leu Lys Ser Ile Ala Asp Gly
 65 70 75 80

Lys Leu Ala Gly Ala Ser Ala Arg Thr Tyr Val Asp Asn His Asp Thr
 85 90 95

Glu

<210> 5
 <211> 1386
 <212> DNA
 <213> Streptomyces sp. B327*

<220>
 <221> CDS
 <222> (1)..(1386)

<220>
 <221> misc_feature
 <222> (1)..(3)
 <223> INIT_MET

<220>
 <221> mat_peptide
 <222> (91)

<400> 5
 gtg ata tcg aga tgg acc gca tcc gct gtc gcc acg gcc gcc gcg ttc 48
 Val Ile Ser Arg Trp Thr Ala Ser Ala Val Ala Thr Ala Ala Ala Phe
 -30 -25 -20 -15

gcc gcc gcg gtg gcc ctg ccg gcc ccc cag gcc gcc tac gcc tcc ccg	96
Ala Ala Ala Val Ala Leu Pro Ala Pro Gln Ala Ala Tyr Ala Ser Pro	
-10 -5 -1 1	
ccc ggt acc aag gac gtc acc gcc gtc ctc ttc gag tgg aac ttc gcc	144
Pro Gly Thr Lys Asp Val Thr Ala Val Leu Phe Glu Trp Asn Phe Ala	
5 10 15	
tcc gtc gcc aag gag tgc acc aac acc ctc ggc ccc gcc gga tac ggc	192
Ser Val Ala Lys Glu Cys Thr Asn Thr Leu Gly Pro Ala Gly Tyr Gly	
20 25 30	
tcc gtg cag gtc tcc ccg ccc gcc gag cac atc cag ggc tca cag tgg	240
Ser Val Gln Val Ser Pro Pro Ala Glu His Ile Gln Gly Ser Gln Trp	
35 40 45 50	
tgg acc tcg tac cag ccg gtc agc tac aag atc gcg ggg cgc ctc ggt	288
Trp Thr Ser Tyr Gln Pro Val Ser Tyr Lys Ile Ala Gly Arg Leu Gly	
55 60 65	
gac gcc acc gcc ttc aag aac atg gtc ggc acc tgc cac gcg gcc ggg	336
Asp Ala Thr Ala Phe Lys Asn Met Val Gly Thr Cys His Ala Ala Gly	
70 75 80	
gtg aag gtc gtc gtc gac acc gtc atc aac cac atg tcc gcg ggc agc	384
Val Lys Val Val Val Asp Thr Val Ile Asn His Met Ser Ala Gly Ser	
85 90 95	
ggc acc ggt acc ggc gga tcg tcg tac acg aag tac aac tac ccc ggc	432
Gly Thr Gly Thr Gly Gly Ser Ser Tyr Thr Lys Tyr Asn Tyr Pro Gly	
100 105 110	
ctg tac tcc tcg tac gac atg gac gac tgc acg tcg acc atc acc gac	480
Leu Tyr Ser Ser Tyr Asp Met Asp Asp Cys Thr Ser Thr Ile Thr Asp	
115 120 125 130	
tac acc aac cgc ggc aac gtc cag aac tgc gaa ctc gtc ggc ctc gcc	528
Tyr Thr Asn Arg Gly Asn Val Gln Asn Cys Glu Leu Val Gly Leu Ala	
135 140 145	
gac ctg gac acc ggc gag gag tac gtc cgc gcc acc atc gcc ggc tac	576
Asp Leu Asp Thr Gly Glu Glu Tyr Val Arg Ala Thr Ile Ala Gly Tyr	
150 155 160	
ctg aac tcg ctg ctc ggc tac ggc gtc gac ggc ttc cgc atc gac gcg	624
Leu Asn Ser Leu Leu Gly Tyr Gly Val Asp Gly Phe Arg Ile Asp Ala	
165 170 175	
gcc aag cac atc ccg gcg acc gac ctc gcc aac atc aag tcg cgt ctg	672
Ala Lys His Ile Pro Ala Thr Asp Leu Ala Asn Ile Lys Ser Arg Leu	
180 185 190	
acg aac ccc tcc gtc tac tgg aag cag gag gtc atc tac ggc agc ggg	720
Thr Asn Pro Ser Val Tyr Trp Lys Gln Glu Val Ile Tyr Gly Ser Gly	
195 200 205 210	
gag gcc gtc cag ccc acc gag tac acg ggc aac ggg gac gtc cag gag	768
Glu Ala Val Gln Pro Thr Glu Tyr Thr Gly Asn Gly Asp Val Gln Glu	
215 220 225	

ttc cgc tac gcc tac gac ctc aag cgc gtc ttc aac aac gag aac ctc	816
Phe Arg Tyr Ala Tyr Asp Leu Lys Arg Val Phe Asn Asn Glu Asn Leu	
230 235 240	
gcc tat ctg aag aac tac ggc gag ggc tgg ggg tac ctg aac agc tcg	864
Ala Tyr Leu Lys Asn Tyr Gly Glu Gly Trp Gly Tyr Leu Asn Ser Ser	
245 250 255	
gtg gcc ggc gtc ttc gtc gac aac cac gac acc gag cgc aac ggc tcc	912
Val Ala Gly Val Phe Val Asp Asn His Asp Thr Glu Arg Asn Gly Ser	
260 265 270	
acg ctc aac tac aag gac ggc gcg aac tac acc ctc gcc aac gtc ttc	960
Thr Leu Asn Tyr Lys Asp Gly Ala Asn Tyr Thr Leu Ala Asn Val Phe	
275 280 285 290	
atg ctc gcc tac ccg tac ggc gcc ccg gac atc aac tca ggc tac gag	1008
Met Leu Ala Tyr Pro Tyr Gly Ala Pro Asp Ile Asn Ser Gly Tyr Glu	
295 300 305	
tgg tcc gac acg gac gcg ggc ccg ccc aac aac ggc tcc gtg agc gcc	1056
Trp Ser Asp Thr Asp Ala Gly Pro Pro Asn Asn Gly Ser Val Ser Ala	
310 315 320	
tgt tgg cag gac ggc tgg aag tgt cag cac gcc tgg ccg gag atc ctc	1104
Cys Trp Gln Asp Gly Trp Lys Cys Gln His Ala Trp Pro Glu Ile Leu	
325 330 335	
cgc atg gtc gcc ttc cgc aac gcc acc cgc ggt gag tcg gtc acc aac	1152
Arg Met Val Ala Phe Arg Asn Ala Thr Arg Gly Glu Ser Val Thr Asn	
340 345 350	
tgg tgg gac aac ggc ggc gac gcg atc gcc ttc ggg cgg ggc gcc aag	1200
Trp Trp Asp Asn Gly Gly Asp Ala Ile Ala Phe Gly Arg Gly Ala Lys	
355 360 365 370	
ggc tat gtc gcc atc aac cac gag tcc ggc agc ctg agc cgg acc tac	1248
Gly Tyr Val Ala Ile Asn His Glu Ser Gly Ser Leu Ser Arg Thr Tyr	
375 380 385	
cag acc tcg ctg ccc gcc ggc acg tac tgc aac gtg cag aac aac acg	1296
Gln Thr Ser Leu Pro Ala Gly Thr Tyr Cys Asn Val Gln Asn Asn Thr	
390 395 400	
agc gtg acg gtc ggc tcc aac ggt cag ttc acg gcc acg ctc ggg tcc	1344
Ser Val Thr Val Gly Ser Asn Gly Gln Phe Thr Ala Thr Leu Gly Ser	
405 410 415	
aac acg gca ctg gcg atc tac gcg ggc aag gcc aac tgc tga	1386
Asn Thr Ala Leu Ala Ile Tyr Ala Gly Lys Ala Asn Cys	
420 425 430	

<210> 6

<211> 461

<212> PRT

<213> Streptomyces sp. B327*

<400> 6

Val	Ile	Ser	Arg	Trp	Thr	Ala	Ser	Ala	Val	Ala	Thr	Ala	Ala	Ala	Phe
1				5					10					15	
Ala	Ala	Ala	Val	Ala	Leu	Pro	Ala	Pro	Gln	Ala	Ala	Tyr	Ala	Ser	Pro
			20					25					30		
Pro	Gly	Thr	Lys	Asp	Val	Thr	Ala	Val	Leu	Phe	Glu	Trp	Asn	Phe	Ala
		35					40					45			
Ser	Val	Ala	Lys	Glu	Cys	Thr	Asn	Thr	Leu	Gly	Pro	Ala	Gly	Tyr	Gly
	50					55					60				
Ser	Val	Gln	Val	Ser	Pro	Pro	Ala	Glu	His	Ile	Gln	Gly	Ser	Gln	Trp
65					70					75					80
Trp	Thr	Ser	Tyr	Gln	Pro	Val	Ser	Tyr	Lys	Ile	Ala	Gly	Arg	Leu	Gly
				85					90					95	
Asp	Ala	Thr	Ala	Phe	Lys	Asn	Met	Val	Gly	Thr	Cys	His	Ala	Ala	Gly
			100					105					110		
Val	Lys	Val	Val	Val	Asp	Thr	Val	Ile	Asn	His	Met	Ser	Ala	Gly	Ser
		115					120					125			
Gly	Thr	Gly	Thr	Gly	Gly	Ser	Ser	Tyr	Thr	Lys	Tyr	Asn	Tyr	Pro	Gly
	130					135						140			
Leu	Tyr	Ser	Ser	Tyr	Asp	Met	Asp	Asp	Cys	Thr	Ser	Thr	Ile	Thr	Asp
145					150					155					160
Tyr	Thr	Asn	Arg	Gly	Asn	Val	Gln	Asn	Cys	Glu	Leu	Val	Gly	Leu	Ala
				165					170					175	
Asp	Leu	Asp	Thr	Gly	Glu	Glu	Tyr	Val	Arg	Ala	Thr	Ile	Ala	Gly	Tyr
			180					185					190		
Leu	Asn	Ser	Leu	Leu	Gly	Tyr	Gly	Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala
		195					200					205			
Ala	Lys	His	Ile	Pro	Ala	Thr	Asp	Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu
	210					215					220				
Thr	Asn	Pro	Ser	Val	Tyr	Trp	Lys	Gln	Glu	Val	Ile	Tyr	Gly	Ser	Gly
225					230					235					240
Glu	Ala	Val	Gln	Pro	Thr	Glu	Tyr	Thr	Gly	Asn	Gly	Asp	Val	Gln	Glu
				245					250					255	
Phe	Arg	Tyr	Ala	Tyr	Asp	Leu	Lys	Arg	Val	Phe	Asn	Asn	Glu	Asn	Leu
			260					265					270		
Ala	Tyr	Leu	Lys	Asn	Tyr	Gly	Glu	Gly	Trp	Gly	Tyr	Leu	Asn	Ser	Ser
		275					280					285			
Val	Ala	Gly	Val	Phe	Val	Asp	Asn	His	Asp	Thr	Glu	Arg	Asn	Gly	Ser
	290					295					300				
Thr	Leu	Asn	Tyr	Lys	Asp	Gly	Ala	Asn	Tyr	Thr	Leu	Ala	Asn	Val	Phe
305					310					315					320
Met	Leu	Ala	Tyr	Pro	Tyr	Gly	Ala	Pro	Asp	Ile	Asn	Ser	Gly	Tyr	Glu
				325					330					335	
Trp	Ser	Asp	Thr	Asp	Ala	Gly	Pro	Pro	Asn	Asn	Gly	Ser	Val	Ser	Ala
			340					345					350		
Cys	Trp	Gln	Asp	Gly	Trp	Lys	Cys	Gln	His	Ala	Trp	Pro	Glu	Ile	Leu
		355					360					365			
Arg	Met	Val	Ala	Phe	Arg	Asn	Ala	Thr	Arg	Gly	Glu	Ser	Val	Thr	Asn
	370					375					380				
Trp	Trp	Asp	Asn	Gly	Gly	Asp	Ala	Ile	Ala	Phe	Gly	Arg	Gly	Ala	Lys
385					390					395					400
Gly	Tyr	Val	Ala	Ile	Asn	His	Glu	Ser	Gly	Ser	Leu	Ser	Arg	Thr	Tyr
				405					410					415	
Gln	Thr	Ser	Leu	Pro	Ala	Gly	Thr	Tyr	Cys	Asn	Val	Gln	Asn	Asn	Thr
			420					425					430		
Ser	Val	Thr	Val	Gly	Ser	Asn	Gly	Gln	Phe	Thr	Ala	Thr	Leu	Gly	Ser
		435					440					445			
Asn	Thr	Ala	Leu	Ala	Ile	Tyr	Ala	Gly	Lys	Ala	Asn	Cys			
	450					455						460			

<210> 7
 <211> 1377
 <212> DNA
 <213> Streptomyces sp. B400B

<220>
 <221> CDS
 <222> (1)..(1377)

<220>
 <221> misc_feature
 <222> (1)..(3)
 <223> INIT_MET

<220>
 <221> mat_peptide
 <222> (88)

<400> 7
 ttg agt tcc cgc gcc gca cgc gca acc ctg gcg ggc ctg ctc gcc gcc 48
 Leu Ser Ser Arg Ala Ala Arg Ala Thr Leu Ala Gly Leu Leu Ala Ala
 -25 -20 -15

ggt ggc ctc acg gtc ctc gcc ccc tgg cct tcc cag gcg acc cca ccg 96
 Gly Gly Leu Thr Val Leu Ala Pro Trp Pro Ser Gln Ala Thr Pro Pro
 -10 -5 -1 1

ggc gag aag acc gtc acc gcc acc ctc ttc gag tgg aag tac gac gcg 144
 Gly Glu Lys Thr Val Thr Ala Thr Leu Phe Glu Trp Lys Tyr Asp Ala
 5 10 15

gtg gcc acc gcc tgc acc gac acc ctg ggc ccg gcc ggc tac ggc tac 192
 Val Ala Thr Ala Cys Thr Asp Thr Leu Gly Pro Ala Gly Tyr Gly Tyr
 20 25 30 35

gtc gag gtc tcg ccc gcc acc gag cac atc cag ggc gac cag tgg tgg 240
 Val Glu Val Ser Pro Ala Thr Glu His Ile Gln Gly Asp Gln Trp Trp
 40 45 50

acc tcg tac cag ccg gtc agc tac cgg atc gcg ggc cgt ctc ggt gac 288
 Thr Ser Tyr Gln Pro Val Ser Tyr Arg Ile Ala Gly Arg Leu Gly Asp
 55 60 65

cgg gac tcc ttc gcc gcg atg gtg gag agc tgc cac gcg gcc ggg gtc 336
 Arg Asp Ser Phe Ala Ala Met Val Glu Ser Cys His Ala Ala Gly Val
 70 75 80

cgg gtc gtg gcg gac gcc gtg atc aac cac atg gcc gcc ggc tcc ggg 384
 Arg Val Val Ala Asp Ala Val Ile Asn His Met Ala Ala Gly Ser Gly
 85 90 95

acc ggg acg ggc ggc acg tcg tac acc aag tac gac tac ccc ggc acg 432
 Thr Gly Thr Gly Gly Thr Ser Tyr Thr Lys Tyr Asp Tyr Pro Gly Thr
 100 105 110 115

ttc cag gac cag gac ttc cac gcc tgc cgc aag gac atc gcg aac tac 480

Phe	Gln	Asp	Gln	Asp	Phe	His	Ala	Cys	Arg	Lys	Asp	Ile	Ala	Asn	Tyr		
				120					125					130			
ggc	gac	cgc	ggc	gac	gtc	cag	aac	tgc	gaa	ctg	gtc	ggc	ctc	gcg	gac	528	
Gly	Asp	Arg	Gly	Asp	Val	Gln	Asn	Cys	Glu	Leu	Val	Gly	Leu	Ala	Asp		
			135					140					145				
ctg	gac	acc	ggc	agc	gac	gcc	gta	cgc	acg	acg	atc	gcc	gcc	tac	ctc	576	
Leu	Asp	Thr	Gly	Ser	Asp	Ala	Val	Arg	Thr	Thr	Ile	Ala	Ala	Tyr	Leu		
			150				155					160					
tcc	gac	ctc	cgc	tcc	ctg	ggc	gtc	gac	ggc	ttc	cgc	atc	gac	gcc	gcc	624	
Ser	Asp	Leu	Arg	Ser	Leu	Gly	Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala		
		165				170					175						
aag	cac	atg	tcc	gcc	gac	gac	gtc	gcc	gcg	atc	aag	ggg	aag	atg	agc	672	
Lys	His	Met	Ser	Ala	Asp	Asp	Val	Ala	Ala	Ile	Lys	Gly	Lys	Met	Ser		
180				185						190					195		
gac	ccg	ggg	ttc	tgg	gtc	acc	gag	gtc	atc	cac	ggc	ggg	gga	gag	gcg	720	
Asp	Pro	Gly	Phe	Trp	Val	Thr	Glu	Val	Ile	His	Gly	Gly	Gly	Glu	Ala		
				200					205					210			
gtc	cag	ccg	gag	gag	tac	acc	tcg	atc	ggg	gac	gtc	gac	gag	ttc	cgt	768	
Val	Gln	Pro	Glu	Glu	Tyr	Thr	Ser	Ile	Gly	Asp	Val	Asp	Glu	Phe	Arg		
			215					220					225				
tac	ggc	ggc	cac	ctc	aag	tcc	gcc	ttc	cag	ggc	ggc	ggc	ctg	ccc	ggc	816	
Tyr	Gly	Gly	His	Leu	Lys	Ser	Ala	Phe	Gln	Gly	Gly	Gly	Leu	Pro	Gly		
			230				235					240					
ctg	aag	tcg	atc	gcc	gac	ggc	aaa	ctg	gcc	ggc	gcc	tcc	gcc	cgt	acg	864	
Leu	Lys	Ser	Ile	Ala	Asp	Gly	Lys	Leu	Ala	Gly	Ala	Ser	Ala	Arg	Thr		
		245				250					255						
ttc	gtc	gac	aac	tgg	gac	acc	gag	cgc	aac	ggc	tcc	acc	ctc	acc	cac	912	
Phe	Val	Asp	Asn	Trp	Asp	Thr	Glu	Arg	Asn	Gly	Ser	Thr	Leu	Thr	His		
260				265					270					275			
aag	gac	ggc	gcc	gcc	tac	acc	ctg	gcc	aac	gtc	ttc	atg	ctg	gcc	tcg	960	
Lys	Asp	Gly	Ala	Ala	Tyr	Thr	Leu	Ala	Asn	Val	Phe	Met	Leu	Ala	Ser		
			280						285				290				
ccc	tac	ggc	tcc	ccg	aac	gtc	ttc	tcc	ggc	tac	acc	tgg	acc	gac	aag	1008	
Pro	Tyr	Gly	Ser	Pro	Asn	Val	Phe	Ser	Gly	Tyr	Thr	Trp	Thr	Asp	Lys		
			295					300					305				
gac	gcc	ggc	ccg	ccg	aac	ggc	ggc	gcg	gcc	gac	tgc	ggc	tcc	ggc	gcg	1056	
Asp	Ala	Gly	Pro	Pro	Asn	Gly	Gly	Ala	Ala	Asp	Cys	Gly	Ser	Gly	Ala		
		310				315					320						
tgg	acc	tgc	acg	cac	gcc	cag	cag	gcg	gtc	acc	ggc	atg	gtc	ggc	ttc	1104	
Trp	Thr	Cys	Thr	His	Ala	Gln	Gln	Ala	Val	Thr	Gly	Met	Val	Gly	Phe		
		325				330					335						
cac	aac	gcc	gtc	gcg	ggc	gcg	gag	ctg	acc	gac	tgg	tgg	gac	gac	ggc	1152	
His	Asn	Ala	Val	Ala	Gly	Ala	Glu	Leu	Thr	Asp	Trp	Trp	Asp	Asp	Gly		
340				345					350						355		

```

tcc tcc gcc ctc gcc ttc gcc cgc gcg ggc aag ggc ttt gtc gcc gtc 1200
Ser Ser Ala Leu Ala Phe Ala Arg Ala Gly Lys Gly Phe Val Ala Val
          360          365          370

aac aac ggc gac gcg gag ctg aac cgc acc ttc acg acg acg ctg ccg 1248
Asn Asn Gly Asp Ala Glu Leu Asn Arg Thr Phe Thr Thr Thr Leu Pro
          375          380          385

gcg ggc acg tac tgc aat gtg gtc gcc gcg gcc ccc gac tcc tgc gac 1296
Ala Gly Thr Tyr Cys Asn Val Val Ala Ala Ala Pro Asp Ser Cys Asp
          390          395          400

ggc aac ggg acc acg gtc gcg gac gac ggc acg gcg acg atc acg gtc 1344
Gly Asn Gly Thr Thr Val Ala Asp Asp Gly Thr Ala Thr Ile Thr Val
          405          410          415

ccg gcg cgc gga gcg gtg gcg ctg cac acc tag 1377
Pro Ala Arg Gly Ala Val Ala Leu His Thr
420          425          430

```

<210> 8
 <211> 458
 <212> PRT
 <213> Streptomyces sp. B400B

```

<400> 8
Leu Ser Ser Arg Ala Ala Arg Ala Thr Leu Ala Gly Leu Leu Ala Ala
 1          5          10          15
Gly Gly Leu Thr Val Leu Ala Pro Trp Pro Ser Gln Ala Thr Pro Pro
          20          25          30
Gly Glu Lys Thr Val Thr Ala Thr Leu Phe Glu Trp Lys Tyr Asp Ala
          35          40          45
Val Ala Thr Ala Cys Thr Asp Thr Leu Gly Pro Ala Gly Tyr Gly Tyr
          50          55          60
Val Glu Val Ser Pro Ala Thr Glu His Ile Gln Gly Asp Gln Trp Trp
          65          70          75          80
Thr Ser Tyr Gln Pro Val Ser Tyr Arg Ile Ala Gly Arg Leu Gly Asp
          85          90          95
Arg Asp Ser Phe Ala Ala Met Val Glu Ser Cys His Ala Ala Gly Val
          100          105          110
Arg Val Val Ala Asp Ala Val Ile Asn His Met Ala Ala Gly Ser Gly
          115          120          125
Thr Gly Thr Gly Gly Thr Ser Tyr Thr Lys Tyr Asp Tyr Pro Gly Thr
          130          135          140
Phe Gln Asp Gln Asp Phe His Ala Cys Arg Lys Asp Ile Ala Asn Tyr
          145          150          155          160
Gly Asp Arg Gly Asp Val Gln Asn Cys Glu Leu Val Gly Leu Ala Asp
          165          170          175
Leu Asp Thr Gly Ser Asp Ala Val Arg Thr Thr Ile Ala Ala Tyr Leu
          180          185          190
Ser Asp Leu Arg Ser Leu Gly Val Asp Gly Phe Arg Ile Asp Ala Ala
          195          200          205
Lys His Met Ser Ala Asp Asp Val Ala Ala Ile Lys Gly Lys Met Ser
          210          215          220
Asp Pro Gly Phe Trp Val Thr Glu Val Ile His Gly Gly Gly Glu Ala
          225          230          235          240
Val Gln Pro Glu Glu Tyr Thr Ser Ile Gly Asp Val Asp Glu Phe Arg
          245          250          255

```

Tyr Gly Gly His Leu Lys Ser Ala Phe Gln Gly Gly Gly Leu Pro Gly
 260 265 270
 Leu Lys Ser Ile Ala Asp Gly Lys Leu Ala Gly Ala Ser Ala Arg Thr
 275 280 285
 Phe Val Asp Asn Trp Asp Thr Glu Arg Asn Gly Ser Thr Leu Thr His
 290 295 300
 Lys Asp Gly Ala Ala Tyr Thr Leu Ala Asn Val Phe Met Leu Ala Ser
 305 310 315 320
 Pro Tyr Gly Ser Pro Asn Val Phe Ser Gly Tyr Thr Trp Thr Asp Lys
 325 330 335
 Asp Ala Gly Pro Pro Asn Gly Gly Ala Ala Asp Cys Gly Ser Gly Ala
 340 345 350
 Trp Thr Cys Thr His Ala Gln Gln Ala Val Thr Gly Met Val Gly Phe
 355 360 365
 His Asn Ala Val Ala Gly Ala Glu Leu Thr Asp Trp Trp Asp Asp Gly
 370 375 380
 Ser Ser Ala Leu Ala Phe Ala Arg Ala Gly Lys Gly Phe Val Ala Val
 385 390 395 400
 Asn Asn Gly Asp Ala Glu Leu Asn Arg Thr Phe Thr Thr Thr Leu Pro
 405 410 415
 Ala Gly Thr Tyr Cys Asn Val Val Ala Ala Ala Pro Asp Ser Cys Asp
 420 425 430
 Gly Asn Gly Thr Thr Val Ala Asp Asp Gly Thr Ala Thr Ile Thr Val
 435 440 445
 Pro Ala Arg Gly Ala Val Ala Leu His Thr
 450 455

<210> 9
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PCR primer (GEX024)

<400> 9
 cgtcgacggc ttccgsatcg acrc

24

<210> 10
 <211> 25
 <212> DNA
 <213> Artificial sequence

<220>
 <223> PCR primer (GEX026)

<400> 10
 gtcggtgtc gtggttgctc acgwa

25

<210> 11
 <211> 24
 <212> DNA
 <213> Artificial sequence

<220>

<223> PCR primer (GEX029)

<400> 11
cggcgtcgac ggctkscgbn tsga

24

<210> 12
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> PCR primer (GEX031)

<400> 12
gctgggtgtc gtggttgtes acsma

25

<210> 13
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> PCR primer (GEX015)

<400> 13
ggtggacgtc ctaccagccs gt

22

<210> 14
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> PCR primer (GEX016)

<400> 14
gcacccgcag gagcacrycs agg

23

<210> 15
<211> 18
<212> DNA
<213> Artificial sequence

<220>
<223> PCR primer (GEX017)

<400> 15
cgcggccggc gtsaagrt

18

<210> 16
<211> 22
<212> DNA
<213> Artificial sequence

<220>
<223> PCR primer (GEX018)

<400> 16
tggtcaacac ctgccacgms gc 22

<210> 17
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> PCR primer (GEX019)

<400> 17
cgcggcgtcg atgckgaagm mgtc 24

<210> 18
<211> 26
<212> DNA
<213> Artificial sequence

<220>
<223> PCR primer (GEX020)

<400> 18
ggagccgtac ggccasgcsa gcatga 26

<210> 19
<211> 23
<212> DNA
<213> Artificial sequence

<220>
<223> PCR primer (GEX021)

<400> 19
cccttgctgc cgcgsscga sgc 23

<210> 20
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> PCR primer (GEX022)

<400> 20
ggcgtcctcg tggttgawsg csac 24

<210> 21
<211> 27
<212> DNA
<213> Artificial sequence

<220>

<223> PCR primer (GEX023)

<400> 21

ggtctacgcc gacgtcgtsw wcaacca

27

<210> 22

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer (GEX025)

<400> 22

ggcgtcgatg cggaascgt c

21

<210> 23

<211> 31

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer (GEX027)

~~<400> 23~~

gcgtccaggt ctacgtcgac rysgtshtsa a

31.

<210> 24

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer (GEX028)

<400> 24

caggtctacg tcgacgtcgt shtsaacca

29

<210> 25

<211> 27

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer (GEX030)

<400> 25

cggcggggat gtgctksrcc rmgtcsa

27

<210> 26

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer (GEX036)

<400> 26

gtacgccgac gccgtnwtha ayca

24

<210> 27

<211> 26

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer (GEX037)

<400> 27

gtacgccgac gccgtnwtha aycaya

26

<210> 28

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer (GEX038)

<400> 28

ggcggcgtag atcckraanc crtc

24

<210> 29

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer (GEX039)

<400> 29

cttggcggcg tcgatnckra ancc

24

<210> 30

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer (GEX040)

<400> 30

tcttgctcgg cgtggayggn ttymg

25

<210> 31

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer (GEX041)

<400> 31

ccggatcgac gccgynaarc ayat

24

<210> 32

<211> 26

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer (GEX042)

<400> 32

cgctcggtgt cgtggtntc nacvma

26

<210> 33

<211> 28

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer (GEX043)

<400> 33

cgttcgctc ggtgctgyrr ttntcnac

28

<210> 34

<211> 100

<212> PRT

<213> Streptomyces sp. B1002

<400> 34

Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Met	Pro	Ala	Ala	Asp
1				5					10					15	

Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Gly	Asp	Pro	Asn	Val	Tyr	Trp	Lys
		20						25					30		

Gln	Glu	Ala	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Ser	Pro	Asp	Glu	Tyr
		35					40					45			

Thr	Gly	Thr	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Arg	Gly	Leu	Lys
	50					55					60				

Gln	Val	Phe	Asn	Asn	Glu	Asn	Leu	Ala	Tyr	Leu	Lys	Asn	Tyr	Gly	Glu
65					70					75				80	

Gly	Trp	Gly	Phe	Met	Pro	Ser	Ser	Lys	Ala	Ala	Val	Tyr	Val	Asp	Asn
				85					90					95	

His Asp Thr Glu

100

<210> 35
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1003B

<400> 35
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Gly Asp Pro Asn Val Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Asp Glu Tyr
 35 40 45
 Thr Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Gly Leu Lys
 50 55 60
 Gln Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Phe Met Pro Ser Ser Lys Ala Ala Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 36
 <211> 97
 <212> PRT
 <213> Streptomyces sp. B1006

<400> 36
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Ser Ala Ala Asp
 1 5 10 15
 Val Ala Ala Val Lys Gly Lys Met Arg Asp Pro Gly Tyr Trp Val Gln
 20 25 30
 Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Asp Glu Tyr Thr
 35 40 45
 Gly Ile Gly Asp Val Asp Glu Phe Arg Tyr Gly Ser His Leu Lys Ser
 50 55 60
 Ala Phe Gln Gly Gly Asn Ile Ala Gln Leu Lys Ser Val Ala Asp Gly
 65 70 75 80
 Lys Leu Gly Ser Asp Lys Ala Arg Thr Tyr Val Asp Asn His Asp Thr
 85 90 95
 Glu

<210> 37
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1008A1

<400> 37
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Glu Asp Asp
 1 5 10 15
 Leu Ala Ala Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 Gln Glu Thr Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Leu Thr Thr Gly Asp Ala Gln Glu Phe Arg Tyr Ser Trp Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Ser Glu Lys Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Ala Gly Gly Lys Ala Ser Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 38
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1009A

<400> 38
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 39
 <211> 100
 <212> PRT

<213> Streptomyces sp. B1010

<400> 39

Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Ile	Pro	Ala	Ala	Asp	1	5	10	15
Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Ser	Asn	Pro	Gly	Val	Tyr	Trp	Lys	20	25	30	
His	Glu	Val	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Gln	Pro	Thr	Glu	Tyr	35	40	45	
Thr	Gly	Ser	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Tyr	Asp	Leu	Lys	50	55	60	
Arg	Val	Phe	Thr	Asn	Glu	Asn	Leu	Ala	Tyr	Leu	Lys	Asn	Tyr	Gly	Glu	65	70	75	80
Gly	Trp	Gly	Tyr	Leu	Asn	Ser	Gly	Val	Ser	Gly	Val	Tyr	Val	Asp	Asn	85	90	95	
His	Asp	Thr	Glu													100			

<210> 40

<211> 100

<212> PRT

<213> Streptomyces sp. B1011

<400> 40

Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Ile	Pro	Ala	Ala	Asp	1	5	10	15
Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Thr	Lys	Pro	Asp	Val	Tyr	Trp	Lys	20	25	30	
Gln	Glu	Val	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Gln	Pro	Thr	Glu	Tyr	35	40	45	
Thr	Gly	Asn	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Tyr	Asp	Leu	Lys	50	55	60	
Arg	Val	Phe	Arg	Asn	Glu	Arg	Leu	Ala	Tyr	Leu	Lys	Asn	Tyr	Gly	Glu	65	70	75	80
Gly	Trp	Gly	Tyr	Met	Asn	Ser	Ser	Val	Ala	Gly	Val	Tyr	Val	Asp	Asn	85	90	95	
His	Asp	Thr	Glu													100			

<210> 41

<211> 100

<212> PRT

<213> Streptomyces sp. B1012B

<400> 41

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Lys Pro Asp Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Arg Asn Glu Arg Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Asn Ser Ser Val Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 42
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1014A1

<400> 42
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Lys Pro Asp Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Arg Asn Glu Arg Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Asn Ser Ser Val Ala Gly Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 43
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1017C

<400> 43
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Lys Pro Asp Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Arg Asn Glu Arg Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Asn Ser Ser Val Ala Gly Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 44
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1019

<400> 44
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Lys Pro Asp Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Arg Asn Glu Lys Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Asn Ser Ser Val Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 45
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B101A

<400> 45
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Ala Ala Asp
 1 5 10 15
 Leu Ala Asp Ile Lys Ser Arg Leu Ser Asp Pro Asp Val Tyr Trp Lys
 20 25 30

```

<400> 47
Gly Ser Lys His Met Pro Ala Ala Asp Ile Ala Ala Ile Lys Ala Lys
 1             5             10             15
Leu Asn Arg Ser Ala Tyr Leu Val Gln Glu Val Asn Tyr Gly Ala Gly
      20             25             30
Glu Pro Ile Gln Pro Thr Glu Tyr Thr Gly Asn Gly Asp Val His Glu
      35             40             45

```

Phe Arg Tyr Gly Lys Asp Leu Ala Arg Met Phe Asn Asn Glu Arg Leu
 50 55 60

Ala Tyr Leu Arg Asn Phe Gly Glu Ser Trp Gly Tyr Leu Ser Ser Ala
 65 70 75 80

Lys Ala Val Val

<210> 48
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1020C

<400> 48
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Glu Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Asn Ala Tyr Trp Lys
 20 25 30

Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gly Glu Tyr
 35 40 45

Thr Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Asn Ser Thr Thr Ala Gly Val Phe Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 49
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1022A

<400> 49
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Ala Ala Gly Asp
 1 5 10 15

Leu Ala Pro Ile Lys Ser Arg Leu Ser Asn Thr Asn Val Tyr Trp Lys
 20 25 30

Gln Glu Val Ile His Gly Ala Gly Glu Ala Val Gln Pro Gly Glu Tyr
 35 40 45

Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Ser Glu
 65 70 75 80

His Asp Thr Glu
100

<210> 52
<211> 100
<212> PRT
<213> Streptomyces sp. B1030A

<400> 52
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Gly Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
20 25 30
Gln Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Asp Glu Tyr
35 40 45
Ala Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Ser Leu Lys
50 55 60
Gln Val Phe Asn Asn Glu Asn Leu Ala Asn Leu Lys Asn Phe Gly Glu
65 70 75 80
Gly Trp Gly Phe Met Pro Ser Ser Lys Ala Ala Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 53
<211> 100
<212> PRT
<213> Streptomyces sp. B1035B

<400> 53
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Ala Glu Asp Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Thr Asp Pro Gly Val Tyr Trp Lys
20 25 30
Gln Glu Thr Ile Gly Ala Ala Gly Glu Ala Val Gln Pro Ser Glu Tyr
35 40 45
Tyr Asn Thr Gly Asp Val Gln Glu Phe His Tyr Ala Tyr Asp Leu Lys
50 55 60
Arg Val Phe Thr Gly Glu Lys Leu Ala Glu Leu Lys Asn Phe Gly Glu
65 70 75 80
Ala Trp Gly Tyr Val Pro Ser Gly Lys Ala Ser Val Phe Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 54
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1036

<400> 54
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Ala Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Ala Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Gly Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Ser Glu Lys Leu Ala Tyr Leu Asn Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Pro Gly Asn Val Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 55
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1037A

<400> 55
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Ala Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Asn Ala Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Phe Gln Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Ala Ser Gly Gln Ser Ala Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 56
 <211> 100

<212> PRT

<213> Streptomyces sp. B1039A

<400> 56

Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Met	Ala	Ala	Gly	Asp
1				5					10					15	

Leu	Ala	Ala	Ile	Lys	Ser	Arg	Leu	Thr	Asn	Pro	Asn	Val	Tyr	Trp	Lys
			20					25					30		

His	Glu	Ala	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Ser	Pro	Ser	Glu	Tyr
		35					40					45			

Leu	Gly	Ser	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Arg	Asp	Leu	Lys
	50					55					60				

Arg	Val	Phe	Gly	Ser	Glu	Asn	Leu	Ala	Tyr	Leu	Lys	Asn	Phe	Gly	Glu
65					70					75					80

Ser	Trp	Gly	Tyr	Met	Pro	Ser	Gly	Gln	Ser	Ala	Val	Tyr	Val	Asp	Asn
				85					90					95	

His	Asp	Thr	Glu
			100

<210> 57

<211> 100

<212> PRT

<213> Streptomyces sp. B103A

<400> 57

Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Met	Pro	Ala	Ala	Asp
1				5					10					15	

Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Ser	Asn	Pro	Gly	Val	Tyr	Trp	Lys
			20					25					30		

His	Glu	Ala	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Ser	Pro	Ser	Glu	Tyr
		35					40					45			

Leu	Gly	Ser	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Gly	Arg	Gly	Leu	Lys
	50					55					60				

Gln	Val	Phe	Asn	Asn	Glu	Asn	Leu	Ala	His	Leu	Lys	Asn	Phe	Gly	Glu
65					70					75					80

Gly	Trp	Gly	Phe	Met	Glu	Ser	Gly	Lys	Ser	Ala	Val	Phe	Val	Asp	Asn
				85					90					95	

His	Asp	Thr	Glu
			100

<210> 58

<211> 100

<212> PRT

<213> Streptomyces sp. B1041A1

<400> 58

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Lys Pro Asp Val Tyr Trp Lys
 20 25 30

Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45

Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Arg Asn Glu Arg Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Met Asn Ser Ser Val Ala Gly Val Phe Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 59

<211> 100

<212> PRT

<213> Streptomyces sp. B1043A

<400> 59

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Ala Ala Ala Asp
 1 5 10 15

Leu Ala Ala Ile Lys Ser Arg Leu Ser Asn Pro Asn Val Tyr Trp Lys
 20 25 30

His Glu Ala Ile Tyr Gly Ala Gly Glu Thr Val Ser Pro Thr Glu Tyr
 35 40 45

Val Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60

Arg Val Phe Asn Gly Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80

Ala Trp Gly His Leu Pro Ser Asp Glu Ala Ala Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 60

<211> 100

<212> PRT

<213> Streptomyces sp. B1044C

<400> 60

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Ala Thr Glu Asp
 1 5 10 15

Leu Ala Ala Val Lys Ala Lys Leu Ser Lys Pro Asp Val Tyr Trp Lys
 20 25 30
 Gln Glu Thr Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gln Glu Tyr
 35 40 45
 Leu Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Phe Gln Ser Glu Arg Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Pro Gly Asp Arg Ala Ser Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 61
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1045

<400> 61
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Thr Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Ser Ser Ser Val Ala Gly Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 62
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1046A

<400> 62
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Ala Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asp Pro Asn Val Tyr Trp Lys
 20 25 30

Val Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60

Arg Val Phe Asn Gly Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80

Ala Trp Gly His Leu Pro Ser Asp Glu Ala Ala Val Phe Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 65
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1049A

<400> 65
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Ala Ala Gly Asp
 1 5 10 15

Leu Ala Ala Ile Lys Ser Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
 20 25 30

His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45

Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60

Arg Val Phe Gly Ser Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80

Ser Trp Gly Tyr Met Pro Ser Gly Gln Ser Ala Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 66
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1050A

<400> 66
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Ala Ala Gly Asp
 1 5 10 15

Leu Ala Ala Ile Lys Ser Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
 20 25 30

His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45

Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60

Arg Val Phe Gly Ser Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
65 70 75 80

Ser Trp Gly Tyr Met Pro Ser Gly Gln Ser Ala Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 67

<211> 100

<212> PRT

<213> Streptomyces sp. B1052A2

<400> 67

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Ala Ala Gly Asp
1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
20 25 30

His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ala Glu Tyr
35 40 45

Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
65 70 75 80

Ser Trp Gly Tyr Leu Pro Ser Asp Gln Ala Ala Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 68

<211> 100

<212> PRT

<213> Streptomyces sp. B1053

<400> 68

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
1 5 10 15

Leu Thr Ala Ile Lys Ala Lys Val Gly Asn Gly Ser Thr Tyr Trp Lys
20 25 30

Gln Glu Ala Ile His Gly Ala Gly Glu Ala Val Gln Pro Ser Glu Tyr
35 40 45

Leu Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
50 55 60

Arg Val Phe Gln Asn Glu Asn Leu Ala His Leu Lys Xaa Phe Gly Glu
65 70 75 80

His Asp Thr Glu
100

<210> 71
<211> 100
<212> PRT
<213> Streptomyces sp. B1061B

<400> 71
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Pro Ser Asn Pro Gly Val Tyr Trp Lys
20 25 30
His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
35 40 45
Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Gly Leu Lys
50 55 60
Gln Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
65 70 75 80
Gly Trp Gly Phe Met Glu Ser Gly Arg Ser Ala Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 72
<211> 100
<212> PRT
<213> Streptomyces sp. B1065

<400> 72
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Gly Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Asn Val Tyr Trp Lys
20 25 30
His Glu Ala Ile Phe Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
35 40 45
Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys
50 55 60
Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
65 70 75 80
Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Ala Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 73
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1067A

<400> 73
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Gly Leu Lys
 50 55 60
 Gln Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Phe Met Glu Ser Gly Arg Ser Ala Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 74
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1068

<400> 74
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Gly Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Asn Val Tyr Trp Lys
 20 25 30
 His Glu Ala Ile Phe Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys
 50 55 60
 Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Ala Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 75

<211> 100
 <212> PRT
 <213> Streptomyces sp. B1069B

<400> 75
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Thr Ala Ile Lys Ala Lys Val Gly Asp Gly Gly Thr Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile His Gly Ala Gly Glu Ala Val Gln Pro Ser Glu Tyr
 35 40 45
 Leu Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Phe Gln Asn Glu Asn Leu Ala His Leu Lys Asn Phe Asp Glu
 65 70 75 80
 Asp Trp Gly His Met Gln Ser Gly Arg Ser Ala Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 76
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B106C

<400> 76
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asp Pro Gly Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Phe Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Lys Ser Ser Ser Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 77
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B107

<400> 77

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Pro Arg Leu Thr Asn Pro Ser Ala Tyr Trp Lys
 20 25 30

Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gly Glu Tyr
 35 40 45

Thr Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Asn Asn Glu Ser Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Lys Ser Ser Ser Ala Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 78

<211> 100

<212> PRT

<213> Streptomyces sp. B1070A

<400> 78

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Val Tyr Trp Lys
 20 25 30

Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45

Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Met Ser Ser Ser Val Ala Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 79

<211> 100

<212> PRT

<213> Streptomyces sp. B1071

<400> 79

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Gly Asp

1	5	10	15												
Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Ser	Asn	Pro	Asn	Val	Tyr	Trp	Lys
			20					25					30		
His	Glu	Ala	Ile	Phe	Gly	Ala	Gly	Glu	Ala	Val	Ser	Pro	Ser	Glu	Tyr
		35					40					45			
Leu	Gly	Ser	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Gly	Arg	Ser	Leu	Lys
	50					55					60				
Gln	Val	Phe	Leu	Asn	Glu	Asn	Leu	Ala	His	Leu	Lys	Asn	Phe	Gly	Glu
	65				70					75					80
Gly	Trp	Gly	Phe	Met	Glu	Ser	Gly	Lys	Ser	Ala	Val	Tyr	Val	Asp	Asn
				85					90					95	
His	Asp	Thr	Glu												
			100												

<210> 80
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B1072A

<400> 80
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Val Tyr Trp Lys
20 25 30
Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45
Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60
Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80
Gly Trp Gly Tyr Met Ser Ser Ser Val Ala Gly Val Phe Val Asp Asn
85 90 95
His Asp Thr Glu
100

<210> 81
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B108

<400> 81
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Val Phe Trp Lys

	20		25		30										
Met	Glu	Ala	Ile	His	Gly	Ala	Gly	Glu	Ala	Val	Ser	Pro	Ser	Glu	Tyr
		35					40					45			
Leu	Gly	Ser	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Arg	Asp	Leu	Lys
	50					55					60				
Arg	Val	Leu	Gln	Asn	Glu	Lys	Leu	Ala	His	Leu	Lys	Asn	Phe	Gly	Glu
	65				70					75					80
Ser	Trp	Gly	Tyr	Met	Pro	Ser	Gly	Gln	Ser	Gly	Val	Tyr	Val	Asp	Asn
				85					90					95	
His	Asp	Thr	Glu												
			100												

<210> 82
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B109A

Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Met	Pro	Ala	Ala	Asp
	1			5					10					15	
Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Thr	Lys	Pro	Gly	Val	Tyr	Trp	Lys
			20					25					30		
Gln	Glu	Ala	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Gln	Pro	Ser	Glu	Tyr
		35					40					45			
Thr	Gly	Thr	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Tyr	Asp	Leu	Lys
	50					55					60				
Arg	Val	Phe	Asn	Asn	Glu	Asn	Leu	Ala	Tyr	Leu	Lys	Asn	Tyr	Gly	Glu
	65				70					75					80
Gly	Trp	Gly	Tyr	Met	Asn	Ser	Gly	Val	Ser	Gly	Val	Tyr	Val	Asp	Asn
				85					90					95	
His	Asp	Thr	Glu												
			100												

<210> 83
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B114C

Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Ile	Pro	Ala	Ala	Asp
	1			5					10					15	
Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Ser	Asn	Pro	Gly	Val	Tyr	Trp	Lys
			20					25					30		
His	Glu	Val	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Gln	Pro	Thr	Glu	Tyr

35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 84
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B115

<400> 84
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asp Ile Lys Ser Arg Leu Thr Asn Pro Ser Ala Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Phe Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ala Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Ser Ala Gly Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 85
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B117A1

<400> 85
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Ser Tyr Ala Tyr Asp Leu Lys

50	55	60
Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu		
65	70	75 80
Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn		
	85	90 95
His Asp Thr Glu		
	100	

<210> 86
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B118

<400> 86
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Ala Val Gly Asp
1 5 10 15
Leu Ala Asp Ile Lys Ser Arg Leu Gly Asn Pro Asp Val His Trp Lys
20 25 30
His Glu Ala Ile His Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
35 40 45
Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
50 55 60
Arg Val Leu Thr Gly Gly Ser Leu Ala His Leu Arg Asn Phe Gly Glu
65 70 75 80
Gly Trp Gly Tyr Met Ala Ser Asp Arg Ser Asn Val Phe Val Asp Asn
85 90 95
His Asp Thr Glu
100

<210> 87
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B119E

<400> 87
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Glu Asp Asp
1 5 10 15
Leu Ala Ala Ile Lys Ser Arg Leu Ser Asn Gln Gly Val Tyr Trp Lys
20 25 30
Gln Glu Thr Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45
Leu Thr Thr Gly Asp Ala Gln Glu Leu Arg Tyr Ser Trp Asp Leu Lys
50 55 60
Arg Val Phe Thr Ser Glu Lys Leu Ala Tyr Leu Lys Asn Phe Gly Glu

65 70 75 80
 Gly Trp Gly Tyr Met Ala Gly Gly Lys Ala Ser Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 88
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B120alt

<400> 88
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Ala Tyr Trp Lys
 20 25 30

His Glu Val Ile Phe Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45

Thr Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Thr Ser Gly Ser Ala Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 89
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B123

<400> 89
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15

Leu Thr Ala Ile Lys Ala Xaa Val Gly Asp Gly Gly Thr Tyr Trp Lys
 20 25 30

Gln Glu Ala Ile His Gly Ala Gly Glu Ala Val Gln Pro Ser Glu Tyr
 35 40 45

Leu Gly Thr Cys Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60

Arg Val Phe Gln Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
 65 70 75 80

Asp Trp Gly His Met Gln Ser Gly Arg Ser Ala Val Phe Val Asp Asn

85

90

95

His Asp Thr Glu
100

<210> 90
<211> 100
<212> PRT
<213> Streptomyces sp. B124

<400> 90
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
20 25 30
His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45
Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60
Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80
Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Phe Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 91
<211> 100
<212> PRT
<213> Streptomyces sp. B125C

<400> 91
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Ala Ala Gly Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
20 25 30
His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ala Glu Tyr
35 40 45
Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
50 55 60
Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
65 70 75 80
Ser Trp Gly Tyr Leu Pro Ser Asp Gln Ala Ala Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu

100

<210> 92
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B126A

<400> 92
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asp Ile Lys Ser Arg Leu Thr Asn Pro Ser Ala Tyr Trp Lys
 20 25 30
 His Glu Val Ile Phe Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ala Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Thr Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Phe Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 93
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B127A

<400> 93
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Lys Pro Gly Val Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Ser Glu Tyr
 35 40 45
 Thr Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 94
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B128B

<400> 94
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Ala Tyr Trp Lys
 20 25 30
 His Glu Val Ile Phe Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Xaa Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Thr Ser Gly Ser Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 95
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B130B

<400> 95
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Ala Tyr Trp Lys
 20 25 30
 Leu Glu Ala Ile His Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Leu Gln Ser Glu Lys Leu Ala His Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Ala Trp Gly Tyr Met Pro Ser Ala Gln Ser Gly Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 96
 <211> 100
 <212> PRT

<213> Streptomyces sp. B131

<400> 96

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Val Phe Trp Lys
 20 25 30

Met Glu Ala Ile His Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45

Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60

Arg Val Leu Gln Asn Glu Lys Leu Ala His Leu Lys Asn Phe Gly Glu
 65 70 75 80

Ser Trp Gly Tyr Met Pro Ser Gly Gln Ser Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 97

<211> 100

<212> PRT

<213> Streptomyces sp. B134

<400> 97

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Ala Tyr Trp Lys
 20 25 30

Leu Glu Ala Ile His Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45

Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60

Arg Ile Val Gln Ser Glu Lys Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80

Ala Trp Gly Tyr Met Pro Ser Gly Gln Ser Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 98

<211> 100

<212> PRT

<213> Streptomyces sp. B135A

<400> 98

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asp Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile His Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Ser Ser Gly Ala Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 99
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B137

<400> 99
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Gly Asp
 1 5 10 15
 Pro Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Asn Val Tyr Trp Lys
 20 25 30
 His Glu Ala Ile Phe Gly Ala Gly Glu Ala Val Ser Pro Ser Glu His
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys
 50 55 60
 Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Ala Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 100
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B138

<400> 100
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Asp Ala Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile His Gly Ala Gly Glu Ala Val Gln Pro Gly Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe His Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Lys Asn Ser Ser Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 101
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B138A

<400> 101
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Asp Ala Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile His Gly Ala Gly Glu Ala Val Gln Pro Gly Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe His Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Lys Asn Ser Ser Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 102
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B138A2

<400> 102
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Asp Ala Tyr Trp Lys
 20 25 30

Gln Glu Val Ile His Gly Ala Gly Glu Ala Val Gln Pro Gly Glu Tyr
 35 40 45

Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe His Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Lys Asn Ser Ser Ala Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 103
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B140

<400> 103
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Ala Tyr Trp Lys
 20 25 30

Leu Glu Ala Ile His Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45

Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60

Arg Ile Val Gln Ser Glu Lys Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80

Ala Trp Gly Tyr Met Pro Ser Gly Gln Ser Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 104
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B141

<400> 104
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Ala Tyr Trp Lys
 20 25 30

Leu Glu Ala Ile His Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45

```

<400> 106
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Gly
  1             5             10             15
Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Ala Tyr Trp Lys
      20             25             30
Leu Glu Ala Ile His Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
      35             40             45
Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
      50             55             60

```

Arg Ile Val Gln Ser Glu Lys Leu Ala Tyr Leu Lys Asn Phe Gly Glu
65 70 75 80

Ala Trp Gly Tyr Met Pro Ser Gly Gln Ser Gly Val Phe Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 107

<211> 100

<212> PRT

<213> Streptomyces sp. B148A

<400> 107

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Ala Asp
1 5 10 15

Leu Ala Asp Ile Lys Ser Arg Leu Thr Asn Pro Ser Ala Tyr Trp Lys
20 25 30

Gln Glu Val Ile Xaa Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45

Thr Gly Ala Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80

Gly Trp Gly Tyr Leu Asn Ser Gly Phe Ala Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 108

<211> 100

<212> PRT

<213> Streptomyces sp. B152A

<400> 108

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
20 25 30

Gln Glu Ala Ile His Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
35 40 45

Leu Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
50 55 60

Arg Ile Phe Gly Ser Glu Lys Leu Ser His Leu Ser Thr Phe Gly Glu
65 70 75 80

```
<400> 110
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Asp Ala Ala Asp
   1                       5                      10                   15

Leu Ala Asp Ile Lys Ser Arg Leu Ser Asn Pro Ser Val Tyr Trp Lys
          20                     25                             30

Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
      35                               40                           45

Thr Ser Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
    50                                55                            60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
  65                        70                          75                80

Gly Trp Gly Tyr Met Ser Ser Gly Val Ser Gly Val Tyr Val Asp Asn
                        85                              90                 95
```

His Asp Thr Glu
100

<210> 111
<211> 100
<212> PRT
<213> Streptomyces sp. B156B

<400> 111
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Ala Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Thr Asp Pro Asn Val Tyr Trp Lys
20 25 30
His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ala Glu Tyr
35 40 45
Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
50 55 60
Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
65 70 75 80
Ala Trp Gly Tyr Leu Pro Ser Asp Gln Ala Ala Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 112
<211> 100
<212> PRT
<213> Streptomyces sp. B157C

<400> 112
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Asp Ala Ala Asp
1 5 10 15
Leu Ala Asp Ile Lys Ser Arg Leu Ser Asn Pro Ser Val Tyr Trp Lys
20 25 30
Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45
Thr Ser Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60
Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80
Gly Trp Gly Tyr Met Ser Ser Gly Val Ser Gly Val Phe Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 113
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B158A

<400> 113
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 114
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B159

<400> 114
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 115
 <211> 100

<212> PRT

<213> Streptomyces sp. B160B

<400> 115

Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Ile	Pro	Ala	Ala	Asp
1				5					10					15	

Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Ser	Asn	Pro	Gly	Val	Tyr	Trp	Lys
		20					25					30			

His	Glu	Val	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Gln	Pro	Thr	Glu	Tyr
	35				40						45				

Thr	Gly	Ser	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Tyr	Asp	Leu	Lys
	50				55						60				

Arg	Val	Phe	Thr	Asn	Glu	Asn	Leu	Ala	Tyr	Leu	Lys	Asn	Tyr	Gly	Glu
65				70					75						80

Gly	Trp	Gly	Tyr	Leu	Asn	Ser	Gly	Val	Ser	Gly	Val	Tyr	Val	Asp	Asn
				85					90					95	

His	Asp	Thr	Glu
			100

<210> 116

<211> 100

<212> PRT

<213> Streptomyces sp. B161A

<400> 116

Val	Asp	Gly	Phe	Arg	Ile	Asp	Thr	Ala	Lys	His	Met	Ala	Ala	Ala	Asp
1				5					10					15	

Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Thr	Asp	Pro	Asn	Val	Tyr	Trp	Lys
		20					25					30			

His	Glu	Ala	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Gln	Pro	Ser	Glu	Tyr
	35				40						45				

Leu	Gly	Thr	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Arg	Asp	Leu	Lys
	50				55						60				

Arg	Val	Phe	Gln	Asn	Glu	Asn	Leu	Ala	His	Leu	Lys	Asn	Phe	Gly	Glu
65				70					75						80

Asp	Trp	Gly	Tyr	Met	Ala	Ser	Gly	Lys	Ser	Ala	Val	Phe	Val	Asp	Asn
				85					90					95	

His	Asp	Thr	Glu
			100

<210> 117

<211> 100

<212> PRT

<213> Streptomyces sp. B166B

<400> 117

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Asn Asn Pro Ser Ala Tyr Trp Lys
 20 25 30

Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gly Glu Tyr
 35 40 45

Thr Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Lys Ser Gly Ser Ala Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 118

<211> 100

<212> PRT

<213> Streptomyces sp. B168

<400> 118

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30

His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45

Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 119

<211> 100

<212> PRT

<213> Streptomyces sp. B179

<400> 119

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
 20 25 30
 His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys
 50 55 60
 Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Ala Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 120
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B181C

<400> 120
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 121
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B183B

<400> 121
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Thr Ala Ile Lys Ala Lys Val Gly Asn Gly Ser Thr Tyr Trp Lys
 20 25 30

Gln Glu Ala Ile His Gly Ala Gly Glu Ala Val Gln Pro Ser Glu Tyr
 35 40 45
 Leu Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Phe Gln Asn Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Ala Ser Gly Lys Ser Ala Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 122
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B184

<400> 122
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Thr Ala Ile Lys Ala Lys Val Gly Asn Gly Ser Thr Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile His Gly Ala Gly Glu Ala Val Gln Pro Ser Glu Tyr
 35 40 45
 Leu Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Phe Gln Asn Gly Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Ala Ser Gly Lys Ser Ala Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 123
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B185(B)

<400> 123
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
65 70 75 80

Ser Trp Gly Tyr Leu Pro Ser Asp Gln Ala Ala Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 126

<211> 100

<212> PRT

<213> Streptomyces sp. B187A2

<400> 126

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Ala Ala Gly Asp
1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
20 25 30

His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ala Glu Tyr
35 40 45

Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
65 70 75 80

Ser Trp Gly Tyr Leu Pro Ser Asp Gln Ala Ala Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 127

<211> 97

<212> PRT

<213> Streptomyces sp. B194A

<400> 127

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ser Asp
1 5 10 15

Leu Glu Ala Ile Lys Ala Arg Met Ser Asn Pro Asn Val Phe Trp Val
20 25 30

His Glu Val Ile Gly Ala Ala Gly Glu Pro Ile Gln Pro Ser Glu Tyr
35 40 45

Leu Gly Ser Gly Asp Ser His Glu Phe Asp Tyr Ala Arg Gln Leu Lys
50 55 60

Arg Asp Phe Asp Gly Gln Ile Lys Asn Leu Arg Tyr Ile Gly Asp Gly
65 70 75 80

Lys Leu Pro Tyr Asp Arg Ala Gly Val Phe Val Asp Asn His Asp Thr
 85 90 95

Glu

<210> 128
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B194B1

<400> 128
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 129
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B196A2C

<400> 129
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Asp
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
100

<210> 130
<211> 100
<212> PRT
<213> Streptomyces sp. B196B

<400> 130
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
20 25 30
His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45
Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60
Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Asp
65 70 75 80
Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 131
<211> 100
<212> PRT
<213> Streptomyces sp. B197B

<400> 131
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
20 25 30
His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Xaa Tyr
35 40 45
Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60
Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Asp
65 70 75 80
Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Phe Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 132
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B198C2

<400> 132
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Ala Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ala Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Ser Ala Gly Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 133
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B200B

<400> 133
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 134

<211> 100
 <212> PRT
 <213> Streptomyces sp. B201A

<400> 134
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asp Ile Lys Ser Arg Leu Ser Asp Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Ser Ser Gly Ala Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 135
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B202A

<400> 135
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Xaa Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 136
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B202B

<400> 136

Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Ile	Pro	Ala	Ala	Asp
1				5					10					15	
Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Ser	Asn	Pro	Gly	Val	Tyr	Trp	Lys
			20					25					30		
His	Glu	Val	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Gln	Pro	Thr	Glu	Tyr
		35					40					45			
Thr	Gly	Ser	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Tyr	Asp	Leu	Lys
	50					55					60				
Arg	Val	Phe	Thr	Asn	Glu	Asn	Leu	Ala	Tyr	Leu	Lys	Asn	Tyr	Gly	Glu
	65				70					75					80
Gly	Trp	Gly	Tyr	Leu	Asn	Ser	Gly	Val	Ser	Gly	Val	Tyr	Val	Asp	Asn
				85					90					95	
His	Asp	Thr	Glu												
			100												

<210> 137

<211> 100

<212> PRT

<213> Streptomyces sp. B206A

<400> 137

Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Ile	Pro	Ala	Ala	Asp
1				5					10					15	
Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Ser	Asn	Pro	Gly	Val	Tyr	Trp	Lys
			20					25					30		
His	Glu	Val	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Gln	Pro	Thr	Glu	Tyr
		35					40					45			
Thr	Gly	Ser	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Tyr	Asp	Leu	Lys
	50					55					60				
Arg	Val	Phe	Thr	Asn	Glu	Asn	Leu	Ala	Tyr	Leu	Lys	Asn	Tyr	Gly	Glu
	65				70					75					80
Gly	Trp	Gly	Tyr	Leu	Asn	Ser	Gly	Val	Ser	Gly	Val	Tyr	Xaa	Asp	Asn
				85					90					95	
His	Asp	Thr	Glu												
			100												

<210> 138

<211> 100

<212> PRT

<213> Streptomyces sp. B207

<400> 138

Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Ile	Pro	Ala	Ala	Asp
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

1	5	10	15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys	20	25	30
His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr	35	40	45
Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys	50	55	60
Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu	65	70	75
Gly Trp Gly Tyr Leu Asn Ser Gly Val Ala Gly Val Phe Val Asp Asn	85	90	95
His Asp Thr Glu	100		

<210> 139
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B208B

<400> 139
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Ala Ala Gly Asp
1 5 10 15
Leu Ala Ala Ile Lys Ser Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
20 25 30
His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
35 40 45
Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
50 55 60
Arg Val Phe Gly Ser Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
65 70 75 80
Ser Trp Gly Tyr Met Pro Ser Gly Gln Ser Ala Val Tyr Val Asp Asn
85 90 95
His Asp Thr Glu
100

<210> 140
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B209B

<400> 140
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys

	20		25		30										
His	Glu	Val	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Gln	Pro	Thr	Glu	Tyr
	35				40				45						
Thr	Gly	Ser	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Tyr	Asp	Leu	Lys
	50				55				60						
Arg	Val	Phe	Thr	Asn	Glu	Asn	Leu	Ala	Tyr	Leu	Lys	Asn	Tyr	Gly	Glu
	65				70				75					80	
Gly	Trp	Gly	Tyr	Leu	Asn	Ser	Gly	Val	Ser	Gly	Val	Tyr	Val	Asp	Asn
				85					90					95	
His	Asp	Thr	Glu												
			100												

<210> 141
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B210

	<400> 141														
Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Met	Ala	Ala	Gly	Asp
1				5					10					15	
Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Thr	Asn	Pro	Asn	Val	Tyr	Trp	Lys
			20					25					30		
His	Glu	Ala	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Ser	Pro	Ala	Glu	Tyr
		35					40					45			
Leu	Gly	Ser	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Arg	Asp	Leu	Lys
	50					55					60				
Arg	Val	Phe	Asn	Asn	Glu	Asn	Leu	Ala	Tyr	Leu	Lys	Asn	Phe	Gly	Glu
	65				70					75				80	
Ser	Trp	Gly	Tyr	Leu	Pro	Ser	Asp	Gln	Ala	Ala	Val	Tyr	Val	Asp	Asn
				85					90					95	
His	Asp	Thr	Glu												
			100												

<210> 142
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B211A

	<400> 142														
Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Ile	Pro	Ala	Ala	Asp
1				5					10					15	
Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Ser	Asn	Pro	Gly	Val	Tyr	Trp	Lys
			20					25					30		
His	Glu	Val	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Gln	Pro	Thr	Glu	Tyr

35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 143
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B212B1

<400> 143
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 144
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B213

<400> 144
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Arg Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Thr Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys

50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 145
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B214B

<400> 145
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Xaa Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
 20 25 30
 His Glu Ala Ile Tyr Trp Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys
 50 55 60
 Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Ala Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 146
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B214C

<400> 146
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
 20 25 30
 His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys
 50 55 60
 Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu

65 70 75 80
 Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Ala Val Phe Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 147
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B215

<400> 147
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30

His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45

Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Phe Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 148
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B218D2

<400> 148
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30

His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45

Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Val
 65 70 75 80

Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn

85

90

95

His Asp Thr Glu
100

<210> 149
<211> 100
<212> PRT
<213> Streptomyces sp. B219A

<400> 149
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
20 25 30
His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45
Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60
Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80
Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Phe Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 150
<211> 100
<212> PRT
<213> Streptomyces sp. B220B

<400> 150
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
20 25 30
His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45
Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60
Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80
Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu

100

<210> 151
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B221A

<400> 151
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Asp Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 152
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B222(B)

<400> 152
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Ala Ala Gly Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
 20 25 30
 His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ala Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Xaa Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Ser Trp Gly Tyr Leu Pro Ser Asp Gln Ala Ala Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 153
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B223A

<400> 153
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Ala Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gly Glu Tyr
 35 40 45
 Thr Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Lys Ser Ser Ser Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 154
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B224(A)

<400> 154
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Ser Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 155
 <211> 100
 <212> PRT

<213> Streptomyces sp. B225B

<400> 155

Val	Asp	Gly	Phe	Arg	Ile	Asp	Thr	Ala	Lys	His	Ile	Ala	Thr	Glu	Asp
1				5					10					15	
Leu	Ala	Ala	Val	Lys	Ala	Lys	Leu	Ser	Lys	Pro	Asp	Val	Tyr	Trp	Lys
			20					25					30		
Gln	Glu	Thr	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Gln	Ser	Gln	Glu	Tyr
		35					40					45			
Leu	Gly	Asn	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Arg	Asp	Leu	Lys
	50					55					60				
Arg	Val	Phe	Gln	Ser	Glu	Arg	Leu	Ala	Tyr	Leu	Lys	Asn	Tyr	Gly	Glu
	65				70					75					80
Gly	Trp	Gly	Tyr	Leu	Pro	Gly	Asp	Arg	Ala	Ser	Val	Tyr	Val	Asp	Asn
				85					90					95	
His	Asp	Thr	Glu												
			100												

<210> 156

<211> 100

<212> PRT

<213> Streptomyces sp. B226B

<400> 156

Val	Asp	Gly	Phe	Arg	Ile	Asp	Thr	Ala	Lys	His	Met	Ala	Ala	Gly	Asp
1				5					10					15	
Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Thr	Asn	Pro	Asn	Val	Tyr	Trp	Lys
			20					25					30		
His	Glu	Ala	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Ser	Pro	Ala	Glu	Tyr
		35					40					45			
Leu	Gly	Ser	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Arg	Asp	Leu	Lys
	50					55					60				
Arg	Val	Phe	Asn	Asn	Glu	Asn	Leu	Ala	Tyr	Leu	Lys	Asn	Phe	Gly	Glu
	65				70					75					80
Ser	Trp	Gly	Tyr	Leu	Pro	Ser	Asp	Gln	Ala	Ala	Val	Tyr	Val	Asp	Asn
				85					90					95	
His	Asp	Thr	Glu												
			100												

<210> 157

<211> 100

<212> PRT

<213> Streptomyces sp. B227B2

<400> 157

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Ala Thr Glu Asp
 1 5 10 15
 Leu Ala Ala Val Lys Ala Lys Leu Ser Lys Pro Asp Val Tyr Trp Lys
 20 25 30
 Gln Glu Thr Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gln Glu Tyr
 35 40 45
 Leu Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Phe Gln Ser Glu Arg Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Pro Gly Asp Arg Ala Ser Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 158
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B228B

<400> 158
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Asn Asn Pro Ser Ala Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gly Glu Tyr
 35 40 45
 Thr Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Lys Ser Gly Ser Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 159
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B230B1

<400> 159
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Ala Thr Glu Asp
 1 5 10 15

Leu Ala Ala Val Lys Ala Lys Leu Ser Lys Pro Asp Val Tyr Trp Lys
 20 25 30
 Gln Glu Thr Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gln Glu Tyr
 35 40 45
 Leu Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Phe Gln Ser Glu Arg Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Pro Gly Asp Arg Ala Ser Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 160
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B231A

<400> 160
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Ala Thr Glu Asp
 1 5 10 15
 Leu Ala Ala Val Lys Ala Lys Leu Ser Lys Pro Asp Val Tyr Trp Lys
 20 25 30
 Gln Glu Thr Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gln Glu Tyr
 35 40 45
 Leu Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Phe Gln Ser Glu Arg Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Pro Gly Asp Arg Ala Ser Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 161
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B233C

<400> 161
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Ala Thr Glu Asp
 1 5 10 15
 Leu Ala Ala Val Lys Ala Lys Leu Ser Lys Pro Asp Val Tyr Trp Lys
 20 25 30

Gln Glu Thr Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gln Glu Tyr
 35 40 45

Leu Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60

Arg Val Phe Gln Ser Glu Arg Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Pro Gly Asp Arg Ala Ser Val Phe Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 162
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B234

<400> 162
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30

His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45

Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 163
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B235A

<400> 163
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Ala Thr Glu Asp
 1 5 10 15

Leu Ala Ala Val Lys Ala Lys Leu Ser Lys Pro Asp Val Tyr Trp Lys
 20 25 30

Gln Glu Thr Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gln Glu Tyr
 35 40 45

Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80

Gly Trp Gly Tyr Leu Asn Ser Gly Val Ala Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 166

<211> 100

<212> PRT

<213> Streptomyces sp. B240A

<400> 166

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Ala Asp
1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
20 25 30

His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45

Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60

Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80

Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 167

<211> 100

<212> PRT

<213> Streptomyces sp. B241B2

<400> 167

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Ala Tyr Trp Lys
20 25 30

His Glu Val Ile Phe Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45

Thr Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80

His Asp Thr Glu
100

<210> 170
<211> 100
<212> PRT
<213> Streptomyces sp. B244B2

<400> 170
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Ala Thr Glu Asp
1 5 10 15
Leu Ala Ala Val Lys Ala Lys Leu Ser Lys Pro Asp Val Tyr Trp Lys
20 25 30
Gln Glu Thr Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gln Glu Tyr
35 40 45
Leu Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
50 55 60
Arg Val Phe Gln Ser Glu Arg Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80
Gly Trp Gly Tyr Leu Pro Gly Asp Arg Ala Ser Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 171
<211> 100
<212> PRT
<213> Streptomyces sp. B246

<400> 171
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
20 25 30
His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45
Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60
Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80
Gly Trp Gly Tyr Leu Asn Ser Gly Val Ala Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 172
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B247A

<400> 172
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Ala Thr Glu Asp
 1 5 10 15
 Leu Ala Ala Val Lys Ala Lys Leu Ser Lys Pro Asp Val Tyr Trp Lys
 20 25 30
 Gln Glu Thr Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gln Glu Tyr
 35 40 45
 Leu Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Phe Gln Ser Glu Arg Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Pro Gly Asp Arg Ala Ser Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 173
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B248B2

<400> 173
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Gly Leu Lys
 50 55 60
 Gln Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Ala Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 174
 <211> 100

<212> PRT

<213> Streptomyces sp. B249A

<400> 174

Val	Asp	Gly	Phe	Arg	Ile	Asp	Thr	Ala	Lys	His	Ile	Ala	Thr	Glu	Asp
1				5					10					15	
Leu	Ala	Ala	Val	Lys	Ala	Lys	Leu	Ser	Lys	Pro	Asp	Val	Tyr	Trp	Lys
			20					25					30		
Gln	Glu	Thr	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Gln	Pro	Gln	Glu	Tyr
		35					40					45			
Leu	Gly	Asn	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Arg	Asp	Leu	Lys
	50					55					60				
Arg	Val	Phe	Gln	Ser	Glu	Arg	Leu	Ala	Tyr	Leu	Lys	Asn	Tyr	Gly	Glu
	65				70					75					80
Gly	Trp	Gly	Tyr	Leu	Pro	Gly	Asp	Arg	Ala	Ser	Val	Phe	Val	Asp	Asn
				85					90					95	
His	Asp	Thr	Glu												
			100												

<210> 175

<211> 100

<212> PRT

<213> Streptomyces sp. B249C

<400> 175

Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Ile	Pro	Glu	Asp	Asp
1				5					10					15	
Leu	Ala	Ala	Ile	Lys	Ser	Arg	Leu	Ser	Asn	Pro	Gly	Val	Tyr	Trp	Lys
			20					25					30		
Gln	Glu	Thr	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Gln	Pro	Thr	Glu	Tyr
		35					40					45			
Leu	Thr	Thr	Gly	Asp	Ala	Gln	Glu	Phe	Arg	Tyr	Ser	Trp	Asp	Leu	Lys
	50					55					60				
Arg	Val	Phe	Thr	Ser	Glu	Lys	Leu	Ala	Tyr	Leu	Lys	Asn	Phe	Gly	Glu
	65				70					75					80
Gly	Trp	Gly	Tyr	Met	Ala	Gly	Gly	Lys	Ala	Ser	Val	Tyr	Val	Asp	Asn
				85					90					95	
His	Asp	Thr	Glu												
			100												

<210> 176

<211> 100

<212> PRT

<213> Streptomyces sp. B250A2

<400> 176

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Asp Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Ser Val Tyr Trp Lys
 20 25 30

Gln Glu Ala Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45

Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Met Ser Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 177

<211> 100

<212> PRT

<213> Streptomyces sp. B251B

<400> 177

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30

His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45

Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Phe Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 178

<211> 100

<212> PRT

<213> Streptomyces sp. B252A

<400> 178

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15

```

<400> 180
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
  1             5             10             15
Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Ala Tyr Trp Lys
      20             25             30

```

```

<400> 182
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
 1             5             10             15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asp Pro Gly Val Tyr Trp Lys
      20             25             30

Gln Glu Val Ile Phe Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
      35             40             45

```


Arg Val Phe Thr Gln Gly Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80

Asp Trp Gly Tyr Leu Ser Ser Thr Thr Ala Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 185

<211> 100

<212> PRT

<213> Streptomyces sp. B278

<400> 185

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Ala Ala Gly Asp
1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
20 25 30

His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ala Glu Tyr
35 40 45

Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Phe Gly Glu
65 70 75 80

Ser Trp Gly Tyr Leu Pro Ser Asp Gln Ala Ala Val Tyr Xaa Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 186

<211> 100

<212> PRT

<213> Streptomyces sp. B279

<400> 186

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
20 25 30

His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45

Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60

Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80

Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

```
<210> 187
<211> 100
<212> PRT
<213> Streptomyces sp. B280C
```

<400> 187
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Ala Ala Gly Asp
1 5 10 15

Leu Ala Pro Ile Lys Ser Arg Leu Ser Asn Pro Asn Val Tyr Trp Lys
20 25 30

Gln Glu Val Ile His Gly Ala Gly Glu Ala Val Gln Pro Gly Glu Tyr
35 40 45

Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80

Gly Trp Gly Tyr Leu Asn Ser Ser Val Ser Gly Val Phe Val Asp Asn
85 90 95

His Asp Thr Glu
100

```
<210> 188
<211> 100
<212> PRT
<213> Streptomyces sp. B284A
```

```
<400> 188
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
  1             5             10             15
```

Leu Ala Asn Ile Lys Ser Arg Leu Thr Lys Pro Gly Val Tyr Trp Lys
20 25 30

Gln Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Ser Glu Tyr
35 40 45

Thr Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80

Gly Trp Gly Tyr Met Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 189
<211> 100
<212> PRT
<213> Streptomyces sp. B286A

<400> 189
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Ser Val Tyr Trp Lys
20 25 30
Gln Glu Val Ile Phe Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45
Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60
Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80
Gly Trp Gly Tyr Met Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 190
<211> 100
<212> PRT
<213> Streptomyces sp. B287

<400> 190
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Gly Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Asn Val Tyr Trp Lys
20 25 30
Gln Glu Ala Ile His Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
35 40 45
Leu Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys
50 55 60
Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
65 70 75 80
Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 191
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B292A

<400> 191
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Ala Phe Trp Lys
 20 25 30
 Leu Glu Ala Ile His Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Leu Gln Asn Glu Lys Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Ala Trp Gly Tyr Met Pro Ser Gly Gln Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 192
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B3001org

<400> 192
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Ala Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Cys Tyr Gly Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Ser Glu Lys Leu Ala Tyr Leu Asn Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Ile Pro Gly Asn Val Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 193

<211> 100
 <212> PRT
 <213> Streptomyces sp. B3002org

<400> 193
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Ala Thr Glu Asp
 1 5 10 15
 Leu Ala Ala Val Lys Ala Lys Leu Ser Lys Pro Asp Val Tyr Trp Lys
 20 25 30
 Gln Glu Thr Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gln Glu Tyr
 35 40 45
 Leu Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Phe Gln Ser Glu Arg Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Pro Gly Asp Arg Ala Ser Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 194
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B3003org

<400> 194
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Asp Thr Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Ala Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Ser Asn Ser Val Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 195
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B3017

<400> 195

Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ser	Lys	His	Met	Pro	Ala	Asp	Asp
1				5					10					15	

Leu	Ala	Ala	Ile	Lys	Gly	Lys	Leu	Ala	Asn	Pro	Gly	Val	Tyr	Trp	Lys
			20					25					30		

His	Glu	Ala	Ile	His	Gly	Ala	Gly	Glu	Ala	Val	Ser	Pro	Ser	Glu	Tyr
		35					40					45			

Leu	Gly	Ser	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Gly	Arg	Gly	Leu	Lys
	50					55					60				

Gln	Val	Phe	Thr	Gly	Gly	Ser	Leu	Ala	His	Leu	Lys	Asn	Phe	Gly	Glu
65					70					75					80

Gly	Trp	Gly	Phe	Met	Glu	Ser	Gly	Lys	Ser	Ala	Val	Tyr	Val	Asp	Asn
				85					90					95	

His	Asp	Thr	Glu
			100

<210> 196

<211> 100

<212> PRT

<213> Streptomyces sp. B306

<400> 196

Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Met	Pro	Ala	Ala	Asp
1				5					10					15	

Leu	Ala	Asn	Ile	Lys	Ser	Arg	Leu	Thr	Asn	Pro	Gly	Val	Tyr	Trp	Lys
			20					25					30		

His	Glu	Ala	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Ser	Pro	Ala	Glu	Tyr
		35					40					45			

Leu	Gly	Ser	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Arg	Asp	Leu	Lys
	50					55					60				

Arg	Val	Phe	Asn	Asn	Glu	Asn	Leu	Ala	Tyr	Leu	Lys	Asn	Tyr	Gly	Glu
65					70					75					80

Gly	Trp	Gly	Tyr	Leu	Asn	Ser	Gly	Ser	Ala	Gly	Val	Tyr	Val	Asp	Asn
				85					90					95	

His	Asp	Thr	Glu
			100

<210> 197

<211> 100

<212> PRT

<213> Streptomyces sp. B308

<400> 197

Val	Asp	Gly	Phe	Arg	Ile	Asp	Thr	Ala	Lys	His	Ile	Pro	Ala	Ala	Asp
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

1	5	10	15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys	20	25	30
His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr	35	40	45
Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys	50	55	60
Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu	65	70	75
Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn	85	90	95
His Asp Thr Glu	100		

<210> 198
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B311

<400> 198
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Gly Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
20 25 30
His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
35 40 45
Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys
50 55 60
Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
65 70 75 80
Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Ala Val Tyr Val Asp Asn
85 90 95
His Asp Thr Glu
100

<210> 199
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B315

<400> 199
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys

	20		25		30										
His	Glu	Val	Ile	Tyr	Gly	Ala	Gly	Glu	Ala	Val	Gln	Pro	Thr	Glu	Tyr
		35					40				45				
Thr	Gly	Ser	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Ala	Tyr	Asp	Leu	Lys
	50					55					60				
Arg	Val	Phe	Thr	Asn	Glu	Asn	Leu	Ala	Tyr	Leu	Lys	Asn	Tyr	Gly	Asp
	65				70					75				80	
Gly	Trp	Gly	Tyr	Leu	Asn	Ser	Gly	Val	Ser	Gly	Val	Tyr	Val	Asp	Asn
				85					90					95	
His	Asp	Thr	Glu												
			100												

<210> 200
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B317

	20		25		30										
Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Met	Pro	Ala	Ala	Asp
	1			5					10					15	
Leu	Ala	Ala	Ile	Lys	Ser	Arg	Leu	Thr	Asn	Pro	Asn	Val	Tyr	Trp	Lys
			20					25					30		
Gln	Glu	Ala	Ile	His	Gly	Ala	Gly	Glu	Ala	Val	Ser	Pro	Ser	Glu	Tyr
		35					40					45			
Leu	Gly	Thr	Gly	Asp	Val	Gln	Glu	Phe	Arg	Tyr	Gly	Arg	Ser	Leu	Lys
	50					55					60				
Gln	Val	Phe	Leu	Asn	Glu	Asn	Leu	Ala	His	Leu	Lys	Asn	Phe	Gly	Glu
	65				70					75				80	
Gly	Trp	Gly	Phe	Met	Glu	Ser	Gly	Lys	Ser	Gly	Val	Tyr	Val	Asp	Asn
				85					90					95	
His	Asp	Thr	Glu												
			100												

<210> 201
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B318

	20		25		30										
Val	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Ala	Lys	His	Met	Pro	Ala	Gly	Asp
	1			5					10					15	
Leu	Ala	Asp	Ile	Lys	Ser	Arg	Leu	Ser	Asn	Pro	Asn	Val	Tyr	Trp	Lys
			20					25					30		
Gln	Glu	Ala	Ile	Tyr	Gly	Ala	Asn	Glu	Ala	Val	Ser	Pro	Thr	Glu	Tyr

35 40 45
 Leu Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Gly Leu Lys
 50 55 60
 Gln Thr Phe Leu Gly Gly Asn Leu Ala Asp Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Phe Met Glu Ser Gly Arg Ser Ala Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 202
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B319

<400> 202
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 203
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B320A

<400> 203
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Ala Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Cys Tyr Gly Tyr Asp Leu Lys

50 55 60
 Arg Val Phe Asn Ser Glu Lys Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Ser Ser Ser Val Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 204
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B321

<400> 204
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Ala Val Gly Asp
 1 5 10 15
 Leu Ala Asp Ile Lys Ser Arg Leu Gly Asn Pro Asp Val His Trp Lys
 20 25 30
 His Glu Ala Ile His Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Leu Thr Gly Gly Ser Leu Ala His Leu Arg Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Ala Ser Asp Arg Ser Asn Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 205
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B322A

<400> 205
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu

65		70		75		80
Gly Trp Gly Tyr Leu Asn Ser Gly Val Ala Gly Val Tyr Val Asp Asn						
		85		90		95
His Asp Thr Glu						
		100				

<210> 206
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B323

<400> 206
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Thr Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
20 25 30
His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
35 40 45
Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys
50 55 60
Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
65 70 75 80
Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Gly Val Phe Val Asp Asn
85 90 95
His Asp Thr Glu
100

<210> 207
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B326

<400> 207
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
20 25 30
Gln Glu Ala Ile Phe Gly Ala Gly Glu Ala Val Gln Pro Ser Glu Tyr
35 40 45
Thr Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60
Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80
Gly Trp Gly Tyr Met Ser Ser Gly Val Ser Gly Val Tyr Val Asp Asn

85

90

95

His Asp Thr Glu
100

<210> 208
<211> 100
<212> PRT
<213> Streptomyces sp. B327B

<400> 208
Val Asp Gly Phe Xaa Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
1 5 10 15
Leu Thr Ala Ile Lys Ala Lys Val Gly Asp Gly Gly Thr Tyr Trp Lys
20 25 30
Gln Glu Ala Ile His Gly Ala Gly Glu Ala Val Gln Pro Ser Glu Tyr
35 40 45
Leu Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
50 55 60
Arg Val Phe Gln Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
65 70 75 80
Asp Trp Gly His Met Gln Ser Gly Arg Ser Ala Val Phe Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 209
<211> 100
<212> PRT
<213> Streptomyces sp. B335org

<400> 209
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Thr Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
20 25 30
His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
35 40 45
Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys
50 55 60
Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
65 70 75 80
Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Gly Val Phe Val Asp Asn
85 90 95

His Asp Thr Glu

100

<210> 210
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B345

<400> 210
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Asp Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asp Pro Asn Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile His Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Gly Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Asn Ser Ser Val Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 211
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B346

<400> 211
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Asp Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Ser Val Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Asn Ser Ser Val Ser Gly Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 212
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B347

<400> 212
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Val Ala Asp
 1 5 10 15
 Leu Asn Ala Ile Trp Ala Lys Leu Asp Asp Thr Thr Ala Gly Gly Glu
 20 25 30
 Pro Tyr Ile Phe Gln Glu Val Tyr Pro Gly Ser Thr Pro Ala Ala Ser
 35 40 45
 Asp Tyr Tyr Ser Ala Gly Asp Val Leu Asp Phe Thr Tyr Ala Ser Arg
 50 55 60
 Val Lys Ser Ala Phe Gln Gly Asn Val Ser Asp Leu Glu Ser Leu Pro
 65 70 75 80
 Ser Ser Gly Val Leu Pro Pro Ala Asn Ser Val Ser Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 213
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B348

<400> 213
 Val Asp Gly Phe Arg Ile Asp Ala Ala Arg His Ile Asp Thr Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Ala Tyr Arg Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Arg Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Pro Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Ser Ser Pro Ser Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 214
 <211> 100
 <212> PRT

<213> Streptomyces sp. B350

<400> 214

```

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Asp Ala Ala Asp
 1              5              10              15
Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Val Tyr Trp Lys
              20              25              30
Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
              35              40              45
Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
              50              55              60
Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
              65              70              75              80
Gly Trp Gly Tyr Met Lys Ser Gly Val Ser Gly Val Tyr Val Asp Asn
              85              90              95

His Asp Thr Glu
              100

```

<210> 215

<211> 100

<212> PRT

<213> Streptomyces sp. B352

<400> 215

```

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Asp Ala Ala Asp
 1              5              10              15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Ser Val Tyr Trp Lys
              20              25              30
Gln Glu Ala Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
              35              40              45
Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
              50              55              60
Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
              65              70              75              80
Gly Trp Gly Tyr Met Asn Ser Ser Val Ala Gly Val Tyr Val Asp Asn
              85              90              95

His Asp Thr Glu
              100

```

<210> 216

<211> 100

<212> PRT

<213> Streptomyces sp. B353

<400> 216

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Asp Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Ser Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile His Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Leu Thr Thr Gly Asp Ala Gln Glu Phe Arg Tyr Ser Trp Asp Leu Lys
 50 55 60
 Arg Val Phe Thr Ser Glu Lys Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Ala Gly Gly Lys Ala Ser Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 217
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B354

<400> 217
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Asp Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Ser Val Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile Phe Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Gly Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Ser Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly His Met Asn Ser Ser Val Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 218
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B355

<400> 218
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Asp Ala Ala Asp
 1 5 10 15

Leu Thr Asn Ile Lys Ser Arg Leu Ser Asn Pro Ser Ala Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile Phe Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Gly Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asp Asn Glu Asn Leu Ala Tyr Leu Arg Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Asn Ser Ser Val Ala Gly Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 219
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B356

<400> 219
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Asp Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile His Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Leu Lys Ser Ser Gly Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 220
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B357

<400> 220
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Ala Val Gly Asp
 1 5 10 15
 Leu Ala Asp Ile Lys Ser Arg Leu Gly Ser Pro Asp Val His Trp Lys
 20 25 30

```
<400> 222  
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Asp Ala Ala Asp  
   1                               10                          15  
  
Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Val Tyr Trp Lys  
          20                      25                        30  
  
Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr  
      35                40                  45
```

Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Arg Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Met Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 223
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B360

<400> 223
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Asp Thr Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Asn Ala Tyr Trp Lys
 20 25 30

Gln Glu Val Ile His Gly Ser Gly Glu Ala Val Gln Pro Gly Glu Tyr
 35 40 45

Thr Arg Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Ser Ser Ser Ser Ala Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 224
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B361

<400> 224
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Val Gly Asp
 1 5 10 15

Leu Asn Ala Ile Arg Ala Lys Leu Asp Asp Thr Thr Ser Gly Ala Glu
 20 25 30

Pro Tyr Ile Phe Gln Glu Val Tyr Pro Gly Ala Thr Pro Ala Ala Ser
 35 40 45

Asp Tyr Tyr Ser Ala Gly Asp Val Leu Asp Phe Thr Tyr Ala Ser Arg
 50 55 60

Val Lys Ser Ala Phe Gln Gly Asn Val Ser Asp Leu Glu Ser Leu Pro
 65 70 75 80
 Ser Ser Gly Val Leu Thr Pro Ala Asn Ser Val Ser Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 225
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B362

<400> 225
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Asp Ala Ala Asp
 1 5 10 15
 Leu Ala Xaa Ile Lys Ser Arg Leu Ser Asn Pro Ser Val Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Ser Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 226
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B363org

<400> 226
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Ala Tyr Trp Lys
 20 25 30
 Gln Gly Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Gly Glu Tyr
 35 40 45
 Thr Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asp Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Lys Ser Ser Ser Ala Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 227
<211> 100
<212> PRT
<213> Streptomyces sp. B366

<400> 227
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Asp Ala Ala Asp
1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Thr Ser Val Tyr Trp Lys
20 25 30

Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45

Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60

Arg Val Phe Asn Ser Glu Asn Leu Ala His Leu Lys Asn Tyr Gly Glu
65 70 75 80

Gly Trp Gly Tyr Met Ser Ser Ser Val Ala Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 228
<211> 100
<212> PRT
<213> Streptomyces sp. B368

<400> 228
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Asp Thr Ala Asp
1 5 10 15

Leu Ala Thr Ile Lys Ser Arg Leu Thr Asn Pro Asn Ala Tyr Trp Lys
20 25 30

Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45

Thr Arg Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80

Gly Trp Gly Tyr Met Ser Ser Ser Val Ala Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 229
<211> 100
<212> PRT
<213> Streptomyces sp. B370

<400> 229
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Gly Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val His Trp Lys
20 25 30
His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Thr Glu Tyr
35 40 45
Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Ser Leu Lys
50 55 60
Gln Thr Phe Asn Asn Glu Asn Leu Ala Asn Leu Lys Asn Phe Gly Glu
65 70 75 80
Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Ala Val Phe Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 230
<211> 100
<212> PRT
<213> Streptomyces sp. B371

<400> 230
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Asp Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Val Tyr Trp Lys
20 25 30
Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45
Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60
Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80
Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Phe Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 231
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B372

<400> 231
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Asp Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Ser Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Ser Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 232
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B373

<400> 232
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Asp Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Ser Val Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Ser Ser Gly Val Ser Gly Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 233
 <211> 100

<212> PRT

<213> Streptomyces sp. B374B

<400> 233

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Asp Thr Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Ala Tyr Trp Lys
 20 25 30

Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45

Thr Arg Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Ser Ser Ser Ser Ala Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 234

<211> 100

<212> PRT

<213> Streptomyces sp. B375

<400> 234

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Asp Ser Ala Asp
 1 5 10 15

Leu Ala Thr Ile Lys Ser Arg Leu Ser Asn Pro Ser Val Tyr Trp Lys
 20 25 30

Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45

Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Met Ser Ser Ser Val Ala Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 235

<211> 100

<212> PRT

<213> Streptomyces sp. B376

<400> 235

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Asp Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Val Tyr Trp Lys
 20 25 30

Gln Glu Val Ile His Gly Ala Gly Glu Ala Val Gln Pro Ala Glu Tyr
 35 40 45

Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Lys Ser Ser Gly Ala Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 236

<211> 100

<212> PRT

<213> Streptomyces sp. B380

<400> 236

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Asp Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Ser Val Tyr Trp Lys
 20 25 30

Gln Glu Ala Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45

Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Met Ser Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 237

<211> 100

<212> PRT

<213> Streptomyces sp. B382

<400> 237

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Ala Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Gly Val Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Cys Tyr Gly Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Ser Glu Lys Leu Ala Tyr Leu Asn Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Ile Pro Gly Asn Val Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 238
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B390

<400> 238
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Thr Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
 20 25 30
 His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys
 50 55 60
 Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Gly Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 239
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B392A

<400> 239
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Ala Ala Ala Asp
 1 5 10 15
 Leu Ala Ala Ile Lys Ser Arg Leu Ser Asn Pro Asn Val Tyr Trp Lys
 20 25 30

Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Lys Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Ser Ser Ser Val Ala Gly Val Phe Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 244
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B400

<400> 244
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asp Ile Lys Ser Arg Leu Thr Asn Thr Ser Val Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80
 Gly Trp Gly Tyr Met Ser Ser Ser Val Ser Gly Val Xaa Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 245
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B4006

<400> 245
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Asp Thr Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Ala Tyr Trp Lys
 20 25 30
 Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45
 Thr Arg Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60
 Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

```

<400> 247
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
  1                               5                10                15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
                20                        25                30
His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
                35                        40                45
Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
  50                        55                60
Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
  65                        70                75                80
Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
                85                        90                95

```

His Asp Thr Glu
100

<210> 248
<211> 100
<212> PRT
<213> Streptomyces sp. B400A2

<400> 248
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Ile Pro Ala Thr Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Ser Val Tyr Trp Lys
20 25 30
Gln Glu Val Ile Tyr Gly Ser Gly Glu Ala Val Gln Pro Thr Glu Tyr
35 40 45
Thr Gly Asn Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
50 55 60
Arg Val Phe Asn Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
65 70 75 80
Gly Trp Gly Tyr Leu Asn Ser Ser Val Ala Gly Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 249
<211> 100
<212> PRT
<213> Streptomyces sp. B400B3

<400> 249
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Gly Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Asn Val Tyr Trp Lys
20 25 30
His Glu Ala Ile Phe Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
35 40 45
Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys
50 55 60
Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
65 70 75 80
Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Ala Val Tyr Val Asp Asn
85 90 95

His Asp Thr Glu
100

<210> 250
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B400C

<400> 250
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Thr Ala Ile Lys Ala Lys Val Gly Asp Gly Gly Thr Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile His Gly Ala Gly Glu Ala Val Gln Pro Ser Glu Tyr
 35 40 45
 Leu Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Phe Gln Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Asp Trp Gly His Met Gln Ser Gly Arg Ser Ala Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 251
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B400C2

<400> 251
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Thr Ala Ile Lys Ala Lys Val Gly Asp Gly Gly Thr Tyr Trp Lys
 20 25 30
 Gln Gly Ala Ile His Gly Ala Gly Glu Ala Val Gln Ser Ser Glu Tyr
 35 40 45
 Leu Gly Thr Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Phe Gln Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Asp Trp Gly Arg Met Gln Ser Gly Arg Ser Ala Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 252

<211> 100
 <212> PRT
 <213> Streptomyces sp. B400D

<400> 252
 Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asp Pro Gly Ala Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile His Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Leu Gln Asn Glu Lys Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Ala Trp Gly His Met Pro Ser Gly Arg Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 253
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B400D2

<400> 253
 Val Asp Gly Phe Arg Ile Asp Xaa Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asp Pro Gly Ala Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile His Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Leu Gln Asn Glu Lys Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Ala Trp Gly His Met Pro Ser Gly Arg Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 254
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B400E

<400> 254

Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Gly Asp
 1 5 10 15

Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Asn Val Tyr Trp Lys
 20 25 30

His Glu Ala Ile Phe Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45

Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys
 50 55 60

Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
 65 70 75 80

Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Ala Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 255

<211> 100

<212> PRT

<213> Streptomyces sp. B400G

<400> 255

Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Pro Ala Ala Asp
 1 5 10 15

Leu Ala Asn Ile Glu Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys
 20 25 30

His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr
 35 40 45

Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys
 50 55 60

Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu
 65 70 75 80

Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn
 85 90 95

His Asp Thr Glu
 100

<210> 256

<211> 100

<212> PRT

<213> Streptomyces sp. B400G2

<400> 256

Val Asp Gly Phe Arg Ile Asp Xaa Ala Lys His Ile Pro Ala Ala Asp

1	5	10	15
Leu Ala Asn Ile Lys Ser Arg Leu Ser Asn Pro Gly Val Tyr Trp Lys	20	25	30
His Glu Val Ile Tyr Gly Ala Gly Glu Ala Val Gln Pro Thr Glu Tyr	35	40	45
Thr Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Tyr Asp Leu Lys	50	55	60
Arg Val Phe Thr Asn Glu Asn Leu Ala Tyr Leu Lys Asn Tyr Gly Glu	65	70	75
Gly Trp Gly Tyr Leu Asn Ser Gly Val Ser Gly Val Tyr Val Asp Asn	85	90	95
His Asp Thr Glu	100		

<210> 257
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B400I

<400> 257
Val Asp Gly Phe Arg Ile Asp Thr Ala Lys His Met Pro Ala Ala Asp
1 5 10 15
Leu Ala Asn Ile Lys Ser Arg Leu Thr Asn Pro Asn Val Tyr Trp Lys
20 25 30
His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
35 40 45
Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys
50 55 60
Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
65 70 75 80
Gly Trp Gly Phe Met Glu Ser Gly Lys Ser Ala Val Tyr Val Asp Asn
85 90 95
His Asp Thr Glu
100

<210> 258
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B400J

<400> 258
Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Val Ala Asp
1 5 10 15
Leu Asn Ala Ile Trp Ala Lys Leu Asp Asn Thr Thr Ser Gly Ala Glu

35 40 45
 Asp Tyr Tyr Ser Ala Gly Asp Val Leu Asp Phe Ser Tyr Ala Ser Lys
 50 55 60
 Val Lys Ser Ser Phe Gln Gly Asn Ile Ser Asp Leu Glu Ser Leu Pro
 65 70 75 80
 Ser Ser Gly Ala Leu Thr Pro Ala Asn Ser Val Ser Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 261
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B402.

<400> 261
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Ser Arg Leu Thr Asp Pro Gly Ala Tyr Trp Lys
 20 25 30
 Gln Glu Ala Ile His Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Ala Arg Asp Leu Lys
 50 55 60
 Arg Val Leu Gln Asn Glu Lys Leu Ala Tyr Leu Lys Asn Phe Gly Glu
 65 70 75 80
 Ala Trp Gly His Met Pro Ser Gly Arg Ala Gly Val Tyr Val Asp Asn
 85 90 95
 His Asp Thr Glu
 100

<210> 262
 <211> 100
 <212> PRT
 <213> Streptomyces sp. B907

<400> 262
 Val Asp Gly Phe Arg Ile Asp Ala Ala Lys His Met Pro Ala Ala Asp
 1 5 10 15
 Leu Ala Asn Ile Lys Thr Arg Leu Ala Asn Pro Asn Val Tyr Trp Lys
 20 25 30
 His Glu Ala Ile Tyr Gly Ala Gly Glu Ala Val Ser Pro Ser Glu Tyr
 35 40 45
 Leu Gly Ser Gly Asp Val Gln Glu Phe Arg Tyr Gly Arg Ser Leu Lys

50 55 60
Gln Val Phe Leu Asn Glu Asn Leu Ala His Leu Lys Asn Phe Gly Glu
65 70 75 80
Gly Trp Gly Phe Met Glu Ser Gly Lys Pro Gly Val Tyr Val Asp Asn
85 90 95
His Asp Thr Glu
100

<210> 263
<211> 100
<212> PRT
<213> Artificial sequence

<220>
<221> VARIANT
<222> (6)
<223> Ile or Leu

<220>
<221> VARIANT
<222> (9)
<223> Ala or Ser

<220>
<221> VARIANT
<222> (10)
<223> Lys or Arg

<220>
<221> VARIANT
<222> (12)
<223> Met or Ile

<220>
<221> VARIANT
<222> (13)
<223> Ser or Pro or Asp or Ala

<220>
<221> VARIANT
<222> (14)
<223> Ala or Thr or Ser or Glu or Val

<220>
<221> VARIANT
<222> (15)
<223> Asp or Ala or Glu or Thr or Gly or Ser

<220>
<221> VARIANT
<222> (16)
<223> Asp or Gly

<220>
<221> VARIANT

<222> (17)
<223> Val or Leu or Pro or Ile

<220>
<221> VARIANT
<222> (18)
<223> Ala or Thr or Glu or Asn or Gln

<220>
<221> VARIANT
<222> (19)
<223> Ala or Asn or Asp or His or Thr or Pro

<220>
<221> VARIANT
<222> (20)
<223> Ile or Val

<220>
<221> VARIANT
<222> (21)
<223> Lys or Glu or Trp or Arg or Leu

<220>
<221> VARIANT
<222> (22)
<223> Gly or Ser or Pro or Ala or Thr

<220>
<221> VARIANT
<222> (23)
<223> Lys or Arg

<220>
<221> VARIANT
<222> (24)
<223> Met or Leu or Val or Pro

<220>
<221> VARIANT
<222> (25)
<223> Ser or Arg or Thr or Gly or Asn or Ala or Asp or
Lys or none

<220>
<221> VARIANT
<222> (26)
<223> Asp or Asn or Ser or Lys or Arg

<220>
<221> VARIANT
<222> (27)
<223> Pro or Arg or Thr or Gln or Gly or Val

<220>
<221> VARIANT
<222> (28)
<223> Gly or Asp or Ser or Asn or Thr-Ala-Gly-Gly-Glu or
Thr-Ser-Gly-Ala-Glu or

Tyr-Pro-Ala-Trp-Gly-Gly-Gly-Lys

<220>
<221> VARIANT
<222> (29)
<223> Val or Ala or Thr or Pro or none

<220>
<221> VARIANT
<222> (30)
<223> Phe or Tyr or His

<220>
<221> VARIANT
<222> (31)
<223> Trp or Arg or Ile or Leu

<220>
<221> VARIANT
<222> (32)
<223> Val or Lys or Phe

<220>
<221> VARIANT
<222> (33)
<223> Thr or Gln or His or Leu or Met

<220>
<221> VARIANT
<222> (34)
<223> Glu or Gly

<220>
<221> VARIANT
<222> (35)
<223> Val or Ala or Thr

<220>
<221> VARIANT
<222> (36)
<223> Ile or Thr or Met or Tyr or Asn

<220>
<221> VARIANT
<222> (37)
<223> His or Tyr or Phe or Gly or Pro or Ala

<220>
<221> VARIANT
<222> (38)
<223> Gly or Ala or Ser or Trp or Asp

<220>
<221> VARIANT
<222> (39)
<223> Gly or Ala or Asp or Ser

<220>
<221> VARIANT

<222> (40)
<223> Gly or Asn or Thr

<220>
<221> VARIANT
<222> (41)
<223> Glu or Pro or Ile

<220>
<221> VARIANT
<222> (42)
<223> Ala or Thr or Pro or Ser

<220>
<221> VARIANT
<222> (43)
<223> Val or Ile or Ala or Thr

<220>
<221> VARIANT
<222> (44)
<223> Gln or Ser or Gly

<220>
<221> VARIANT
<222> (45)
<223> Pro or Ser or none

<220>
<221> VARIANT
<222> (46)
<223> Glu or Asp or Thr or Gly or Ser or Ala or Gln or
none

<220>
<221> VARIANT
<222> (47)
<223> Glu or Asp or Ser

<220>
<221> VARIANT
<222> (48)
<223> Tyr or His

<220>
<221> VARIANT
<222> (49)
<223> Thr or Leu or Tyr or Val or Ala

<220>
<221> VARIANT
<222> (50)
<223> Ser or Gly or Asp or Arg or Thr or Asn or His

<220>
<221> VARIANT
<222> (51)
<223> Ile or Ser or Asn or Ala or Thr or Leu

<220>
<221> VARIANT
<222> (52)
<223> Gly or Cys

<220>
<221> VARIANT
<222> (53)
<223> Asp or Ser

<220>
<221> VARIANT
<222> (54)
<223> Val or Ala or Ser

<220>
<221> VARIANT
<222> (55)
<223> Asp or Gln or His or Leu or Thr

<220>
<221> VARIANT
<222> (56)
<223> Glu or Asp

<220>
<221> VARIANT
<222> (57)
<223> Phe or Leu or Ser

<220>
<221> VARIANT
<222> (58)
<223> Arg or Ser or Cys or His or Asp or Thr or Gln

<220>
<221> VARIANT
<222> (59)
<223> Tyr or His

<220>
<221> VARIANT
<222> (60)
<223> Gly or Ala or Ser or His

<220>
<221> VARIANT
<222> (61)
<223> Gly or Ser or Tyr or Arg or Trp or Lys

<220>
<221> VARIANT
<222> (62)
<223> His or Asp or Ser or Gly or Gln or Arg or Lys

<220>
<221> VARIANT
<222> (63)
<223> Leu or Val or Ile

<220>
<221> VARIANT
<222> (64)
<223> Lys or Ser or Ala

<220>
<221> VARIANT
<222> (65)
<223> Ser or Arg or Gln or His

<220>
<221> VARIANT
<222> (66)
<223> Ala or Val or Ile or Thr or Ser or Asp or Met

<220>
<221> VARIANT
<222> (67)
<223> Phe or Val or Leu

<220>
<221> VARIANT
<222> (68)
<223> Gln or Thr or Arg or Asn or Asp or Gly or His or
Leu or Ala

<220>
<221> VARIANT
<222> (69)
<223> Gly or Asn or Gln or Arg or Ser or Asp or none

<220>
<221> VARIANT
<222> (70)
<223> Gly or Glu or none

<220>
<221> VARIANT
<222> (71)
<223> Gly or Asn or Arg or His or Ser or Lys or Asp or
Gln

<220>
<221> VARIANT
<222> (72)
<223> Leu or Pro or Ile or Val

<220>
<221> VARIANT
<222> (73)
<223> Pro or Ala or Thr or Ser or Lys

<220>
<221> VARIANT
<222> (74)
<223> Gly or Gln or Tyr or His or Glu or Asp or Asn

<220>

<221> VARIANT
<222> (76)
<223> Arg or Asn or Ser or Glu or Thr

<220>
<221> VARIANT
<222> (77)
<223> Ser or Asn or Lys or Thr or Tyr or Gly

<220>
<221> VARIANT
<222> (78)
<223> Ile or Val or Tyr or Phe or Leu

<220>
<221> VARIANT
<222> (79)
<223> Ala or Gly or Ser or Asp or Pro

<220>
<221> VARIANT
<222> (80)
<223> Asp or Glu or Val or Ser

<220>
<221> VARIANT
<222> (81)
<223> Gly or Asp or Ala or Ser or none

<220>
<221> VARIANT
<222> (82)
<223> Gly or Trp or none

<220>
<221> VARIANT
<222> (83)
<223> Gly or Val or Ala or none

<220>
<221> VARIANT
<222> (84)
<223> Lys or Tyr or His or Arg or Phe or Leu

<220>
<221> VARIANT
<222> (85)
<223> Leu or Met or Ile or Val or Pro or Thr

<220>
<221> VARIANT
<222> (86)
<223> Ala or Gly or Asn or Ser or Thr or Pro or Lys or
Gln or Glu

<220>
<221> VARIANT
<222> (87)
<223> Gly or Ser or Asn or Tyr or Ala

<220>
 <221> VARIANT
 <222> (88)
 <223> Ala or Asp or Gly or Ser or Thr or Pro or Asn

<220>
 <221> VARIANT
 <222> (89)
 <223> Ser or Lys or Val or Ala or Phe or Thr or Gly or
 Gln or Arg or Glu or none

<220>
 <221> VARIANT
 <222> (90)
 <223> Ala or Ser or Pro

<220>
 <221> VARIANT
 <222> (91)
 <223> Arg or Gly or Ser or Asn or Ala or Val

<220>
 <221> VARIANT
 <222> (92)
 <223> Thr or Val or Ser

<220>
 <221> VARIANT
 <222> (93)
 <223> Tyr or Phe or Trp

<220>
 <221> VARIANT
 <222> (100)
 <223> Glu or Gln

<220>
 <221> VARIANT
 <222> (8)
 <223> Ala or Thr or Gly

<220>
 <223> Consensus sequence

<400> 263
 Val Asp Gly Phe Arg Xaa Asp Xaa Xaa Xaa His Xaa Xaa Xaa Xaa Xaa
 1 5 10 15
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 20 25 30
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 35 40 45
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 50 55 60
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

65	70	75	80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Val Asp Asn			
	85	90	95
His Asp Thr Xaa			
100			

WO 03/002711

- 126 -

H04890PCT/US/JP
PCT/EP02/06842**What is claimed is:**

1. An amylolytic protein whose amino acid sequence comprises a portion of which 98%, preferably 99%, particularly preferably 100%, are described by the consensus sequence of SEQ ID NO. 263, in particular via the subregion corresponding to positions 8 to 93.
2. An amylolytic protein, whose amino acid sequence comprises a portion which is 98%, preferably 99%, particularly preferably 100%, identical to any of the amino acid sequences indicated in SEQ ID NO. 34 to SEQ ID NO. 262, in particular via the subregion corresponding to positions 8 to 93 according to the consensus sequence of SEQ ID NO. 263.
3. An amylolytic protein, whose amino acid sequence comprises a portion which is 98%, preferably 99%, particularly preferably 100%, identical to any of the amino acid sequences indicated in SEQ ID NO. 45, 83, 97, 98, 101, 108, 109, 111, 112, 113, 115, 116, 232, 234, 236, 238, 239 and 241 or which can be traced back in every homologous position directly to any of these sequences, in particular via the subregion corresponding to positions 8 to 93 according to the consensus sequence of SEQ ID NO. 263.
4. An amylolytic protein whose amino acid sequence comprises a portion which is 95%, preferably 97.5%, particularly preferably 100%, identical to any of the amino acid sequences indicated in SEQ ID NO. 2, 4 and 208, in particular via the subregion corresponding to positions 8 to 93 according to the consensus sequence of SEQ ID NO. 263.
5. An amylolytic protein whose amino acid sequence in each individual homologous position can be traced back,

- 127 -

preferably directly, by a conserved substitution to either of the two sequences SEQ ID NO. 6 and SEQ ID NO. 8.

- 5 6. An amylolytic protein having an amino acid sequence which is at least 85% identical to the amino acid sequence indicated in SEQ ID NO. 6, preferably in positions 31 to 461.
- 10 7. An amylolytic protein having an amino acid sequence which is at least 95% identical to the amino acid sequence indicated in SEQ ID NO. 6, preferably in positions 31 to 461, particularly preferably in positions 210 to 300.
- 15 8. An amylolytic protein having an amino acid sequence which is identical to the amino acid sequence indicated in SEQ ID NO. 6, preferably in positions 31 to 461, particularly preferably in positions 210 to
20 300.
9. An amylolytic protein having an amino acid sequence which is at least 80% identical to the amino acid sequence indicated in SEQ ID NO. 8, preferably in
25 positions 30 to 448, particularly preferably in positions 200 to 296.
10. An amylolytic protein having an amino acid sequence which is at least 90% identical to the amino acid sequence indicated in SEQ ID NO. 8, preferably in
30 positions 30 to 448, particularly preferably in positions 200 to 296.
11. An amylolytic protein having an amino acid
35 sequence which is identical to the amino acid sequence indicated in SEQ ID NO. 8, preferably in positions 30 to 44, particularly preferably in positions 200 to 296.

- 128 -

12. A fragment of an amylolytic protein or amylolytic protein as claimed in any of claims 1 to 11 which is obtainable by deletion mutation.

5 13. An amylolytic protein obtainable by insertion mutation or an amylolytic chimeric protein, which comprises, at least in a portion imparting an amylolytic activity, a protein as claimed in any of claims 1 to 12, particularly a mature protein as
10 claimed in any of claims 1 to 12, very particularly a portion corresponding to positions 8 to 93 according to SEQ ID NO. 263.

14. An amylolytic derivative of a protein as claimed
15 in any of claims 1 to 13.

15. An amylolytic protein or derivative, which shares at least one antigenic determinant with any of the proteins or derivatives as claimed in claims 1 to 14.
20

16. The amylolytic protein or derivative as claimed in any of claims 1 to 15, characterized in that it is obtainable from a natural organism, in particular a microorganism.
25

17. The amylolytic protein or derivative as claimed in claim 16, characterized in that the microorganism is a Gram-positive bacterium.

30 18. The amylolytic protein or derivative as claimed in claim 17, characterized in that the Gram-positive bacterium is any of the order Actinomycetales.

19. The amylolytic protein or derivative as claimed in
35 claim 18, characterized in that it is a Streptomyces species.

- 129 -

20. The amylolytic protein or derivative as claimed in claim 19, characterized in that it is *Streptomyces* sp. B327* or *Streptomyces* sp. B400B.

5 21. A nucleic acid coding for an amylolytic protein whose amino acid sequence comprises a portion of which 98%, preferably 99%, particularly preferably 100%, are described by the consensus sequence of SEQ ID NO. 263, in particular via the subregion corresponding to
10 positions 8 to 93.

22. A nucleic acid coding for an amylolytic protein, whose amino acid sequence comprises a portion which is 98%, preferably 99%, particularly preferably 100%,
15 identical to any of the amino acid sequences indicated in SEQ ID NO. 34 to SEQ ID NO. 262, in particular via the subregion corresponding to positions 8 to 93 according to the consensus sequence of SEQ ID NO. 263.

20 23. A nucleic acid coding for an amylolytic protein, whose amino acid sequence comprises a portion which is 98%, preferably 99%, particularly preferably 100%, identical to any of the amino acid sequences indicated in SEQ ID NO. 45, 83, 97, 98, 101, 108, 109, 111, 112,
25 113, 115, 116, 232, 234, 236, 238, 239 and 241 or which can be traced back in every homologous position directly to any of these sequences, in particular via the subregion corresponding to positions 8 to 93 according to the consensus sequence of SEQ ID NO. 263.

30 24. A nucleic acid coding for an amylolytic protein whose amino acid sequence comprises a portion which is 95%, preferably 97.5%, particularly preferably 100%, identical to any of the amino acid sequences indicated
35 in SEQ ID NO. 2, 4 and 208, in particular via the subregion corresponding to positions 8 to 93 according to the consensus sequence of SEQ ID NO. 263, very

- 130 -

particularly preferably a nucleic acid having a nucleotide sequence indicated in SEQ ID Nos. 1 or 3.

25. A nucleic acid coding for an amylolytic protein
5 whose amino acid sequence in each individual homologous position can be traced back, preferably directly, by a conserved substitution to either of the two sequences SEQ ID NO. 6 and SEQ ID NO. 8.

10 26. A nucleic acid encoding an amylolytic protein, whose sequence is at least 85% identical to the nucleotide sequence indicated in SEQ ID NO. 5, preferably in positions 91 to 1383, particularly preferably in positions 628 to 900.

15 27. A nucleic acid encoding an amylolytic protein, whose sequence is at least 92.5% identical to the nucleotide sequence indicated in SEQ ID NO. 5, preferably in positions 91 to 1383, particularly
20 preferably in positions 628 to 900.

28. A nucleic acid encoding an amylolytic protein, whose sequence is identical to the nucleotide sequence indicated in SEQ ID NO. 5, preferably in positions 91
25 to 1383, particularly preferably in positions 628 to 900.

29. A nucleic acid encoding an amylolytic protein, whose sequence is at least 85% identical to the
30 nucleotide sequence indicated in SEQ ID NO. 7, preferably in positions 88 to 1374, particularly preferably in positions 598 to 888.

30. A nucleic acid encoding an amylolytic protein,
35 whose sequence is at least 90% identical to the nucleotide sequence indicated in SEQ ID NO. 7, preferably in positions 88 to 1374, particularly preferably in positions 598 to 888.

31. A nucleic acid encoding an amyloytic protein, whose sequence is identical to the nucleotide sequence indicated in SEQ ID NO. 7, preferably in positions 88 to 1374, particularly preferably in positions 598 to 888.

32. A nucleic acid encoding amylolytic proteins or fragments as defined in claims 12 to 15.

10

33. An oligonucleotide having any of the sequences indicated in SEQ ID NO. 9 to 33, in particular any of the sequences indicated in SEQ ID NO. 9 to 12.

15 34. A nucleic acid encoding an amylolytic protein, characterized in that it is naturally present in any of the organisms as defined in claims 16 to 20 and, preferably, is naturally utilized by said organism for protein synthesis.

20

35. A natural organism which comprises nucleic acids encoding any of the proteins or protein fragments as defined in the sequence listing under SEQ ID NO. 263, preferably under SEQ ID NO. 34 to 262, particularly preferably under SEQ ID NO. 2, 4, 6 or 8.

25

36. The organism as claimed in claim 35, characterized in that it is a microorganism, preferably a bacterium, particularly preferably a Gram-positive bacterium.

30

37. The organism as claimed in claim 36, characterized in that the Gram-positive bacterium is any of the order of Actinomycetales, in particular any of the genus Streptomyces.

35

38. The organism as claimed in claim 37, characterized in that the members of the genus Streptomyces are Streptomyces sp. 327* or Streptomyces sp. B400B, in

- 132 -

particular either of the two strains DSM 13990 and DSM 13991.

39. A PCR-based method for identifying and/or
5 obtaining new amylases from a collection of organisms or nucleic acids, characterized in that PCR primers having in each case a variable 3' region and a 5' region highly homologous to regions of known amylases are used.

10

40. The method as claimed in claim 39, characterized in that the genes or gene fragments obtained are sequenced.

15 41. The method as claimed in claim 39 or 40, characterized in that peptides which are assayed in an immunochemical method for an epitope of a known amylase, preferably of a protein or derivative as claimed in any of claims 1 to 20, are derived from the
20 genes or gene fragments obtained.

42. The method as claimed in any of claims 39 to 41, characterized in that peptides which are assayed for a contribution to an amylolytic activity, preferably for
25 an amylolytic activity exerted completely by said peptides, are derived from the genes or gene fragments obtained.

43. The method as claimed in any of claims 39 to 42,
30 characterized in that the 3' region of at least one PCR primer is highly variable and/or the 5' region of at least one PCR primer is highly homologous to a region of a known amylase.

35 44. The method as claimed in any of claims 39 to 43, characterized in that the 5' region of at least one PCR primer is derived from a sequence region corresponding to a conserved amylase domain, preferably of a region

corresponding to amino acid positions (A) 58-91,
(B) 94-141, (C) 155-207, (D) 295-345 or (E) 392-427 of
Streptomyces griseus α -amylase, particularly preferably
to either of the domains β 4 and β 7 of the $(\alpha\beta)_8$ barrel
5 structure.

45. The method as claimed in any of claims 39 to 44,
characterized in that one PCR primer, preferably two
PCR primers, which can be derived from any of the amino
10 acid sequences of a protein or fragment as claimed in
any of claims 1 to 20, are used.

46. The method as claimed in any of claims 39 to 45,
characterized in that one, preferably two, PCR
15 primer(s) resulting directly from any of the nucleotide
sequences as claimed in any of claims 21 to 34 are
used.

47. The method as claimed in any of claims 39 to 46,
20 characterized in that at least one primer comprises any
of the sequences indicated in the sequence listing
under SEQ ID NO. 9 to 33, in particular any of the
sequences indicated in sequence listing under SEQ ID
NO. 9 to 12.

25 48. The method as claimed in claim 47, characterized
in that the primers are used in the combination of SEQ
ID NO. 9 with SEQ ID NO. 10 or of SEQ ID NO. 11 with
SEQ ID NO. 12.

30 49. The method as claimed in any of claims 39 to 48,
characterized in that the template DNA used is isolated
nucleic acids of organisms, cell cultures, isolates or
cultured individual strains, or is isolated nucleic
35 acids of a sum of organisms, cell cultures, isolates,
cultured individual strains or isolated nucleic acids.

50. The method as claimed in claim 49, characterized in that the template DNA used is isolated nucleic acids of microorganisms, particularly of bacteria and particularly preferably of Gram-positive bacteria.

5

51. The method as claimed in either of claims 49 and 50, characterized in that members of the order Actinomycetales, in particular those of the genus Streptomyces, are involved.

10

52. The method as claimed in any of claims 49 to 51, characterized in that the members of the genus Streptomyces are Streptomyces sp. 327* or Streptomyces sp. B400B, in particular either of the two strains
15 DSM 13990 and DSM 13991.

53. The method as claimed in any of claims 39 to 52, characterized in that the genes or gene fragments obtained are introduced into an expression gene bank
20 which is then assayed for amylolytic proteins or fragments of amylolytic proteins, preferably by hybridization of nucleic acids, by an immunochemical method or via an activity assay.

25 54. The method as claimed in any of claims 39 to 53, characterized in that the isolated DNA is introduced into an expression vector which provides transcriptional and translational control elements and optionally one or more fragments of an amylase gene,
30 overall resulting, in the positive case, in amylase activity.

55. The method as claimed in any of claims 39 to 54, characterized in that the activity assay comprises the
35 following steps:

(a) screening a gene bank, preferably one with complete genes, with the aid of the PCR fragment obtained or a probe derived therefrom,

- 135 -

- (b) expressing the genes or gene fragments identified in this way, and
- (c) measuring the contribution to an amylolytic activity of the proteins or protein fragments obtained by said expression.

56. The method as claimed in any of claims 39 to 55, characterized in that the nucleic acids obtained after the PCR or the complete genes are introduced into cloning vectors and transformed into host cells, prior to the activity assay.

57. The method as claimed in claim 56, characterized in that the host cells are strains of the genera Escherichia and Streptomyces and Bacillus.

58. The method as claimed in any of claims 39 to 57, which is carried out or repeated on so many different PCR templates that at least two different amino acid sequences having a common consensus sequence are obtained, in particular via individual domains, partial activities, structural elements or complete genes and/or proteins.

59. The method as claimed in claim 58, characterized in that a consensus sequence with sequence identities of at least two sequences contained therein of at least 30%, preferably at least 40%, particularly preferably at least 50%, is obtained.

60. The use of a protein or derivative as claimed in any of claims 1 to 20 for identifying an amylolytic protein, preferably in a method as claimed in any of claims 39 to 59.

61. The use of a nucleic acid as claimed in any of claims 21 to 34 for identifying and/or obtaining a new

- 136 -

amylase, preferably in a method as claimed in any of claims 39 to 59.

5 62. The use of a protein obtained by a method as claimed in claims 39 to 59 for fusion or linkage to another protein, in particular for the development of a new enzyme.

10 63. The use of a nucleic acid obtained by a method as claimed in claims 37 to 57 for fusion to another nucleic acid, in particular for the development of a new enzyme.

15 64. The use as claimed in claim 62 or 63 for targeted fusion, in particular with utilization of highly homologous regions of the amino acid sequences, joint restriction cleavage sites of the nucleic acids or via PCR-based fusion.

20 65. The use as claimed in claim 62 or 63 in a random recombination method, in particular with utilization of highly homologous regions of the amino acid sequences, joint restriction cleavage sites of the nucleic acids or via PCR-based fusion.

25 66. A vector comprising a nucleic acid regions as defined in claims 21 to 34.

30 67. The cloning vector as claimed in claim 66.

68. The expression vector as claimed in claim 66.

35 69. A host cell which expresses or can be induced to express any of the proteins or the derivatives as defined in claims 1 to 20, preferably by using an expression vector as claimed in claim 68.

- 137 -

70. The host cell as claimed in claim 69, characterized in that it is a bacterium, in particular one which secretes the protein or derivative produced into the surrounding medium.

5

71. The host cell as claimed in claim 70, characterized in that it is a Gram-positive bacterium.

72. The host cell as claimed in claim 71, characterized in that it belongs to the genus *Bacillus*, preferably to the species *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis* or *Bacillus alcalophilus*.

73. The host cell as claimed in claim 71, characterized in that it belongs to the order Actinomycetales, in particular to the genus *Streptomyces*, preferably to the species *Streptomyces lividans*, particularly preferably *S. lividans* TK24, or to the species *Streptomyces* sp. 327* and *Streptomyces* sp. B400B, in particular to either of the two strains DSM 13990 and DSM 13991.

74. The host cell as claimed in claim 70, characterized in that it is a Gram-negative bacterium.

75. The host cell as claimed in claim 74, characterized in that it belongs to the genus *Escherichia*, preferably to the species *Escherichia coli*, particularly preferably to any of the strains *E. coli* JM 109, *E. coli* DH100B and *E. coli* DH 12S.

76. The host cell as claimed in claim 69, characterized in that it is a eukaryotic cell, in particular one which posttranslationally modifies the protein produced.

77. A method for preparing a protein or derivative as claimed in any of claims 1 to 20 by using a nucleic acid as claimed in any of claims 21 to 34 and/or using a vector as claimed in any of claims 66 to 68 and/or
5 using a host cell as claimed in any of claims 69 to 76 or using a cell which naturally produces said protein or derivative, in particular a cell as claimed in any of claims 35 to 38.

10 78. A detergent or cleaning agent, characterized in that it comprises a protein or derivative as claimed in any of claims 1 to 20.

79. The use of a protein or derivative as claimed in
15 any of claims 1 to 20 for the treatment of raw materials or intermediates in the manufacture of textiles, in particular for desizing cotton.

80. A process for starch liquefaction, in particular
20 for producing ethanol, characterized in that a protein or derivative as claimed in any of claims 1 to 20 is used.

81. The use of a protein or derivative as claimed in
25 any of claims 1 to 20 for preparing linear and/or short-chain oligosaccharides.

82. The use of a protein or derivative as claimed in
30 any of claims 1 to 20 for hydrolyzing cyclodextrins.

83. The use of a protein or derivative as claimed in
any of claims 1 to 20 for releasing low-molecular weight compounds from polysaccharide supports or cyclodextrins.

35 84. The use of a protein or derivative as claimed in any of claims 1 to 20 for preparing food and/or food ingredients.

85. The use of a protein or derivative as claimed in any of claims 1 to 20 for preparing animal feed and/or animal feed ingredients.

5

86. The use of a protein or derivative as claimed in any of claims 1 to 20 for dissolving starch-containing adhesive bonds.

10 87. A temporary bonding process, characterized in that a protein or derivative as claimed in any of claims 1 to 20 is used.

Application number / numéro de demande: EP 02 / 06842

Figures: _____

Pages: 2, and 11

Unscannable items
received with this application
(Request original documents in File Prep. Section on the 10th floor)

Documents reçu avec cette demande ne pouvant être balayés
(Commander les documents originaux dans la section de préparation des dossiers au
10^{ème} étage)

Figure 1




Figure 3/Part 1

1	2	3	4	5	6	7	8	9	10	11	12	13
V	D	G	F	R	X ₀	D	X ₁	X ₂	X ₃	H	X ₄	X ₅
14	15	16	17	18	19	20	21	22	23	24	25	26
X ₆	X ₇	X ₈	X ₉	X ₁₀	X ₁₁	X ₁₂	X ₁₃	X ₁₄	X ₁₅	X ₁₆	X ₁₇	X ₁₈
27	28	29	30	31	32	33	34	35	36	37	38	39
X ₁₉	X ₂₀	X ₂₁	X ₂₂	X ₂₃	X ₂₄	X ₂₅	X ₂₆	X ₂₇	X ₂₈	X ₂₉	X ₃₀	X ₃₁
40	41	42	43	44	45	46	47	48	49	50	51	52
X ₃₂	X ₃₃	X ₃₄	X ₃₅	X ₃₆	X ₃₇	X ₃₈	X ₃₉	X ₄₀	X ₄₁	X ₄₂	X ₄₃	X ₄₄
53	54	55	56	57	58	59	60	61	62	63	64	65
X ₄₅	X ₄₆	X ₄₇	X ₄₈	X ₄₉	X ₅₀	X ₅₁	X ₅₂	X ₅₃	X ₅₄	X ₅₅	X ₅₆	X ₅₇
66	67	68	69	70	71	72	73	74	75	76	77	78
X ₅₈	X ₅₉	X ₆₀	X ₆₁	X ₆₂	X ₆₃	X ₆₄	X ₆₅	X ₆₆	L	X ₆₇	X ₆₈	X ₆₉
79	80	81	82	83	84	85	86	87	88	89	90	91
X ₇₀	X ₇₁	X ₇₂	X ₇₃	X ₇₄	X ₇₅	X ₇₆	X ₇₇	X ₇₈	X ₇₉	X ₈₀	X ₈₁	X ₈₂
92	93	94	95	96	97	98	99	100				
X ₈₃	X ₈₄	V	D	N	H	D	T	X ₈₅				

Position	Amino acid
1	V
2	D
3	G
4	F
5	R
6	X ₀ = I or L
7	D
8	X ₁ = A or T or G
9	X ₂ = A or S
10	X ₃ = K or R

Figure 3/Part 2

Position	Amino acid
11	H
12	X ₄ = M or I
13	X ₅ = S or P or D or A
14	X ₆ = A or T or S or E or V
15	X ₇ = D or A or E or T or G or S
16	X ₈ = D or G
17	X ₉ = V or L or P or I
18	X ₁₀ = A or T or E or N or Q
19	X ₁₁ = A or N or D or H or T or P
20	X ₁₂ = I or V
21	X ₁₃ = K or E or W or R or L
22	X ₁₄ = G or S or P or A or T
23	X ₁₅ = K or R
24	X ₁₆ = M or L or V or P
25	X ₁₇ = S or R or T or G or N or A or D or K or -
26	X ₁₈ = D or N or S or K or R
27	X ₁₉ = P or R or T or Q or G or V
28	X ₂₀ = G or D or S or N or TAGGE or TSGAE or YPAWGGGK
29	X ₂₁ = V or A or T or P or -
30	X ₂₂ = F or Y or H
31	X ₂₃ = W or R or I or L
32	X ₂₄ = V or K or F
33	X ₂₅ = T or Q or H or L or M
34	X ₂₆ = E or G
35	X ₂₇ = V or A or T
36	X ₂₈ = I or T or M or Y or N
37	X ₂₉ = H or Y or F or G or P or A
38	X ₃₀ = G or A or S or W or D
39	X ₃₁ = G or A or D or S
40	X ₃₂ = G or N or T
41	X ₃₃ = E or P or I
42	X ₃₄ = A or T or P or S
43	X ₃₅ = V or I or A or T

Figure 3/Part 3

Position	Amino acid
44	X ₃₆ = Q or S or G
45	X ₃₇ = P or S or -
46	X ₃₈ = E or D or T or G or S or A or Q or -
47	X ₃₉ = E or D or S
48	X ₄₀ = Y or H
49	X ₄₁ = T or L or Y or V or A
50	X ₄₂ = S or G or D or R or T or N or H
51	X ₄₃ = I or S or N or A or T or L
52	X ₄₄ = G or C
53	X ₄₅ = D or S
54	X ₄₆ = V or A or S
55	X ₄₇ = D or Q or H or L or T
56	X ₄₈ = E or D
57	X ₄₉ = F or L or S
58	X ₅₀ = R or S or C or H or D or T or Q
59	X ₅₁ = Y or H
60	X ₅₂ = G or A or S or H
61	X ₅₃ = G or S or Y or R or W or K
62	X ₅₄ = H or D or S or G or Q or R or K
63	X ₅₅ = L or V or I
64	X ₅₆ = K or S or A
65	X ₅₇ = S or R or Q or H
66	X ₅₈ = A or V or I or T or S or D or M
67	X ₅₉ = F or V or L
68	X ₆₀ = Q or T or R or N or D or G or H or L or A
69	X ₆₁ = G or N or Q or R or S or D or -
70	X ₆₂ = G or E or -
71	X ₆₃ = G or N or R or H or S or K or D or Q
72	X ₆₄ = L or P or I or V
73	X ₆₅ = P or A or T or S or K
74	X ₆₆ = G or Q or Y or H or E or D or N
75	L
76	X ₆₇ = R or N or S or E or T
77	X ₆₈ = S or N or K or T or Y or G
78	X ₆₉ = I or V or Y or F or L

Figure 3/Part 4

Position	Amino acid
79	X ₇₀ = A or G or S or D or P
80	X ₇₁ = D or E or V or S
81	X ₇₂ = G or D or A or S or -
82	X ₇₃ = G or W or -
83	X ₇₄ = G or V or A or -
84	X ₇₅ = K or Y or H or R or F or L
85	X ₇₆ = L or M or I or V or P or T
86	X ₇₇ = A or G or N or S or T or P or K or Q or E
87	X ₇₈ = G or S or N or Y or A
88	X ₇₉ = A or D or G or S or T or P or N
89	X ₈₀ = S or K or V or A or F or T or G or Q or R or E or -
90	X ₈₁ = A or S or P
91	X ₈₂ = R or G or S or N or A or V
92	X ₈₃ = T or V or S
93	X ₈₄ = Y or F or W
94	V
95	D
96	N
97	H
98	D
99	T
100	X ₈₅ = E or Q

Figure 4




Figure 5 / Part 1

		1	80				
U51129	(1)	--MASRTL	SGALALAAATAVLAAPATVAHASPPGTKDVTAVLFEWDYASVAKECTSTLGPAGYGYVQVSPPAEHIQGSQ				
B327*	(1)	-MISRWTASAVATAAAFAAAVALPAQAA	YASPPGTKDVTAVLFEWNEASVAKECTNTLGPAGYGSVQVSPPAEHIQGSQ				
U08602	(1)	MQHRERLIGGTLAGVLT	VAGLTTLAPWQSQATPPGEKTVTVMFERPYADVASACTDQLGPAGYGYVQVSPATEHIQGDQ				
B400B	(1)	--MSSRAARATIAGLLAAGGLTVLAPWPSQATPPGEKTVTATLFEWKYDAVATACTDTLGPAGYGYVEVSPATEHIQGDQ					
		81	160				
U51129	(79)	WWTSYQPVSYK	IAGRLGDRAAFRSMVNTCHAAGVKVVVDTVINHMSAGSGTGTGSSYTKYDYPGLYSAPDEDDCTAEIT				
B327*	(80)	WWTSYQPVSYK	IAGRLGDATAFKNMVG	TCHAAGVKVVVDTVINHMSAGSGTGTGSSYTKYNYPGLYSSYDMDCTSTIT			
U08602	(81)	WWTSYQPVSYR	IAGRLGDRDGEAAMVDACHSAGVKVADAVINHMAAGSGTGTGGTAYTKYDYPGYFGDADFHTC	RTAIK			
B400B	(79)	WWTSYQPVSYR	IAGRLGDRDSEFAAMVESCHAAGVRVADAVINHMAAGSGTGTGGTSYTKYDYPGTFQDQDEHACR	KDIA			
		161	240				
U51129	(159)	DYQDRWNVQHCEL	VGLADLDTGEEYVRQTIAGYMN	DL LSLGVDGFRIDAAKHIPAEDLANIKSR LSNPNAYWKQEV	IYGA		
B327*	(160)	DYTNRGNVQNC	ELVGLADLDTGEEYVRAT	IAGYLN	SL LSGVDGFRIDAAKHIPATDLANIKSR LTNPSVYWKQEV	IYGS	
U08602	(161)	DYTD	RGDVQNC	ELVGLSDLDTGKDEV	RSTIAAYLDGLRSMGVDGFRIDAAKHMAAD	DVA-IQGQDERPPGSGSPE	VIQGG
B400B	(159)	NYGDRGDVQNC	ELVGLADLDTGSDA	VRTTIAAYLS	DLRSLGVDGFRIDAAKHMSAD	DVAIKGKMSDP-GFWVTE	VIHGG

Figure 5 / Part 2

241	320
U51129 (239)	GEAVQGEYTGTDVQEFERYAYDLKRVFTQEHLAYLKNYGEDWGYSSTTAGVFVDNHDTERNGSTLNYKNDATYTLANV
B327* (240)	GEAVQPTEYTGNGDVQEFERYAYDLKRVFNENLAYLKNYGEWGYNSSVAGVFVDNHDTERNGSTLNYKDGANYTLANV
U08602 (240)	GEAVQPEEYTEIGDVEFRYGGHLKSAFQGGGIAQLKAVADR--KLGSASARTFVDNWDTERNGSTLTYKDGAAAYTLANV
B400B (238)	GEAVQPEEYTSIGDVEFRYGGHLKSAFQGGGLPGLKSIADG--KLAGASARTFVDNWDTERNGSTLTHKDGAAAYTLANV
321	400
U51129 (319)	FMLAWPYGAPDINSGYEWSDPDAGPPDGGHVDACWQNGWKQCQHKWPEIASMVAERNATRGEPTVDWDDGADAIAFGRGS
B327* (320)	FMLAYPYGAPDINSGYEWSDDTAGPPNNGSVSACWQDGWKCQHAWPEILRMVAERNATRGESVTNWNWDNGGDAIAFGRGA
U08602 (318)	FMLASPYGSPNVVSGYEWSADADAGPPSGA-----DGWTDTHAQQTITGLVGERNAVGSAEITDWNWDNGGSALA FGRGD
B400B (316)	FMLASPYGSPNVVFSGYTWTDKDAGPPNGGAAD-CGSGAWTCTHAQQQAVTGMVGFHNNAVAGAEITDWNWDNGGSALA FARAG
401	469
U51129 (399)	KGFVAINHESATVQRTYQTSPLPAGTYCDVQ-----SNTTVTVDSAGRFTAALGPD TALALHTGRTSC
B327* (400)	KGYVAINHESGSLSRTYQTSPLPAGTYCNVQ-----NNTSVTVGSNGQFTATLGSNTALAIYAGKANC
U08602 (391)	KGFVALNNADDALTETFTTSLPAGTYCNVAAASPDDCDGNTVTVGDDGAVQATVPARGALALHTGAQAG
B400B (395)	KGFVAVNNGDAELNRTFTTTL PAGTYCNVVAAAPDSCDNGTTVADDGTATITVPARGAVALHT-----

Figure 6

